

Wednesday, October 15, 2025

*Pre-conference workshop/course*

09:30 - 13:30

Salle Maillot

**WAVE workshop**

*Pre-conference workshop/course*

09:30 - 15:00

Room 242 AB

**EACS pre-educational course**

*Pre-conference workshop/course*

09:30 - 09:35

Room 242 AB

**Introduction**

**Introduction**

09:30 - 09:35

Tristan Barber (Royal Free Hospital, United Kingdom)

Agnès Libois (Saint-Pierre University Hospital, Belgium)

*Pre-conference workshop/course*

09:35 - 10:20

Room 242 AB

**Non AIDS Malignancies**

**Non AIDS Malignancies**

09:35 - 09:55

Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)

**Case Presentation**

09:55 - 10:10

Risa Fukuoka (Osaka University / Osaka City General Hospital, Japan)

**Q&A/Discussion**

10:10 - 10:20

*Pre-conference workshop/course*

10:00 - 12:00

Room 241

**EATG STEPS Cure Workshop:**

**STEPS 11: The Giulio Maria Corbelli Workshop - A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection.**

*Pre-conference workshop/course*

10:20 - 10:40

Room 242 AB

**Coffee Break**

*Pre-conference workshop/course*

10:40 - 11:25

Room 242 AB

**HIV and Virology**

**HIV and Virology**

10:40 - 11:00

Toshibumi Taniguchi (Chiba University Hospital, Japan)

**Case Presentation**

11:00 - 11:15

Matthew Valentino (Mater Dei Hospital, Malta)

**Q&A/Discussion**

11:15 - 11:25

*Pre-conference workshop/course*

11:25 - 12:10

Room 242 AB

**HIV Stigma in Healthcare Settings**

**HIV Stigma in Healthcare Settings**

Agata Skrzat-Klapaczyńska (Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Poland, Poland)	11:25 - 11:45
<b>Case Presentation</b>	11:45 - 12:00
Yasmin Walters (Chelsea and Westminster NHS Foundation Trust, United Kingdom)	
<b>Q&amp;A/Discussion</b>	12:00 - 12:10
<i>Industry sponsored session</i> 11:30 - 12:30	Amphithéâtre Bleu
<b>Industry sponsored session</b> Live broadcasted session 	
<i>Industry sponsored session</i> 11:30 - 12:30	Amphithéâtre Bordeaux
<b>Industry sponsored session</b> Live broadcasted session 	
<i>Pre-conference workshop/course</i> 12:10 - 12:45	Room 242 AB
<b>Lunch</b>	
<i>Pre-conference workshop/course</i> 12:10 - 15:00	Room 242 AB
<b>Afternoon Chairs</b> Jose I Bernardino (Hospital Universitario La Paz. IdiPAZ, Spain) Oana Sandulescu (Carol Davila University of Medicine and Pharmacy Bucharest, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania)	
<i>Pre-conference workshop/course</i> 12:45 - 13:30	Room 242 AB
<b>HIV and Weight/GLP-1 Agonists</b>	
<b>HIV and Weight/GLP-1 Agonists</b>	12:45 - 13:05
Marie-Angélique De Scheerder (Ghent University Hospital, Belgium)	
<b>Case Presentation</b>	13:05 - 13:20
Carmen Busca (HIV Unit. Hospital Universitario La Paz. IdiPaz, Spain)	
<b>Q&amp;A/Discussion</b>	13:20 - 13:30
<i>Industry sponsored session</i> 13:00 - 14:30	Amphithéâtre Bleu
<b>Industry sponsored session</b> Live broadcasted session 	
<i>Pre-conference workshop/course</i> 13:30 - 13:40	Room 242 AB
<b>Tea Break</b>	

*Pre-conference workshop/course*

13:40 - 14:25

Room 242 AB

**The Future of HIV Treatment****The Future of HIV Treatment**

13:40 - 14:00

Jose Arribas (Hospital La Paz, Spain)

**Case Presentation**

14:00 - 14:15

Alexandra Riczu (Central Hospital of Southern Pest, National Institute of Haematology and Infectious Diseases, Hungary)

**Q&A/Discussion**

14:15 - 14:25

*Pre-conference workshop/course*

14:25 - 14:50

Room 242 AB

**NEAT-ID****NEAT-ID**

14:25 - 14:35

Esteban Martínez (Hospital Clínic &amp; University of Barcelona, Spain)

**NEAT-ID**

14:35 - 14:45

Laura Waters (Central &amp; North West London NHS Trust, United Kingdom)

*Pre-conference workshop/course*

14:50 - 14:55

Room 242 AB

**Summary**

Oana Sandulescu (Carol Davila University of Medicine and Pharmacy Bucharest, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania)

*Pre-conference workshop/course*

14:55 - 15:00

Room 242 AB

**Future of YING, and Close**

Jose I Bernardino (Hospital Universitario La Paz. IdiPAZ, Spain)

*Industry sponsored session*


15:00 - 16:30

Amphithéâtre Bleu

**Industry sponsored session**Live broadcasted session *Ceremony*

16:45 - 18:00

Grand Amphitheatre


**Opening ceremony**Live broadcasted session 

Thursday, October 16, 2025

*Industry sponsored session*


08:00 - 09:00

Amphithéâtre Bleu

**Industry sponsored session**Live broadcasted session *Roundtable Discussion*

08:00 - 09:00

Amphithéâtre Bordeaux

**RT1 - Community-based and participatory research in the field of HIV**Live broadcasted session 

Paulie "Amanita" Calderón-Cifuentes (Trans Europe and Central Asia (TGEU), Germany)

**Roundtable Discussion on Community-based and participatory research in the field of HIV**

08:00 - 09:00

Nicolas Lorente (Coalition PLUS, Spain)


Grzegorz Jezierski (Lambda Warszawa Association, Poland)

Perrine Roux (INSERM, France)

*Meet-the-expert*

08:00 - 09:00

Salle Maillot

**MTE1 - Statin guidelines implementation after REPRIEVE: one year later**Live broadcasted session 

Esteban Martínez (Hospital Clínic &amp; University of Barcelona, Spain)

Franck Boccara (SORBONNE UNIVERSITY, France)

MTE1.1

**Impact of REPRIEVE indications on statin prescription in people with HIV in a real-life setting**


08:00 - 08:09

Rebecka Papaioannu Borjesson (IRCCS San Raffaele Scientific Institute, Italy)

*Meet-the-expert*

08:00 - 09:00

Room 242 AB

**MTE2 - Tuberculosis in 2025**Live broadcasted session 

Nathalie De Castro (APHP-Hôpital Saint-Louis, France)

Daria Podlekareva (CHIP, Rigshospitalet, University of Copenhagen and

Statens Serum Institute, Denmark)

MTE.C2.1

**A Diagnostic and Therapeutic Odyssey in Advanced HIV: Disseminated Tuberculosis with Hematologic and Renal Involvement**

08:00 - 08:09

Sabri Atalay (Health Sciences University Tepecik Training and Research Hospital, Turkey)

MTE.C2.2

**Use of Anakinra for Corticosteroid-Refractory Paradoxical IRIS in Patients with HIV and Tuberculous Lymphadenitis: Two Case Reports**

08:09 - 08:18

Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)

MTE.C2.3

**The case of cutaneous TB in person living with HIV from Eastern European country of Georgia**

08:18 - 08:27

Shorena DVALI (T.Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)

## ePosters

09:00 - 18:00

ePoster Exhibition

**ePosters on Display**

	<b>A. Basic and Translational Science</b>	09:00 - 09:00
eP001	<b>Refining the resistance landscape of lenacapavir in HIV-1 through cell-based selection</b> Jolieke A. T. van Osch (Erasmus University Medical Center, Netherlands)	09:00 - 09:00
eP002	<b>Dasatinib enhances innate macrophage restriction and limits HIV-1 replication</b> Clara Sánchez Menéndez (National Center of Microbiology, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP003	<b>HIV persistence in cisgender women after long periods on ART: could be shaped by the route and moment of HIV acquisition?</b> Lucia Baquero (CONICET-Universidad de Buenos Aires. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Argentina)	09:00 - 09:00
eP004	<b>HIV-specific CD8+ T-cell response drives viral selection and integration site in silent regions in individuals treated during the acute phase of HIV acquisition</b> Pien van Paassen (Amsterdam UMC, Netherlands)	09:00 - 09:00
eP005	<b>HIV-specific T-cell immune response in elite controllers</b> Leonel Cruces (Institute for Biomedical Research on Retrovirus and Aids (INBIRS), Argentina)	09:00 - 09:00
eP006	<b>Linking Gut Microbiome to HIV Reservoir Size in People Living with HIV</b> Oscar Kieri (Karolinska Institutet, Sweden)	09:00 - 09:00
eP007	<b>Longitudinal dynamics of virology, immunity, and HIV-1 reservoir in people living with HIV and cancer: impact of antitumor therapy and immune checkpoint inhibitors</b> Jingchun Mao (Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, China)	09:00 - 09:00
eP008	<b>Machine learning identified genetic features associated with HIV Sequences in the Monocytes</b> Xiaorong Peng (zhejiang university, China)	09:00 - 09:00
eP009	<b>Variations in sero-biomarkers of gut barrier dysfunction and sCD14 in ART-naïve PWH initiating ART</b> Valentina Iannone (Università Cattolica del Sacro Cuore, Roma, Italy)	09:00 - 09:00
eP010	<b>Decoding HIV: Two Technologies, One Genome</b> Federica Stefanelli (IRCCS San Martino Hospital, Italy)	09:00 - 09:00
eP011	<b>False Positivity in HIV Screening Using Fourth-Generation Assay: Performance and Potential Influencing Factors in a Low Prevalence Population</b> Lily Shui-kuen Cheng (United Christian Hospital, Hong Kong)	09:00 - 09:00
eP012	<b>Feasibility and reliability of decentralized HIV-1 viral load monitoring on self-sampled blood</b> Kyra Mendes de Leon (Amsterdam UMC, Netherlands)	09:00 - 09:00
eP013	<b>Limited Performance of FIB-4 and NAFLD Fibrosis Score for Detecting Liver Fibrosis in People Living with HIV</b> Rahma Mohamed (Cairo University, Egypt)	09:00 - 09:00
eP014	<b>Whole-Genome Sequencing for HIV-1 drug resistance testing: are we ready?</b> Federica Stefanelli (IRCCS San Martino Hospital, Italy)	09:00 - 09:00

eP015	<b>Dynamic Crosstalk Between MAIT Cells and NK Cells in Incomplete Immune Reconstitution of Individuals acquiring HIV</b> Zhuoya Deng (Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP016	<b>Dynamics and Immunological Signature of <math>\gamma\delta</math> T Cells Following Antiretroviral Therapy Initiation in Acute HIV-1 Infection</b> Zhen Li (Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP017	<b>Extracellular Acyl-CoA-Binding Protein prevents autophagy and T-cell function in people with HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP018	<b>Immune checkpoint patterns in cerebrospinal fluid after ART initiation related to neurocognitive decline among PWH</b> ANA JOY LOZANO (UNIVERSITY OF THE PHILIPPINES MANILA, Philippines)	09:00 - 09:00
eP019	<b>Modulation of TLR-Driven Monocyte Activation by JAK-STAT Inhibitors in People With HIV</b> Marion Camard (Université Paris-Saclay, Inserm, CEA, France)	09:00 - 09:00
eP020	<b>Reduction of immune- senescence in People with HIV (PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine</b> Mariasilvia Guardiani (Sapienza University of Rome, Italy)	09:00 - 09:00
eP021	<b>Tenascin-C Bridges Biomarker Discovery and Immune Modulation in Incomplete Immune Reconstitution Among People Living with HIV</b> Zhuoya Deng (Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP022	<b>Type I Interferon Drives Myeloid-Mediated T-Cell Activation in People Living with HIV Under Antiretroviral Therapy</b> Léo Plaçais (Unité INSERM U1184, laboratoire IDMIT, Commissariat à l'énergie atomique, France)	09:00 - 09:00
eP023	<b>ANTIOXIDANT CAPACITY IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY</b> Radoslava Emilova (National Center of Infectious and Parasitic Diseases, Bulgaria)	09:00 - 09:00
eP024	<b>Differential expression of ER-TR7 following challenge with more recent antiretroviral drugs: an <i>in vitro</i> model</b> Maria Aurora Carleo (AO dei Colli - PO "D. Cotugno", Italy)	09:00 - 09:00
eP026	<b>Functional characterization of the HIV-2 V3 loop: Insights into host interaction and viral tropism</b> Paloma Gonçalves (Research Institute for Medicines, Faculty of pharmacy, Universidade de Lisboa, Portugal)	09:00 - 09:00
eP027	<b>High levels of anti-HHV-8 IgG binding capacity are linked with low HHV-8 viremia in people with and without HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP028	<b>Identification of transcriptional active SIV-infected cells in Rhesus Macaques</b> Jerome Estaquier (Université Laval, Canada)	09:00 - 09:00
eP029	<b>Impaired Immune Reconstitution in PLWH: the Role of CD4<sup>+</sup>T-Cell-Associated NKG2D Ligands and CD4<sup>+</sup>T-Cell Subsets Imbalance</b>	09:00 - 09:00

	Peng Xu (Beijing Youan Hospital, Capital Medical University, China)	
eP030	<b>Markers of astroglial/monocyte activation and inflammation are associated with neurocognitive impairment in people with HIV on suppressive ART</b> Matteo Augello (University of Milan, Italy)	09:00 - 09:00
eP031	<b>Microglia cause HIV-induced transcriptional and metabolomic changes in human brain organoids leading to neurological impairment</b> Pamela E. Capendale (OrganoVIR Labs, Emma Children's Hospital, Department of Pediatric Infectious Diseases, Amsterdam UMC, location Academic Medical Center,, Netherlands)	09:00 - 09:00
eP032	<b>Myeloid production of the mitokine GDF15 is associated with HIV reservoir size and non-AIDS comorbidity marker in ART-treated people with HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP033	<b>Single-Cell Transcriptomic Analysis Reveals Nef-Induced Dysregulation of Hematopoietic Stem Cell Development and Aging-Associated Pathways in HIV Infection</b> Wei Zou (Nanchang University/the 1st affiliated hospital, China)	09:00 - 09:00
eP034	<b>A Systematic Analysis of Immune Responses Following BCG Vaccination in People with HIV</b> Johannes Nemeth (University Hospital Zurich, Switzerland)	09:00 - 09:00
eP035	<b>Optimized Expression of CD4-Inducible (CD4i) Epitopes in HIV-1 Vaccine Prototypes Based on Virus-Like Particles (VLPs)</b> ALMUDENA RUBIO-PEREZ (CENTRO NACIONAL DE MICROBIOLOGÍA, INSTITUTO DE SALUD CARLOS III, Spain)	09:00 - 09:00
eP036	<b>Development of diagnostic/prognostic marker and therapeutic target for HCV-mono- and HIV/HCV-co-infection-mediated liver diseases</b> IN-WOO PARK (University of North Texas Health Science Center, United States)	09:00 - 09:00
eP037	<b>Low-level viraemia (LLV) in people living with HIV and its management at an HIV centre in London</b> Matthew Valentino (Mater Dei Hospital, Malta)	09:00 - 09:00
eP038	<b>Novel NGS-based Pipeline for HIV-1 pol Region Analysis</b> Arina Syrkina (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP039	<b>Proviral DNA genotyping among patients living with HIV with Undetectable Viral Load or Low-Level Viral Load</b> Dan Turner (Tel Aviv Sourasky Medical Center/ Faculty of Medicine, Tel Aviv University, Israel)	09:00 - 09:00
eP040	<b>Exploration of the genetic diversity and the evolution of HIV-1 non-B subtypes in Serbia: phylogenetic information beyond viral spread</b> Marina Siljic (University of Belgrade, Faculty of Medicine, Institute of Microbiology and Immunology, Serbia)	09:00 - 09:00
eP041	<b>Using Nanopore sequence data to analyse drug resistance profile and its association with phylodynamics from HIV quasispecies</b> Tsz Ho Kwan (The Chinese University of Hong Kong, Hong Kong)	09:00 - 09:00
	<b>B1. Clinical Science - Antiretroviral therapy</b>	09:00 - 09:00
eP042	<b>A Clinical Pathway for the Use of Long-Acting Injectable antiretroviral therapy (LAI-ART) in Adherence Challenged People Living with HIV</b>	09:00 - 09:00

	Siobhan Quirke (GUIDe Clinic, Ireland)	
eP043	<b>A combined dolutegravir-rilpivirine oral regimen as lead-in therapy for long-acting injectable antiretroviral treatment in people living with HIV</b> Mayda Rahi (Assistance Publique – Hôpitaux de Paris, Nord. Hôpital Bichat-Claude Bernard, France)	09:00 - 09:00
eP044	<b>Adverse events and treatment discontinuation in a large, observational cohort of PLHIV starting Dolutegravir or non-Dolutegravir-based antiretroviral therapy (ART) in Brazil: The CODE cohort</b> Carlos Brites (FEDERAL UNIVERSITY OF BAHIA, Brazil)	09:00 - 09:00
eP045	<b>Analysis of viral load and INSTI resistance in people with HIV-1A6 receiving oral second generation INSTI</b> Maarten van de Klundert (Karolinska institutet, Sweden)	09:00 - 09:00
eP046	<b>Antiviral exposure and risk of Metabolic Dysfunction-Associated Steatotic Liver Disease</b> Magnus Søltø Lindhardt (Copenhagen University Hospital - Amager and Hvidovre, Denmark)	09:00 - 09:00
eP047	<b>B/F/TAF in Latin American Elderly PLWH: A 96-Week Analysis of Effectiveness, Safety, and Metabolic Outcomes from the BICTARG Cohort</b> Cinthia Lamaizon (Helios Salud, Argentina)	09:00 - 09:00
eP048	<b>Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV Aged ≥50: Low Discontinuation Rates and Favorable Metabolic Outcomes Over 36 Months</b> Andrea De Vito (University of Sassari, Italy)	09:00 - 09:00
eP049	<b>CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France</b> Patrick Philibert (Hôpital Européen Marseille, France)	09:00 - 09:00
eP050	<b>Changes in Neuronal Injury and Inflammation Biomarkers in CSF of People Switching to Doravirine plus Raltegravir</b> Analuz Fernández (Hospital Universitari de Bellvitge, Spain)	09:00 - 09:00
eP051	<b>CHANGES IN QUALITY OF LIFE IN PEOPLE LIVING WITH HIV SWITCHING TO DOLUTEGRAVIR-BASED REGIMENS, FROM STABLE OR FAILING CURRENT ANTIRETROVIRAL REGIMENS IN THE CODE COHORT</b> Liliane Lins-Kusterer (FEDERAL UNIVERSITY OF BAHIA, Brazil)	09:00 - 09:00
eP052	<b>Changes in weight and BMI associated with switching to doravirine/lamivudine/tenofovir disoproxil fumarate vs. continuing an integrase inhibitor- or protease inhibitor-based regimen- an observational prospective case-control study</b> Charlotte-Paige Rolle (Orlando Immunology Center, United States)	09:00 - 09:00
eP053	<b>Characteristics and Outcomes of People with HIV (PWH) Virally Suppressed on Complex Regimens</b> Richard Elion (Trio Health, United States)	09:00 - 09:00
eP054	<b>Clinical and immunovirological outcomes in advanced people living with HIV receiving dual versus triple drug regimens: a real-world cohort study</b> Emanuela Zappulo (University of Naples Federico II, Naples, Italy, Italy)	09:00 - 09:00
eP055	<b>Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2-drug or continuing 3-drug therapy over 18-months</b>	09:00 - 09:00



	<b>of follow-up</b> Lia Fiaschi (University of Siena, Italy)	
eP056	<b>Comparative Dynamics of Inflammatory Biomarkers in Antiretroviral-Naïve MSM with HIV initiating DTG/3TC versus BIC/FTC/TAF</b> Ran Wang (Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP057	<b>Comparison of HIV diagnosis and treatment features in cis- and trans-gender women in two different European Centres (London and Padua)</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP058	<b>COMPARISON OF THE RESPONSE TO ANTIRETROVIRAL TREATMENT BETWEEN LATE PRESENTING AND OTHER ADULT PEOPLE LIVING WITH HIV: A 13- YEAR SINGLE-CENTER EXPERIENCE</b> Narmin Huseynova (Izmir Katip Celebi University, Atatürk Education Research Hospital, Turkey)	09:00 - 09:00
eP059	<b>Differences on Clinical and Virological Outcomes of Cabotegravir + Rilpivirine Long Acting between Men and Women in the Dat'AIDS Cohort</b> Clotilde Allavena (CHU Nantes, France)	09:00 - 09:00
eP060	<b>Discontinuations of long-acting injectable cabotegravir and rilpivirine in observational cohorts</b> Chloe Pasin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP061	<b>Does adherence to CAB + RPV decrease over time in real world? A substudy from the RELATIVITY cohort</b> Luis Buzon Martín (Hospital Universitario de Burgos, Spain)	09:00 - 09:00
eP062	<b>DOLAM-500: 48 and 96-Week Real-World Efficacy and Safety of Dolutegravir Plus Lamivudine in ART-Naïve Individuals with Baseline HIV-1 RNA <math>\geq 500,000</math> copies/mL</b> Asuman İnan (Saglik Bilimleri University, Turkey)	09:00 - 09:00
eP063	<b>DOLANKA: Real World Data on the use of two drug regimen Dolutegravir (DTG) + Lamivudine (3TC) in treatment-naïve people living with HIV in Ankara-Turkey: Interim analysis results</b> MELIHA CAGLA SONMEZER (Hacettepe University Faculty Of Medicine, Turkey)	09:00 - 09:00
eP064	<b>DTG/3TC AS INITIAL THERAPY IN PEOPLE LIVING WITH HIV AND VIRAL LOAD <math>&gt;500,000</math> COPIES/ML AND CD4 CELL COUNT <math>\geq 200/\text{mm}^3</math></b> Juan Martin-Torres (Hospital Universitario 12 de Octubre, Spain)	09:00 - 09:00
eP065	<b>Dual Antiretroviral Therapy Is More Commonly Used in Men than in Women Living with HIV - Findings from the German North-Rhine Cohort</b> Heribert Knechten (PZB Aachen, Germany)	09:00 - 09:00
eP066	<b>Durability and reasons for treatment discontinuation of BIC/FTC/TAF in real life: data from 927 Persons With HIV in charge to "D. Cotugno" hospital, Naples, Southern Italy</b> Francesco Maria Fusco ("D. Cotugno" hospital, Azienda Ospedaliera dei Colli, Italy)	09:00 - 09:00
eP067	<b>Durability of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)</b> Filippo Lagi (Azienda Ospedaliero Universitaria Careggi, Italy)	09:00 - 09:00

eP068	<b>Durability of viral suppression following antiretroviral therapy optimization to TLD among treatment-experienced adults living with HIV in Tajikistan</b> Aziz Nabidzhonov (U.S. Centers for Disease Control and Prevention, Tajikistan)	09:00 - 09:00
eP069	<b>Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV TR cohort</b> Halis Akalın (Bursa Uludağ University Faculty of Medicine, Turkey)	09:00 - 09:00
eP070	<b>Effectiveness of switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from NNRTI-based ART in virologically suppressed people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH Study)</b> Roberta Gagliardini (INMI L. Spallanzani IRCCS, Italy)	09:00 - 09:00
eP071	<b>Epidemiological situation of HIV treatment in Tunisia, 2024</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP072	<b>Equal risk of confirmed virological failure among individuals using long-acting injectable cabotegravir/rilpivirine during first and second year of follow-up: results from the Dutch ATHENA national observational cohort</b> Ferdinand W. N. M. Wit (Stichting hiv monitoring, Netherlands)	09:00 - 09:00
eP073	<b>High Uptake of Intermittent Drug-Reduced ART Strategies Among Virologically Suppressed People Living with HIV (PWH) at an HIV Clinic in Paris, France</b> Christine Katlama (Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, France)	09:00 - 09:00
eP074	<b>HIV-2: Viraemias in the course of untreated and treated "People Living With HIV-2" (PLWH2) in an observational cohort ("H2O") from Hamburg</b> Dirk Berzow (Praxis Eimsbüttel, Germany)	09:00 - 09:00
eP075	<b>Impact of Antiretroviral Therapy (ART) Regimen Initiation or Switch in Virologically Suppressed People With Human Immunodeficiency Virus-1 (HIV-1) on Lipid Profile at 48 weeks: A Systematic Literature Review</b> Julián Olalla (Hospital Costa del Sol, Spain)	09:00 - 09:00
eP076	<b>Impact of bictegravir/emtricitabine/tenofovir alafenamide (BIC/TAF/FTC) and Dolutegravir/Lamivudine on Depression Symptoms in People Living with HIV: A Retrospective Analysis of Beck Depression Inventory Scores</b> Oguz Karabay (Sakarya University, Turkey)	09:00 - 09:00
eP077	<b>Impact of nucleoside reverse transcriptase inhibitor resistance-associated mutations on long-term virologic suppression of bictegravir/emtricitabine/tenofovir alafenamide: real-world evidence</b> Cinthia Lamaizon (Helios Salud, Argentina)	09:00 - 09:00
eP078	<b>IMPACT OF PREEXISTING K103N ON THE EFFECTIVENESS OF LA-CAB+RPV: REAL-LIFE RELATIVITY COHORT</b> Luz Martín Carbonero (Hospital Universitario La Paz, Spain)	09:00 - 09:00
eP079	<b>Impact of treatment simplification in people living with HIV-2 - a retrospective study conducted in Hospital Beatriz Ângelo</b> Beatriz Adragão Fernandes (Faculdade de Medicina da Universidade de Lisboa, Portugal)	09:00 - 09:00
eP080	<b>Implementation of a same-day ART start model in a real-life setting</b>	09:00 - 09:00

	<b>in Italy</b> Giulia Micheli (National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Italy)	
eP081	<b>Implementation Outcomes and Preliminary Effectiveness of Digitally Administering an Electronic Patient-Reported Outcome Measure of Barriers to Adherence to Antiretrovirals (the I-Score) in HIV Care</b> David LESSARD (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP082	<b>Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCohoLART Study</b> Gabriele Loi (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP083	<b>Living with HIV-2: Clinical and Therapeutic Profile of a Cohort Followed in a Portuguese Local Health Unit</b> Diana Briosa Reis (Unidade Local de Saúde do Algarve, Portugal)	09:00 - 09:00
eP084	<b>Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV</b> Júlia Calvo (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP085	<b>Long-Acting CAB + RPV: Safety, Efficacy, and Discontinuation Risks in ODOACRE Cohort</b> Andrea De Vito (University of Sassari, Italy)	09:00 - 09:00
eP086	<b>Long-Acting Cabotegravir-Rilpivirine in Real-Life: Sex-based Characteristics and Effectiveness</b> Ana González-Cordón (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP087	<b>Long-Acting Cabotegravir-Rilpivirine in Vulnerable Population: Chemsex Practices-based Analysis</b> Maria Martínez-Rebollar (HIV Unit, Infectious Diseases Service, Hospital Clínic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Spain)	09:00 - 09:00
eP088	<b>Long-Acting HIV Treatment in Practice: Promising Outcomes and Real-World Challenges from the CACTUZ Cohort</b> Caroline Matthys (Ghent University Hospital, Belgium)	09:00 - 09:00
eP089	<b>Long-acting injectable cabotegravir and rilpivirine outcomes in HIV individuals with stable treatment with dolutegravir and rilpivirine</b> María José Galindo Puerto (Hospital Clinico Universitario of Valencia, Spain)	09:00 - 09:00
eP090	<b>LONG-TERM BIC/TAF/FTC DURABILITY AND IMPACT OF DTG/3TC OR LONG-ACTING CABO/RPV</b> Ana Moreno Zamora (Hospital Ramón y Cajal, Spain)	09:00 - 09:00
eP091	<b>Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC Study</b> Alessandro Tavelli (Icona Foundation, Italy)	09:00 - 09:00
eP092	<b>Long-Term Metabolic and Safety Profiles of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in HIV Treatment: A Multicenter Retrospective Study Using Mixed-Effects Modeling</b> Oguz Karabay (Sakarya University, Turkey)	09:00 - 09:00
eP093	<b>Modulation of biomarkers of CNS inflammation, immune activation and neuronal injury in PWH switching to long-acting injectable cabotegravir/rilpivirine therapy: 12 months of follow-up</b>	09:00 - 09:00

	Maria Antonella Zingaropoli (Sapienza University of Rome, Italy)	
eP094	<b>One-Year Clinical Outcomes of Second-generation Integrase Inhibitors Therapy in Late HIV Presenters in Egypt and Saudi Arabia</b> Hanan Hamdy (Cairo university, Egypt)	09:00 - 09:00
eP095	<b>PAtient Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis</b> Eva Fernvik (ViiV Healthcare, Sweden)	09:00 - 09:00
eP096	<b>Patient-Reported Health and Virological Outcomes Among People with HIV Switching to Long-Acting Injectable Cabotegravir and Rilpivirine (LANTERN)</b> CHIEN-YU Cheng (Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan)	09:00 - 09:00
eP097	<b>Patient-Reported Outcomes and Experiences in a Diverse HIV Cohort Initiating Rapid B/F/TAF: The ASAP Study</b> Dominic Chu (McGill University, Canada)	09:00 - 09:00
eP098	<b>Profile of comorbidities in individuals who are receiving Long-Acting Cabotegravir and Rilpivirine: Real-World Insights from the RELATIVITY Cohort</b> María José Galindo Puerto (Hospital Clinico Universitario of Valencia, Spain)	09:00 - 09:00
eP099	<b>Real life data of people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide with baseline CD4+ count below 200 cells/mL (BicAdvance study)</b> Diego Ripamonti (ASST Papa Giovanni XXIII, Italy)	09:00 - 09:00
eP100	<b>Real life experience with Doravirine-based treatment: therapeutic efficacy and influence on lipid and T-cell immune profile</b> Riccardo Nardo (Università degli Studi di Milano, Italy)	09:00 - 09:00
eP101	<b>Real world use of lenacapavir in France: a national, observational study</b> Romain Palich (Pitié-Salpêtrière University Hospital, AP-HP, France)	09:00 - 09:00
eP102	<b>Real-Life Effectiveness, Safety, and Patient-Reported Outcomes of Long-Acting Cabotegravir-Rilpivirine: Results from a large single center cohort</b> Ana González-Cordón (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP103	<b>Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence</b> Chloe Orkin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP104	<b>Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The "AReTi" Study Results</b> Dimitrios Athanasopoulos (GSK & ViiV Healthcare, Greece)	09:00 - 09:00
eP105	<b>Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations</b> Chloe Pasin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP106	<b>Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada</b> Jean-Francois Fortin (ViiV Healthcare, Canada)	09:00 - 09:00

eP107	<b>Reasons for switching to long-acting injectable antiretroviral therapy with cabotegravir/rilpivirine among adult people living with HIV: the real-life PANTER study</b> Martin Duracinsky (Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Center (URC-ECO), Hôtel-Dieu Hospital, AP-HP, 75004, France)	09:00 - 09:00
eP108	<b>Results at month 12 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every two months in viral suppressed people with HIV (PWH)</b> Carmen Hidalgo Tenorio (Hospital Universitario Virgen de las Nieves, Spain)	09:00 - 09:00
eP109	<b>Risk of virological failure after switch to a tenofovir-sparing dual therapy in virologically suppressed people with HIV and past HBV infection</b> Alberto Borghetti (Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Istituto Malattie Infettive, Italy)	09:00 - 09:00
eP110	<b>Risk of virological rebound is similar in people with HIV switching to long-acting cabotegravir/rilpivirine or integrase inhibitor-based oral therapy</b> Flavia Badalucco Ciotta (Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP111	<b>Subtype-Dependent Clinical and Immunological Patterns of Acute HIV-1 Acquisition: A Retrospective Analysis from Southern China</b> Qiuyue Zhang (Third People's Hospital of Shenzhen, National Clinical Research Center for infectious Diseases, China)	09:00 - 09:00
eP112	<b>Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting and impact of tenofovir resistance</b> Alain Makinson (CHU de Montpellier, France)	09:00 - 09:00
eP113	<b>Switching to Generic Dolutegravir: Sustained Gains in Immunity, Viral Control, and Metabolic Stability</b> Ahmed M. Kamel (Cairo University, Egypt)	09:00 - 09:00
eP114	<b>Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort</b> Gianmaria Baldin (Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Italy)	09:00 - 09:00
eP115	<b>The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV</b> Maria Jesus Perez Elías (Hospital Universitario Ramón y Cajal, Spain)	09:00 - 09:00
eP116	<b>The Increasing Use of Two-Drug HIV Regimens</b> Sarah Brown (Research Partnership, United Kingdom)	09:00 - 09:00
eP117	<b>TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE</b> Ayse Deniz Gokengin (Ege University Faculty of Medicine Hospital, Turkey)	09:00 - 09:00
eP118	<b>Treatment switch among US Medicare beneficiaries with HIV</b> James Jarrett (Gilead Sciences, United Kingdom)	09:00 - 09:00
eP119	<b>Trends in opportunistic diseases at antiretroviral therapy initiation, Croatia 2009-2023</b> Šime Zekan (University Hospital for Infectious Diseases, Croatia)	09:00 - 09:00

eP120	<b>Two versus three-drug Doravirine based regimens in real life: a multicentric observational study</b> Adriana Cervo (Infectious Diseases Unit, University Hospital of Modena, Italy)	09:00 - 09:00
eP121	<b>Two-year efficacy and durability of cabotegravir and rilpivirine in the SCohoLART study</b> Camilla Muccini (IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP122	<b>Unconventional DORAVIRINE antiretroviral regime: a single-center experience</b> Francesco Giovanni Genderini (Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium, Belgium)	09:00 - 09:00
eP123	<b>Variability in Laboratory Monitoring After Switching to Long-Acting CAB/RPV: Patterns and Associations with Virological Outcomes</b> Maria de Lagarde Sebastian (Hospital Universitario 12 de Octubre, imas12, CIBERINFEC, Spain)	09:00 - 09:00
eP124	<b>Virological Failure on Long-Acting Cabotegravir + Rilpivirine: Associated Factors and Remaining Options in the Real-World Dat'AIDS Cohort</b> Colin Deschanvres (Nantes University Hospital, France)	09:00 - 09:00
eP125	<b>7-Year Sustained Efficacy, Safety, and Immunological Improvement With Fostemsavir-Based Regimens in Individuals With HIV and Limited Treatment Options</b> Judith A. Aberg (Icahn School of Medicine, Mount Sinai Health System, United States)	09:00 - 09:00
eP126	<b>Comparable efficacy but greater discontinuations due to adverse events with dolutegravir-containing two-drug versus three-drug antiretroviral therapy: a systematic review and meta-analysis</b> Cassandra Fairhead (Royal Free London NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP127	<b>Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study</b> Margaret Gartland (ViiV Healthcare, United States)	09:00 - 09:00
eP128	<b>Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a bictegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens</b> Chloe Orkin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP129	<b>Efficacy, and safety of ainoovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP130	<b>Efficacy, and safety of ainoovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP131	<b>Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives</b> Cassidy A Gutner (ViiV Healthcare, United States)	09:00 - 09:00
eP132	<b>Impact of switching from a bictegravir- or dolutegravir-based regimen with emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine on weight and metabolic profiles: a</b>	09:00 - 09:00

	<b>randomized, open-label, multicenter, parallel-group trial</b> Kensuke Minami (Jichi Medical University, Japan)	
eP133	<b>Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results</b> Arman Papadakis Sali (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP134	<b>Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study</b> Carlos Brites (Fundação Bahiana de Infectologia, Brazil)	09:00 - 09:00
eP135	<b>Switch to DOR/TDF/3TC in People With Controlled HIV and history of RNA genotype M184V/I mutation: Interim Results of the DRIVE OFF-ROAD Multicenter Single-Arm Phase II trial</b> Jean-Jacques Parienti (Caen University Hospital, France)	09:00 - 09:00
eP136	<b>Treatment outcomes in people with a late HIV diagnosis: A pooled analysis of participants with advanced HIV disease at diagnosis randomized to receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)</b> Jürgen K Rockstroh (University Hospital Bonn, Germany)	09:00 - 09:00
eP137	<b>LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT</b> Kaddu Muhamed yahya (Abacus parenteral drugs limited, Uganda)	09:00 - 09:00
eP138	<b>Physician specialties involved in prescribing BIC/F/TAF and concomitant drugs in people with HIV (PWH) in Germany: implications for potential drug to drug interaction (DDI)</b> Guido Schäfer (ICH MVZ Grindel, Germany)	09:00 - 09:00
eP139	<b>Virological Outcomes in People Living With HIV on INSTI-based cART Receiving Paclitaxel for Kaposi Sarcoma: A Retrospective Cohort Study</b> Niroshan Dayalan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP140	<b>A French national real-world survey of people with multi-resistant HIV-1 viruses treated with an antiretroviral regimen including fostemsavir</b> Charlotte Charpentier (Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, France)	09:00 - 09:00
eP141	<b>APOBEC-associated mutations in proviral HIV-DNA: assessing their impact on long-acting cabotegravir/rilpivirine treatment suitability</b> Giovanni Massobrio (University of Genoa/IRCCS Ospedale Policlinico San Martino, Italy)	09:00 - 09:00
eP142	<b>Applications and Clinical Utility of Proviral HIV DNA Resistance Testing in Routine Practice: A Real-World Analysis</b> Neva Braccialarghe (University of Rome Tor Vergata, Italy)	09:00 - 09:00
eP143	<b>Distribution of HIV-1 Subtypes and Genotypic Resistance Analysis in People Living with HIV: A 9-Year Retrospective Evaluation</b> Ashhan Candevir (Çukurova University, Turkey)	09:00 - 09:00
eP144	<b>Drug resistance analysis of HIV-1 variants circulated in migrants MSM and transgender women living in Moscow, Russia in 2020-2025</b> Ilya Lapovok (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP145	<b>Dual Validation through Trend Analysis and Spatiotemporal Profiling: A Decade-Long Roadmap for HIV Genotypic Resistance Testing Scale-Up in China's Universal Free ART Programs (2014-2023)</b>	09:00 - 09:00

	Defu Yuan (Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, China)	
eP146	<b>Durability of lenacapavir in viremic HTE PWH: real-world data from the PRESTIGIO Registry</b> Tommaso Clemente (IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP147	<b>Evidence of transmitted resistance to integrase strand transfer inhibitors (INSTIs) within local transmission clusters among antiretroviral therapy-naïve PLHIV in Greece</b> Evangelia Georgia Kostaki (National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP148	<b>Factors associated with maintenance of high CD4 counts in heavily treatment experienced multidrug resistance PWH: data from PRESTIGIO Registry</b> Maria Santoro (University of Rome "Tor Vergata", Italy)	09:00 - 09:00
eP149	<b>High virologic suppression in treatment-naïve people with HIV-1 on ainoovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP150	<b>HIV Drug Resistance in People Living with HIV (PLWH) in Congo: Implications for Optimizing Therapy in Resource-Limited Settings</b> Dominic Rauschnig (University Hospital Cologne, Germany)	09:00 - 09:00
eP151	<b>HIV-1 genetic diversity and transmitted drug resistance among newly diagnosed HIV-positive individuals in Eastern European and Central Asian countries</b> Alina Kirichenko (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP152	<b>HIV-2 Drug Resistance in Portugal: NGS data from 2023-2024</b> Fátima Gonçalves (Hospital de Egas Moniz- Unidade Local de Saúde de Lisboa Ocidental, Portugal)	09:00 - 09:00
eP153	<b>HIVANKA: Temporal Trends of Transmitted Drug Resistance and Subtype Distribution in Newly Diagnosed People in Ankara, Turkey (2016-2024)</b> MELIHA CAGLA SONMEZER (Hacettepe University Faculty Of Medicine, Turkey)	09:00 - 09:00
eP154	<b>Impact of PrEP on HIV-1 Diversity and Drug-Resistance Mutations in Newly Diagnosed HIV-1 Individuals in Málaga (Southern Spain) from 2016 to 2023</b> María López Jódar (Biomedical Research Institute of Malaga. Hospital Universitario Virgen de la Victoria, Spain)	09:00 - 09:00
eP155	<b>Integrase Resistance Mutations in Treatment-Naive Persons with Advanced Immunodeficiency Initiating Dual Therapy with Dolutegravir and Lamivudine</b> Maria Figueroa (Fundacion Huesped, Argentina)	09:00 - 09:00
eP156	<b>Potential for replacing the boosted-PI with doravirine in ART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen</b> Diego Ripamonti (ASST Papa Giovanni XXIII, Italy)	09:00 - 09:00
eP157	<b>Proviral DNA as a Reliable Tool for Resistance Testing in HIV-2: Long-Term Outcomes in a Portuguese Cohort</b> Inês Lopes (Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Portugal)	09:00 - 09:00
eP158	<b>Selection of antiretroviral resistance in treatment-experienced</b>	09:00 - 09:00



	<b>PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study</b> Anne-Genevieve Marcelin (Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, France)	
eP159	<b>Selection rate of resistance to Long-Acting CAB/RPV in a real life French cohort with strict inclusion and monitoring criteria</b> Sidonie LAMBERT-NICLOT (Santé Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique APHP, Hôpital Saint-Antoine, France)	09:00 - 09:00
eP160	<b>Switching to bicitegravir/emtricitabine/tenofovir alafenamide in highly treatment experienced people living with multidrug-resistant HIV</b> Jose Luis Casado Osorio (Ramon y Cajal Hospital, Spain)	09:00 - 09:00
eP161	<b>The profile of surveillance HIV resistance mutations in the migrant population of a tertiary hospital: a 4-year analysis</b> Gonçalo Cruz (ULS Coimbra, Portugal)	09:00 - 09:00
eP162	<b>The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry</b> Tommaso Clemente (IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP163	<b>Trends of HIV drug resistance and associated factors: an analysis of the Uganda national HIV drug resistance program data, 2021-2024</b> Bridget Ainembabazi (Uganda National Institute of Public Health, Uganda)	09:00 - 09:00
eP164	<b>CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF DORAVIRINE: IMPLICATIONS IN NEUROCOGNITIVE IMPAIRMENT</b> Qing Ma (University at Buffalo, United States)	09:00 - 09:00
eP165	<b>Pharmacogenetics of Dolutegravir and Bicitegravir Plasma and Intracellular Pharmacokinetics</b> Leïla Belkhir (Cliniques universitaires Saint-Luc, Belgium)	09:00 - 09:00
eP166	<b>Pharmacokinetics and Safety of MK-8527 in Adults With Moderate or Severe Renal Impairment</b> Jesse C. Nussbaum (Merck & Co., Inc., United States)	09:00 - 09:00
eP167	<b>Real-life switch to long-acting Cabotegravir/Rilpivirine ensures adequate drug levels without short-term impact on viral reservoir or inflammation: the Long-Icona Study</b> Roberta Gagliardini (INMI L. Spallanzani IRCCS, Italy)	09:00 - 09:00
eP168	<b>An audit of antiretroviral regimens in people living with HIV attending an HIV/sexual health clinic in Sydney's Inner West in response to the REPRIEVE study</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP169	<b>Effect of dolutegravir transition in HIV-positive adults at a university-based tertiary care hospital in Thailand</b> Rujipas Sirijatuphat (Mahidol University, Thailand)	09:00 - 09:00
eP170	<b>Safety and durability of treatment with Bicitegravir/Emtricitabine/Tenofovir Alafenamide in a real-life cohort</b> Nicola Squillace (Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Italy)	09:00 - 09:00
eP171	<b>Virologic Outcomes of Dolutegravir-Based ART Among Thai people with HIV Previously Treated with Lopinavir/ritonavir based Second-line regimens: A National Program Analysis</b> Anchalee Avihingsanon (HIVNAT, Thai Red Cross AIDS and Infectious	09:00 - 09:00

	Diseases Research Centre, Thailand)	
	<b>B2. Clinical Science - Co-infection</b>	09:00 - 09:00
eP172	<b>Immune correlates of protection vs vaccine hesitancy in people living with HIV: to be or not to be (vaccinated)</b> Alejandro Vallejo (Ramon y Cajal Hospital, Spain)	09:00 - 09:00
eP173	<b>Comparative Analysis of Mpox Cases in People Living with HIV in Lisbon and Rio de Janeiro During the 2022 Outbreak</b> Raffaele Junior Aliberti (Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Portugal)	09:00 - 09:00
eP174	<b>Enhanced immune response against mpox clade Ib and IIb after a booster dose of MVA-BN vaccine in a high-risk population</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP175	<b>Estimating Hard-to-reach Populations in South Korea Using Mpox Mathematical Modeling</b> Sol Kim (School of Mathematics and Computing (Mathematics), Yonsei University, Korea, Republic of)	09:00 - 09:00
eP176	<b>HIV and mpox co-infection in Israel: a cross-sectional comparative study</b> Zohar Mor (Ministry of Health, Israel)	09:00 - 09:00
eP177	<b>Mpox infection alters HIV-1 reservoir dynamics in ART-treated people with HIV</b> Guiomar Casado Fernández (Centro Nacional de Microbiología, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP178	<b>Mpox infection elicits stronger and more sustained T-cell responses than vaccination in people with HIV and PrEP users</b> Olivia de la Calle-Jiménez (National Center of Microbiology, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP179	<b>Mpox-Specific Humoral and Cellular Immune Responses up to two years from natural infection or MVA-BN vaccination</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP180	<b>Asymptomatic CMV Suppression with Letemovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383</b> John Koethe (Vanderbilt University Medical Center, United States)	09:00 - 09:00
eP181	<b>Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections in People Living (PLWH) with HIV Who Engage in Chemsex: A Descriptive Ambispective Study in Barcelona</b> Maria Martínez-Rebollar (HIV Unit, Infectious Diseases Service, Hospital Clínic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Spain)	09:00 - 09:00
eP182	<b>Experience using a Portable Fundus Camera to Prevention of Blindness in people living with HIV in Ukraine</b> Maryna Sira (L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Science of Ukraine, Ukraine)	09:00 - 09:00
eP183	<b>Influence of a 3-month letemovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP184	<b>Measles in People Living with HIV: A Comparative Analysis with</b>	09:00 - 09:00

	<b>HIV-Negative Patients</b> David Valentin Mangaloiu (Carol Davila University of Medicine and Pharmacy Bucharest, Romania, Romania)	
eP185	<b>Missed opportunities for early HIV diagnosis in people living with HIV in a Romanian tertiary care center</b> Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)	09:00 - 09:00
eP186	<b>Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis</b> Asta Maria Blom Nielsen (Copenhagen University Hospital - Rigshospitalet, Denmark)	09:00 - 09:00
eP187	<b>Resistance profiles and therapeutic approach of <i>Klebsiella pneumoniae</i> strains identified in people living with HIV and other hospitalized individuals</b> Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)	09:00 - 09:00
eP188	<b>Risk of Pneumocystis Pneumonia by CD4 Level in Ukrainian Adults Living With HIV: A Retrospective Analysis</b> Diana Shevchenko (Public Health Center of the Ministry of Health of Ukraine, Ukraine)	09:00 - 09:00
eP189	<b>Severe <i>Rhodococcus equi</i> in Late Presenters With HIV: A Case Series and Therapeutic Challenges</b> Ivana Gmizic (Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Serbia)	09:00 - 09:00
eP190	<b>Systematic Review and Meta-Analysis of Human Papilloma Virus Prevalence and Geno-type Disparity among HIV-positive Women in Africa</b> Yirga Wondu Amare (Pecs University, Hungary)	09:00 - 09:00
eP191	<b>Asociation between plasma inflammatory profile and sexually transmitted infections recurrence in PrEP users and people with HIV</b> Yolanda Campanero Núñez (Hospital Clínico San Carlos-IdISSC, Spain)	09:00 - 09:00
eP192	<b>Assessing the Impact of PrEP on STI Rates: a Real-World Multicenter Cohort from Milan</b> Donatella Maddalena (Luigi Sacco University Hospital, Italy)	09:00 - 09:00
eP193	<b>Awareness and attitudes toward Doxycycline Post-Exposure Prophylaxis (DoxyPEP) among MSM in Greece: A cross-sectional study</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP194	<b>Comparative effectiveness of 250 mg vs 500 mg ceftriaxone in treating uncomplicated gonorrhea in a country of a low prevalence of ceftriaxone-nonsusceptible <i>Neisseria gonorrhoeae</i></b> Tzong-Yow Wu (National Taiwan University Hospital Yunlin Branch, Taiwan)	09:00 - 09:00
eP195	<b>Doxycycline prophylaxis use among MSM attending a reference center for STI and HIV treatment in Rome</b> Alessandra Latini (San Gallicano Dermatological Institute IRCCS, Italy)	09:00 - 09:00
eP196	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Kyrgyz Republic</b> Anastasia Pokrovskaya (Central Research Institute of Epidemiology of Rospotrebnadzor, Russian Federation)	09:00 - 09:00

eP197	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Republic of Belarus</b> Anastasia Pokrovskaya (Central Research Institute of Epidemiology of Rospotrebnadzor, Russian Federation)	09:00 - 09:00
eP198	<b>Real-world effectiveness of doxycycline Post-Exposure Prophylaxis (DoxyPEP) in at-risk MSM in Greece</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP199	<b>Sexually transmitted infections at the time of HIV diagnosis in a sexual health clinic in Spain</b> Inés Armenteros (Centro Sanitario Sandoval - Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP200	<b>AIDS patients with Talaromycosis Marneffeii exhibit inflammatory activation and depletion in their peripheral blood monocytes</b> Pengle Guo (Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou Medical Research Institute of Infectious Diseases, China)	09:00 - 09:00
eP201	<b>Antiretroviral therapy in people with HIV and TB in France: a nationwide retrospective study between 2010 and 2023</b> Hugo Law-Koune (EPI-PHARE (GIS ANSM-CNAM), France)	09:00 - 09:00
eP202	<b>Characterisation of Cryptococcal meningitis - a 12-year retrospective study in a hospital in Lisbon, Portugal</b> Daniel Toscano (Hospital Professor Dr.Fernando Fonseca, Portugal)	09:00 - 09:00
eP203	<b>Epidemiological and Clinical Analysis and Outcomes of Tuberculosis Co-infection Among People Living with HIV in the Turkey ClinSurv HIV Cohort: A Large Case Series</b> Okan Derin (İstanbul Şişli Hamidiye Etfal Training and Research Hospital, Turkey)	09:00 - 09:00
eP204	<b>Factors associated with positive baseline Toxoplasma Gondii IgG antibodies among people living with HIV in recent years</b> Carlo Bieńkowski (Medical University of Warsaw, Poland)	09:00 - 09:00
eP205	<b>Health Outcomes of Individuals Living with HIV Affected by Chronic Neuroinfections in Sub-Saharan Africa: Early Insights from Mozambique</b> Helena Buque (Maputo Central Hospital,, Mozambique)	09:00 - 09:00
eP206	<b>Incidence of opportunistic infections among people living with HIV in Rwanda. Does Differentiated care delivery matters?</b> Mariam Salim Mbwana (Primary Health Care Institute, Tanzania)	09:00 - 09:00
eP207	<b>Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromycosis: a multicenter retrospective study</b> Biao Zhu (The First Affiliated Hospital, School of Medicine, Zhejiang University, China)	09:00 - 09:00
eP208	<b>Neuromeningeal tuberculosis in eighteen PLWHIV</b> NASSIMA BELABAS (UNIVERSITY - ALGERIA 1 - FACULTY OF MEDECINE ZIANIA ALGIERS , ALGERIA, Algeria)	09:00 - 09:00
eP209	<b>Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated Pneumocystis Pneumonia</b> Huan Xia (Tianjin Second People's Hospital, China)	09:00 - 09:00
eP210	<b>Predictors of Recurrence and Survival in HIV-Associated Nontuberculous Mycobacterial Infections: A 20-Year Retrospective Cohort Study</b> Johannes Zielke (Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf,	09:00 - 09:00

	Heinrich Heine University Düsseldorf, Germany)	
eP211	<b>Dynamic Sequential Organ Failure Assessment (SOFA) Score and quick SOFA (qSOFA) predict 30-day mortality in patients with HIV-associated Talaromycosis: a multicenter cohort study</b> Guanjing Lang (The First Affiliated Hospital, Zhejiang University School of Medicine, China)	09:00 - 09:00
eP212	<b>The most common nontuberculous mycobacteria species and their antibiotic resistance among people with HIV</b> Dagny Krankowska (Medical University of Warsaw and Hospital for Infectious Diseases, Poland)	09:00 - 09:00
eP213	<b>Tuberculosis Meningitis and Other Opportunistic Infections of the Central Nervous System in Persons Living with HIV: An Observational Cohort Study in Brazil</b> Mona Gardet (Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Brazil)	09:00 - 09:00
eP214	<b>Tuberculosis profile in a cohort of people living with HIV hospitalized at the National Institute for Infectious Diseases "Prof. Dr. Matei Bals" in Bucharest, Romania</b> Anca Negru (National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Romania)	09:00 - 09:00
eP215	<b>Determinants of Influenza, HBV, and Pneumococcal Vaccination Uptake in People Living with HIV: A Multilevel and Expert Survey Study</b> Hye Seong (Yonsei University College of Medicine, Korea, Republic of)	09:00 - 09:00
eP216	<b>Evaluating Immunization Rates in People Living with HIV based on Influenza Uptake</b> Lee Nguyen (University of California, Irvine School of Pharmacy and Pharmaceutical Sciences, United States)	09:00 - 09:00
eP217	<b>Hepatitis A and B immunization rates among MSM who are at high-risk sees potential for improvement</b> Sven Breitschwerdt (University Hospital Bonn, Germany)	09:00 - 09:00
eP218	<b>Immunity Gaps to Vaccine Preventable Diseases in People with HIV: Real-World Evidence from Japan</b> Michiko Koga (The University of Tokyo, Japan)	09:00 - 09:00
eP219	<b>Serological response to Engerix®-B vaccination in PLWHIV</b> Rita Patrocínio de Jesus (Hospital Prof. Doutor Fernando Fonseca, Portugal)	09:00 - 09:00
eP220	<b>Seropositivity and Vaccination Coverage of HBV, HAV, VZV, Measles, Rubella, and Mumps in People Living with HIV</b> Eunmi Yang (Hallym University Sacred Heart Hospital, Korea, Republic of)	09:00 - 09:00
eP221	<b>Extracellular Vesicle DNA cargo Mirrors Systemic Immune and Microbial Perturbations in People with HIV and HCV Coinfected Individuals</b> Sergio Grande Garcia (Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP222	<b>Factors Associated with HBs Antigen Seroclearance in People Living with HIV and Chronic Hepatitis B</b> Takashi Muramatsu (Tokyo Medical University Hospital, Japan)	09:00 - 09:00
eP223	<b>Impact of intravenous methamphetamine use on Direct-acting Antiviral Agents (DAAs) treatment in people living with HIV and hepatitis C in Mexico</b> Corazón Barrientos-Flores (Clinica Especializada Condesa, Mexico)	09:00 - 09:00
eP224	<b>Lipid dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV co-acquired clients: a retrospective study</b>	09:00 - 09:00

	Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)	
eP225	<b>Lipidomic Profiles After HCV Cure in People with HIV Reflect Changes Linked to Significant Liver Stiffness</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)	09:00 - 09:00
eP226	<b>Long-term persistence alterations in CD4 and CD8 T-cell profile after HCV elimination in people living with HIV</b> Manuel Llamas Adán (Carlos III Institute of Health, Spain)	09:00 - 09:00
eP227	<b>Low HCV Prevalence Among PLWH in Türkiye: Risk Factors and Treatment Gaps</b> Bilge Caglar (Haseki Training and Research Hospital, Turkey)	09:00 - 09:00
eP228	<b>Overt and Occult Hepatitis B Virus Infection among People Living with HIV/AIDS in Bulgaria</b> Radka Komitova (Medical University of Plovdiv, Bulgaria)	09:00 - 09:00
	<b>B3. Clinical Science - Co-morbidities and ageing</b>	09:00 - 09:00
eP230	<b>"The Platinum clinic", a collaborative HIV and Geriatric Medicine clinic for older people living with HIV in Dublin, Ireland</b> Clara O'Flaherty (St. James' Hospital Dublin, Ireland)	09:00 - 09:00
eP231	<b>A Cross-Sectional Comparison of Use of Frailty Assessment Tools in Older People Living with HIV</b> Chloe Knox (University Hospitals Sussex NHS Trust, United Kingdom)	09:00 - 09:00
eP232	<b>A retrospective review of referrals to specialist secondary care HIV-led and Gynaecology-led menopause clinics</b> Kimberley Forbes (St Stephen's Centre, Chelsea and Westminster Hospital, London, United Kingdom)	09:00 - 09:00
eP233	<b>Assessing health risks in ageing adults with HIV and stratifying outcomes thru the use of scores and scales</b> Michael Virata (Yale School of Medicine, United States)	09:00 - 09:00
eP234	<b>Cognitive and locomotor disorders in people living with HIV between 2007 and 2023: outcomes of the ANRS CO3 AQUIVIH-NA cohort</b> Fabrice Bonnet (CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, France)	09:00 - 09:00
eP235	<b>Evaluation of a Healthy Aging Score in a Cohort of Older Adults Living with HIV in Canada</b> Sharon Walmsley (University of Toronto, Canada)	09:00 - 09:00
eP236	<b>Four years frailty transitions in elderly adults living with HIV: Results from the SEPTAVIH Study</b> Clotilde Allavena (CHU Nantes, France)	09:00 - 09:00
eP237	<b>Frailty Screening in People Living with HIV Aged Over 65: Clinical Characteristics and Predictive Factors from a Real-World Cohort in a University Hospital in Florence, Italy</b> Gasparro Giuseppe (University of Florence, Italy, Italy)	09:00 - 09:00
eP238	<b>Gut microbiome and healthy aging in HIV: a sub-analysis of the CHANGE HIV cohort</b> Sharon Walmsley (University of Toronto, Canada)	09:00 - 09:00
eP239	<b>Neurocognitive Impairment in Older People Living with HIV: Preliminary Findings from a Geriatric Care Program</b> Liesbeth Delesie (Ghent University Hospital, Belgium)	09:00 - 09:00
eP240	<b>One score to rule them all? Or maybe not quite ...</b> Beatrice Barda (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00

eP241	<b>Predicting Frailty in Older People Living with HIV Using Machine Learning</b> Jaime Vera (Brighton and Sussex Medical School, United Kingdom)	09:00 - 09:00
eP242	<b>The Prevalence and Predictors of elevated HOMA-IR in People Living with HIV (PLWH)</b> Shu-Ying Chang (Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan)	09:00 - 09:00
eP243	<b>Understanding Frailty and Aging in People Living with HIV in Kazakhstan: A Pilot Investigation</b> Balnur Iskakova (Asfendiyarov Kazakh National Medical University, Kazakhstan)	09:00 - 09:00
eP244	<b>A Comparative Analysis of Echocardiographic Findings in People Living With HIV and Healthy Volunteers</b> AYTAN SEYDALIYEVA (Koç University Hospital, Turkey)	09:00 - 09:00
eP245	<b>A Comparative Analysis of HbA1c, Glycated Albumin, and Fasting Plasma Glucose for Glycemic Assessment in People Living with HIV</b> Tun-Chieh Chen (Kaohsiung Medical University, Taiwan)	09:00 - 09:00
eP246	<b>A rapid scoping review of tools and approaches for medication adherence screening and assessment</b> Nicola Galbraith (Gilead Sciences Ltd, United Kingdom)	09:00 - 09:00
eP247	<b>Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway</b> Kate Alford (Brighton and Sussex Medical School, United Kingdom)	09:00 - 09:00
eP248	<b>Association of Biomarker Clusters With Lung Disease and Mortality in People With HIV</b> Ioannis Konstantinidis (University of Pittsburgh School of Medicine, United States)	09:00 - 09:00
eP249	<b>Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and Incident Hypertension in People With HIV</b> Josefine Loft (Copenhagen University Hospital - Rigshospitalet, Denmark)	09:00 - 09:00
eP250	<b>Bempedoic Acid and Evolocumab Use in People Living with HIV: A Real-World Snapshot of Lipid-Lowering Strategies in Statin-Intolerant or Reluctant individuals</b> Marianna Menozzi (University Hospital of Modena, Italy)	09:00 - 09:00
eP251	<b>Changes in Metabolic Parameters after Switching from Efavirenz to Dolutegravir-based Regimen: A Cohort Study in Thai People Living with HIV</b> Pitchaporn Chongyangyuenvong (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP252	<b>Clinical Features of Transgender People Living with HIV Throughout Europe: multimorbidity and polypharmacy</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP253	<b>Confusion in the sky: to score or not to score?</b> Beatrice Barda (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00
eP254	<b>Determinants of Weight Change in HIV-Positive Individuals Receiving Antiretroviral Therapy</b> EMİNE İLAY DUMAN (University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Turkey)	09:00 - 09:00
eP255	<b>Eating habits and possible effects of Mediterranean diet on body composition in ageing people living with HIV</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University)	09:00 - 09:00

	Hospital, Padua, Italy, Italy)	
eP256	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident cardiovascular events</b> Stefan Esser (University Hospital Essen, University Duisburg Essen, Germany)	09:00 - 09:00
eP257	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident diabetes mellitus</b> Stefan Esser (University Hospital Essen, University Duisburg Essen, Germany)	09:00 - 09:00
eP258	<b>Effects of high-dose probiotic supplementation on immune activation and neurocognitive disorders in people living with HIV on successful antiretroviral treatment: the ProCog study</b> Matteo Vassallo (Centre hospitalier de Cannes, France)	09:00 - 09:00
eP259	<b>Enhancing Transplant Access for People with HIV: A Comparative Study of Liver and Kidney Transplant Outcomes from donors with or without HIV</b> Adriana Cervo (Infectious Diseases Unit, University Hospital of Modena, Italy)	09:00 - 09:00
eP260	<b>Epicardial adipose tissue thickness and cardiometabolic risk in people living with HIV: A comparative study of TAF- and TDF-based regimens</b> Beyza Erol (Katip Celebi University Ataturk Training and Research Hospital, Turkey)	09:00 - 09:00
eP261	<b>From wasting to gaining: The impact of BMI changes on dyslipidemia risk in people living with HIV</b> Jisun Chung (The catholic university of korea, Korea, Republic of)	09:00 - 09:00
eP262	<b>Genetic influence of TM6SF2 rs58542926 genotype on significant liver fibrosis in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD)</b> Win Min Han (HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand; The Kirby Institute, Sydney, Australia, Thailand)	09:00 - 09:00
eP263	<b>How do people living with HIV sleep?</b> Macha Tetart (Tourcoing Hospital, France)	09:00 - 09:00
eP264	<b>Hypertension in People with HIV Starting ART: Association with Regimen Class</b> Jose I Bernardino (Hospital Universitario La Paz. IdiPAZ, Spain)	09:00 - 09:00
eP265	<b>Impact of a Mediterranean Diet-Based Nutritional Intervention on Lipid Profile in People Living with HIV: Interim Results at Week 24 from a Randomized Controlled Clinical Trial</b> Esperanza Cañas-Ruano (Hospital del Mar, Spain)	09:00 - 09:00
eP266	<b>Implementation of FIB-4 Screening and Determinants of Liver Fibrosis Among People Living with HIV: A Real-World Cohort Study</b> Olivier Robineau (Centre Hospitalier Gustave Dron, France)	09:00 - 09:00
eP267	<b>Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT, a randomized phase 3 trial</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP268	<b>Improved body weight, lipid and immune profile and adipose tissue gene expression after a 48-week switch from an INSTI regimen to DOR/3TC/TDF in persons with HIV with INSTI-associated weight gain: The ADDORE study</b>	09:00 - 09:00



	J Capeau (Sorbonne Université, Inserm UMR_S938, CRSA, ICAN, France)	
eP269	<b>Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort</b> Ana Luz Cano Díaz (Instituto Mexicano Del Seguro Social, Mexico)	09:00 - 09:00
eP270	<b>Incidental Detection of Gynecomastia and Adipomastia on Chest CT in Male People Living with HIV: An Opportunistic Imaging Assessment</b> Veysel Akca (Mugla Sitki Kocman University Faculty of Medicine, Turkey)	09:00 - 09:00
eP271	<b>Influence of HIV status on organ procurement and allocation: A Discrete Choice Experiment among Australian Transplant Providers</b> David WJ Griffin (Alfred Health, Australia)	09:00 - 09:00
eP272	<b>Insights from Gut Microbiome Profiling: <i>Eutepia spp.</i> as a Distinctive Marker of Leanness in People with HIV</b> Mackenzie Joe (McGovern Medical School at UTHealth Houston, United States)	09:00 - 09:00
eP273	<b>Longitudinal changes of coronary artery calcium score (CACS) in persons with HIV</b> Maithili Varadarajan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP274	<b>Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to ainoovirine coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP275	<b>Long-term Lipid Metabolism Benefits of Switching to Ainoovirine-based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP276	<b>Medication Optimization in Older People Living with HIV: A Multidisciplinary Approach</b> Fatma Nisa Ballı Turhan (Gazi University Faculty of Pharmacy, Department of Clinical Pharmacy, Turkey)	09:00 - 09:00
eP277	<b>Metabolic Liver Disease in Newly Diagnosed People Living with HIV: MASHIV-TR COHORT</b> Mustafa Kemal Celen (Dicle University, Turkey)	09:00 - 09:00
eP279	<b>Monocyte polarization is related to Atherosclerosis in People Living with HIV on Suppressive ART</b> Javier Lozano-Gerona (John A. Burns School of Medicine, University of Hawaii, United States)	09:00 - 09:00
eP280	<b>Neurocognitive Screening in people living with HIV: 5-year referral and outcomes review</b> Shimu Allan (Royal Free NHS Foundation Trust, Royal Free Hospital, United Kingdom)	09:00 - 09:00
eP281	<b>Non-linear relationships between inflammatory markers and erectile dysfunction in a group of young men living with HIV</b> Federico Cesanelli (University of Brescia, Italy)	09:00 - 09:00
eP282	<b>Obesity in People Living with HIV: A Retrospective Analysis of a cardiovascular disease Risk Clinic Cohort</b> Alice Alicerces (Garcia de Orta Hospital, Portugal)	09:00 - 09:00
eP283	<b>People with HIV at high cardiovascular risk were undertreated with statins independent of gender</b>	09:00 - 09:00

	Maximilian Platte (University Hospital Duisburg-Essen, Germany)	
eP284	<b>Physical inactivity is associated with persistent steatotic liver disease in people with HIV</b> Eloïse Magnenat (Inselspital, Bern University Hospital, Switzerland)	09:00 - 09:00
eP285	<b>Preserved renal function in PWH on a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT study, a randomized phase 3 trial</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP286	<b>Prevalence and Predictors of Obesity and Metabolic Syndrome in HIV-Positive Individuals: A Cross-Sectional Study from Türkiye</b> EMİNE İLAY DUMAN (University of Health Sciences, İzmir Bozyaka Education and Research Hospital, Turkey)	09:00 - 09:00
eP287	<b>Prevalence and risk factors of liver fibrosis in metabolic associated fatty liver disease (MAFLD) among people living with HIV(PLWH) in Shanghai</b> Wei Xu (Shanghai Public Health Clinical Center, China)	09:00 - 09:00
eP288	<b>Prevalence of Steatotic Liver Disease Phenotypes and Clinically Significant Fibrosis Predictors Among People With HIV in The Middle East Region: A Multicenter Study</b> Ahmed Cordie (Cairo University Hospitals HIV Clinic, Endemic Medicine Department, Cairo University, Egypt)	09:00 - 09:00
eP289	<b>Progressive Pulmonary Artery Enlargement in Aging, Virologically Suppressed People With HIV: A 7-Year CT Imaging Study</b> Napon Hiranburana (The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand)	09:00 - 09:00
eP290	<b>Prospective evaluation of cardiovascular risk in PLWH receiving LA-cabotegravir/rilpivirine</b> Marco Bongiovanni (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00
eP291	<b>Relationships Between Lung Health Indicators and Depressive Symptoms, Anxiety, Resilience, and Social Support among Women with HIV</b> Jun Y. Byun (University of Alabama at Birmingham, United States)	09:00 - 09:00
eP292	<b>Research on the Diagnostic Value in Cerebrospinal Fluid and Blood Biomarkers of HIV-Associated Neurocognitive Disorders</b> Jiaqi Wei (Capital Medical University, China)	09:00 - 09:00
eP293	<b>Same Patients, Different Risks: A Head-to-Head of ESC and EACS CVD Guidelines in PLWH</b> Katia Falasca (University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, Italy)	09:00 - 09:00
eP294	<b>Semaglutide Improves Markers of Cardiovascular Risk in People With HIV: The SLIM LIVER Study</b> Jordan Lake (UTHealth Houston, United States)	09:00 - 09:00
eP295	<b>Serum Uric Acid Dynamics in Chinese HIV Patients: A 20-Year Cohort Study</b> Xin Huang (Peking Union Medical College Hospital, China)	09:00 - 09:00
eP296	<b>Severe Acute Chemsex Intoxications in People Living With HIV: Clinical Insights from a Tertiary-Care ID-ICU</b> Ana Sofia Santos (Centro Hospitalar de São João / ULS São João, Portugal)	09:00 - 09:00
eP297	<b>Statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00

eP298	<b>Study on the impact and mechanisms of R-CHOP-Based immunochemotherapy on immune status in ARL people</b> Biao Zhu (The First Affiliated Hospital, School of Medicine, Zhejiang University, China)	09:00 - 09:00
eP299	<b>The FIB-4 is a marker of macrophage activation independently from hepatic disease in people living with HIV on stable and successful treatment</b> Matteo Vassallo (Centre hospitalier de Cannes, France)	09:00 - 09:00
eP300	<b>Understanding hospitalization among people living with HIV (PLWH) in the combination antiretroviral therapy (cART) era: a single-centre retrospective study</b> Antonella Gallicchio (Ospedali dei colli - Cotugno, Italy)	09:00 - 09:00
eP301	<b>Use of statins mitigates the impact of smoking on frailty trajectories in people with HIV: a longitudinal cohort study</b> Jovana Milic (University of Modena and Reggio Emilia, Italy)	09:00 - 09:00
eP302	<b>Weight gain and metabolic complications in a large prospective cohort of overweight and obese people with HIV</b> Lucia Taramasso (Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy, Italy)	09:00 - 09:00
eP303	<b>Women living with HIV in Australia: Development of a clinical monitoring tool to address gender-specific care gaps and standardize care</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP304	<b>A Multidisciplinary Approach to Enhance Quality of Life in Older People Living with HIV: A Comparative Study</b> Fatma Nisa Ballı Turhan (Gazi University Faculty of Pharmacy, Department of Clinical Pharmacy, Turkey)	09:00 - 09:00
eP305	<b>Addressing patient-reported outcome measures (PROMs) in routine care does not improve patient's perspective on the receipt of patient-centered care and self-management behavior</b> Roos D Klungers (University of Amsterdam, Netherlands)	09:00 - 09:00
eP306	<b>Ageing with HIV in France: When PLHIV Needs and Clinical Practice Diverge</b> Daniela Rojas Castro (MoiPatient, France)	09:00 - 09:00
eP307	<b>Assessment of Neurocognitive Functions and Intellectual Capacity in People Living with HIV: A Case-Control Study</b> Yasemin Çakır Kıymaz (Sivas Cumhuriyet University, Turkey)	09:00 - 09:00
eP308	<b>Disability and Physical Activity among Adults Living with HIV in the United Kingdom, Ireland, United States and Canada: A Structural Equation Model Using the Episodic Disability Questionnaire</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP309	<b>Effectiveness of Aerobic Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP310	<b>Effectiveness of Progressive Resistive Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP311	<b>Factors Influencing the Quality of Life Among Men Who Have Sex with Men Living with HIV at an STD Center in Northern Taiwan</b> HsinHao Lai (Division of Infectious Diseases, Taipei City Hospital, Yang-Ming Branch, Taiwan)	09:00 - 09:00

eP312	<b>Integrating HIV and Mental Health Care in Prison: A Complex but Achievable Goal</b> Frederico Duarte (Hospital Pedro Hispano, Portugal)	09:00 - 09:00
eP313	<b>Internalized HIV Stigma and Its Influence on Reproductive Intentions of Women Living with HIV in Kazakhstan</b> Batyrbek Assembekov (Asfendiyarov Kazakh National Medical University, Kazakhstan)	09:00 - 09:00
eP314	<b>Internalized Stigma and Its Impact on Mental Health and Quality of Life among People Living with HIV in Mauritius</b> Monica Pudaruth (PILS (Prévention Information et Lutte contre le SIDA), Mauritius)	09:00 - 09:00
eP315	<b>Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects</b> Francesco Romano (Sapienza University of Rome, Policlinico Umberto I, Italy)	09:00 - 09:00
eP316	<b>Neurocognitive impairment is associated with functional performance deficits and compromised adherence during follow up in people living with HIV</b> Jose Luis Casado Osorio (Ramon y Cajal Hospital, Spain)	09:00 - 09:00
eP317	<b>Oral Lesions in People Living with HIV (LINING HIV)</b> Emmanouil Angelos Rigopoulos (University General Hospital of Patras, Greece)	09:00 - 09:00
eP318	<b>Outcomes of a mental health screening in a cohort of people with HIV</b> Peacchaima Purusothman (Hospital Tengku Ampuan Rahimah, Klang, Malaysia)	09:00 - 09:00
eP319	<b>Poor Sleep and MASLD are Common in People with HIV and Contribute to Poor Health-Related Quality of Life</b> Ana N Hyatt (UTHealth Houston, United States)	09:00 - 09:00
eP320	<b>Sexual satisfaction in men with HIV aged ≤50 years explored with standardized validated questionnaires: prevalence and patterns of various sexual dysfunction, and association with psychosocial factors</b> Nicola Squillace (Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Italy)	09:00 - 09:00
eP321	<b>Social support and mental health in People Living with HIV: A cross-sectional analysis from a Greek cohort</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP322	<b>KS evolution in HIV aviremic PLWH: a prospective cohort of the French CancerVIH Network</b> Alain Makinson (CHU de Montpellier, France)	09:00 - 09:00
eP323	<b>Prevalence of high-risk human papillomavirus and anal precancerous lesions among men who have sex with men living with HIV in Hong Kong</b> T S Kwong (Queen Elizabeth Hospital, Hong Kong)	09:00 - 09:00
eP324	<b>Real-World Clinical Insights into Underrecognized Differences in Prostate Cancer Among People Living with HIV</b> Kyoko Yoshida (Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Japan)	09:00 - 09:00
eP326	<b>Update on German-Austrian Guideline on Screening for Anal Dysplasia and Anal Carcinoma in People Living with HIV</b> David Chromy (Medical University of Vienna, Austria)	09:00 - 09:00

	<b>B4. Clinical Science - Pregnancy, children and adolescents</b>	09:00 - 09:00
eP327	<b>Unintended Pregnancy Among Adolescents Living with HIV in Africa: A Systematic Review</b> Mackline Hope (Infectious Diseases Institute, Uganda)	09:00 - 09:00
eP328	<b>HIV diagnosis in pregnancy accounts for 18% of all diagnoses and may reduce advanced stage HIV diagnosis in women over 30 years in the Netherlands</b> Colette Smit (Stichting HIV Monitoring, Netherlands)	09:00 - 09:00
eP329	<b>Life expectancy of premature babies born to HIV-positive mothers</b> Fatima zohra Bensadoun (Faculté de médecine d'Oran, Algeria)	09:00 - 09:00
eP330	<b>cART use in pregnancy: a real-life experience in Italy</b> Elena Zaninetta (Clinica Malattie Infettive, Università di Milano, ASST Santi Paolo e Carlo, Italy)	09:00 - 09:00
eP331	<b>MISSED OPPORTUNITY: HIV-1 TRANSMISSION CHAIN ACROSS THREE GENERATIONS</b> Ulrike Elisabeth Haars (Infektiologie Krefeld, Germany)	09:00 - 09:00
eP332	<b>Pregnancy monitoring in HIV-serodifferent couples: Support and medical monitoring</b> Fatima zohra Bensadoun (Faculté de médecine d'Oran, Algeria)	09:00 - 09:00
	<b>C1. Epidemiology/ public health / models of care</b>	09:00 - 09:00
eP333	<b>A Multidisciplinary Offer to Support Emerging Practices: Feedback from the Lounge in Toulouse Dedicated to People Engaging in Chemsex</b> Ali Fendri (AIDES, Occitanie, France)	09:00 - 09:00
eP334	<b>Acceptability, feasibility, and systemic challenges of community-based antiretroviral therapy delivery model in Cambodia: A qualitative evaluation using the Framework Method</b> Ziya Tian (National University of Singapore, Singapore)	09:00 - 09:00
eP335	<b>Adaptation and preliminary outcomes of the Community Health Worker Optimization of Antihypertensive Care in HIV (COACH) program: an intervention to address hypertension among people with HIV (PWH) in Tanzania</b> Preeti Manavalan (University of Florida, United States)	09:00 - 09:00
eP336	<b>AI-ntiretroviral preferences</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP337	<b>ANALYSIS OF THE CLINICAL COMPLEXITY OF PEOPLE LIVING WITH HIV BASED ON THE GESIDA STRATIFICATION SYSTEM</b> Carolina Olmos Mata (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP338	<b>ARE WE STILL TOO LATE? MISSED OPPORTUNITIES IN THE DETECTION OF HIV</b> Sara Gómez García (Hospital Clínico Universitario de Valladolid, Spain)	09:00 - 09:00
eP339	<b>Closing the HIV Testing Gap: Readiness of Pharmacy staff Providing Other Prevention Screenings</b> Natalie Crawford (Emory University, United States)	09:00 - 09:00
eP340	<b>Costs Associated With People With HIV in France</b> Alexandre Vimont (Public Health Expertise, France)	09:00 - 09:00
eP341	<b>Decentralization of Care? A Comparison of Primary Care Services and Specialized Services in the Care of People Living with HIV in a State in Southern Brazil</b> Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED),	09:00 - 09:00

	Brazil)	
eP342	<b>Demographic and Risk Profile Analysis of Users Accessing PrEP Through a Paid Digital Service in the Netherlands: Exploring PrEP Uptake Patterns Beyond Traditional Settings</b> John White (Preventx, United Kingdom)	09:00 - 09:00
eP343	<b>Enhancing HIV Self-Testing Uptake through Syringe Vending Machines: A Case Study in Tbilisi, Georgia</b> Irma Kirtadze (Ilia State University, Georgia)	09:00 - 09:00
eP344	<b>EXPERIENCE OF STRUCTURING A TRANSGENDER-SPECIFIC HIV OUTPATIENT CLINIC AT INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS: AN INTEGRATED CARE PATHWAY MODEL</b> Pisci Bruja Garcia de Oliveira (Instituto de Infectologia Emílio Ribas, Brazil)	09:00 - 09:00
eP345	<b>Exploring barriers to pre-exposure prophylaxis among HIV people initiating antiretroviral therapy in Portugal: the POSITIVE CARE study</b> Laura Paixão (MSD Portugal, Portugal)	09:00 - 09:00
eP346	<b>Exploring the Awareness, Attitudes, and Preferences of People Living with HIV Toward Long-Acting Injectable Treatments</b> Berna Karaismailoğlu (Basaksehir Cam and Sakura City Hospital, Turkey)	09:00 - 09:00
eP347	<b>General and Family Doctors' perspectives regarding their knowledge, preparedness level and challenges in preventing the Human Immunodeficiency Virus transmission</b> José Ganicho (ULS São José, Portugal)	09:00 - 09:00
eP348	<b>Health care perspectives of People Living with HIV in Central and Eastern Europe (CEE): Results from a Multi-Country Survey</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP349	<b>HIV PrEP Need, Availability, and Potential Pharmacy Integration: A Rural-Urban Analysis in the Southern US</b> Siena Senn (Rollins School of Public Health at Emory University, United States)	09:00 - 09:00
eP350	<b>HIV Viewpoints: Survey on the Treatment Experiences of People Living with HIV in Europe</b> Megan Dunbar (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP351	<b>Impact of COVID-19 Pandemic on Treatment Outcomes among People Living with HIV in Thailand: A Nested Case-control Study</b> Arnon Techapongsatorn (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP352	<b>Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified and differentiated PrEP delivery</b> Nicoletta Frattini (Milano Check Point ETS, Italy)	09:00 - 09:00
eP353	<b>Inpatient burden and diagnosis-specific trends in a dedicated HIV department (2011-2024): a thirteen-year review</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP354	<b>Introducing late HIV diagnosis cohort reviews in Wales: Exploring missed opportunities for testing</b> Sophie Harker (Public Health Wales, United Kingdom)	09:00 - 09:00
eP355	<b>Linkage to Care and ART initiation: A Retrospective Analysis to guide implementation of rapid ART initiation in outpatient setting</b> Bonnie Chun Kwan Wong (Department of Health, Hong Kong)	09:00 - 09:00

eP356	<b>Mental Well-being and the Work Environment among Healthcare Workers Taking Care of PLWH - Data from the Euroguidelines in Central and Eastern Europe Network Group</b> Agata Skrzat-Klapaczynska (Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Poland, Poland)	09:00 - 09:00
eP357	<b>Navigating PrEP prescription: An exploratory study on barriers and facilitators among healthcare providers in North Louisiana</b> Camila Castro (Unichristus, Brazil)	09:00 - 09:00
eP358	<b>Outcomes of rapid anti-retroviral therapy (ART) initiation in London, UK</b> Gary Whitlock (Chelsea & Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP359	<b>Prevalence of HIV Indicator Conditions in People with Late Diagnosis of HIV, 25 years on: Are we still missing opportunities for earlier care?</b> Ella Spear (Monash Health, Australia)	09:00 - 09:00
eP360	<b>Provider willingness to discuss and prescribe pre-exposure prophylaxis (PrEP) with women at risk of HIV in Kazakhstan</b> Tara McCrimmon (Columbia University Mailman School of Public Health, United States)	09:00 - 09:00
eP361	<b>Quality improvement project aimed at reducing costs of unnecessary investigations in HIV outpatient clinics</b> Aarzo Bhatia (Manchester University Foundation Trust, United Kingdom)	09:00 - 09:00
eP362	<b>Reasons for ART interruption related to the war in Ukraine</b> Kseniia Voronova (AIDS Healthcare Foundation, Ukraine)	09:00 - 09:00
eP363	<b>Reorganizing a HIV clinic in northern Italy for the implementation of Long-Acting Cabotegravir/Rilpivirine for HIV Treatment with limited resources</b> Layla Pagnucco (Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo- University of Pavia - Italy, Italy)	09:00 - 09:00
eP364	<b>Response patterns to a patient-reported outcomes assessment (MyPRO) among racialized women living with and without HIV in a community health clinic in Toronto, Canada</b> Duncan Short (ViiV Healthcare, United Kingdom)	09:00 - 09:00
eP365	<b>Retention of clients diagnosed through Secondary HIV self-testing: A longitudinal analysis over 12 months in Johannesburg, South Africa</b> Mabjala Rosemary Letsoalo (Sefako Makgatho University, South Africa)	09:00 - 09:00
eP366	<b>Risk factors for sexually transmitted infections in men attending clinics in Jerusalem compared with Tel Aviv</b> Karen Olshtain Pops (Hebrew University Medical Center, Israel)	09:00 - 09:00
eP367	<b>Serum cryptococcal antigen titer as predictor of disseminated Cryptococcosis in people living with HIV</b> Victoria Pinto (Hospital General de Agudos Dr. Juan A. Fernández, Argentina)	09:00 - 09:00
eP368	<b>Significant discrepancies Between Clinical Practice and Medical Guidelines for HPV management in HIV - data from ECEE Network Group</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP369	<b>Stigma in the Healthcare Environment: Invisible Barriers</b> Azucena Bautista Hernández (Fundación de investigación biomédica)	09:00 - 09:00

	Hospital de la Princesa. CIBERINFECC., Spain)	
eP370	<b>Telehealth as a tool for expanding PrEP in Argentina</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP371	<b>Tunisian women living with HIV: assessing characteristics and vulnerabilities</b> Rajah Rezgui (La Rabta Hospital, Tunisia)	09:00 - 09:00
eP372	<b>Clinical characteristics and treatment patterns among people living with HIV by ART use in the US, 2021-2024</b> Arlene Nugent (AbbVie Inc., United States)	09:00 - 09:00
eP373	<b>Evaluation of Compliance with EACS Guidelines: Analysis of Error Rates at Baseline, 3, 6, and 12 Months</b> Ece Demirkirkan (Basaksehir Cam and Sakura City Hospital, Turkey)	09:00 - 09:00
eP374	<b>Factors associated with advanced HIV presentation among individuals referred for inpatient rehabilitation: A continuum of care perspective</b> Divyan Moodley (Mildmay Hospital, United Kingdom)	09:00 - 09:00
eP375	<b>HIV COINFECTION AMONG INDIVIDUALS BELONGING TO KEY GROUPS IN UKRAINE</b> Olena Hridasova (AIDS Healthcare Foundation, Ukraine)	09:00 - 09:00
eP376	<b>Outcomes of Rapid Initiation of Antiretroviral Therapy Among People Living with HIV: Real-world Experience from A Tertiary Care Hospital in Thailand</b> Niti Aueaphongkarun (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP377	<b>"Bridging the Last Mile: A Low-Cost, Gender-Responsive Model Integrating Real-Time Viral Load Dashboards and Task-Shifting in Rural Nigeria"</b> Okeoghene Akusu (National Aids & STI's Control Program, Nigeria)	09:00 - 09:00
eP378	<b>Addressing health inequities in HIV testing: Effectiveness of activation of community-based networks and use of app technology to reach and support diverse, marginalized and underserved populations to access HIV self-testing in Canada</b> Sean B. Rourke (Unity Health Toronto, Canada)	09:00 - 09:00
eP379	<b>Breaking STI Chains with <i>Con-Tacto</i>: Acceptability of an Anonymous Partner Notification App Among PrEP Users</b> Felix Straga Napolitano (Hospital Parc Tauli, Spain)	09:00 - 09:00
eP380	<b>Challenges in implementing a strategy for the triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B: the experience of the TRI-MOM project in The Gambia</b> SEYDOU DRABO (Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, France)	09:00 - 09:00
eP381	<b>Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis</b> Toshibumi Taniguchi (Chiba University Hospital, Japan)	09:00 - 09:00
eP382	<b>How Rapid is the Recommended Timing of Antiretroviral Therapy Initiation? Preliminary Findings from a Scoping Review of HIV Clinical Guidelines</b> Moustafa Laymouna (Faculty of Medicine and Health Sciences, McGill University, Canada)	09:00 - 09:00
eP383	<b>If we build it, will they come? Pharmacists' perspectives on recruiting people to a pharmacy-based sexually transmitted and bloodborne infection (STBBI) testing service</b>	09:00 - 09:00



	Deborah Kelly (Memorial University of Newfoundland, Canada)	
eP384	<b>Introducing the CROSS framework for developing and implementing inclusive and scalable research: Insights from the co-production and delivery of a cross-country HIV survey with migrant women within EACS/WAVE's SERAY project (Strengthening health Equity Research through Active involvement of Non-Governmental Organisations and migrant women)</b>	09:00 - 09:00
	Melvina Woode-Owusu (University College London, United Kingdom)	
eP385	<b>Negative Beliefs About Methadone and Barriers to Opioid Agonist Therapy in Kazakhstan: Findings from a Multi-City RDS Study</b>	09:00 - 09:00
	Assel Terlikbayeva (Center for Scientific and Practical Initiatives, Kazakhstan)	
eP386	<b>Piloting the digital distribution and implementation of the Positive Outcomes PROM in HIV Outpatients</b>	09:00 - 09:00
	Rebekah Morris (University Hospitals Sussex NHS Foundation Trust, United Kingdom)	
eP387	<b>Psychosocial Needs in Migrants with HIV: Implications for Care</b>	09:00 - 09:00
	Joanna Cano-Smith (La Paz- Carlos III University Hospital, Spain)	
eP388	<b>The impact of Shared Decision-Making on Long-Acting Injectable Antiretroviral Therapy in People Living with HIV in Taiwan</b>	09:00 - 09:00
	LIAN LIN (Chung Shan Medical University hospital, Taiwan)	
eP389	<b>Using Mixed-Methods Operations Research to Evaluate Community-Led Monitoring for Improved HIV Service Delivery in Nigeria</b>	09:00 - 09:00
	Joy Egwu (National Agency for the Control of AIDS, NACA Abuja, Nigeria)	
eP390	<b>Willingness and Ability of People Living with HIV to use Patient-Reported Outcome Measures in Routine HIV Care: Preliminary Results from the PRO-CARE Study</b>	09:00 - 09:00
	Olivia Borchmann (Copenhagen University Hospital, Hvidovre, Denmark)	
eP391	<b>Causes of Death in People Living with Human Immunodeficiency Virus in Türkiye: A Multicentre Retrospective Study</b>	09:00 - 09:00
	Selda Sayın Kutlu (Pamukkale University, Turkey)	
eP392	<b>Challenges in Managing People Living with HIV in Critical Care: Experience from Mexico</b>	09:00 - 09:00
	Paulina Carreño Pérez (Instituto Nacional de Enfermedades Respiratorias, Mexico)	
eP393	<b>Unstable housing and its associations with mental health and alcohol use among persons living with HIV (PLWH): Findings from the Florida Cohort Wave 4 survey</b>	09:00 - 09:00
	Yan Wang (University of Florida, United States)	
eP394	<b>Demographics of under-housed individuals living with HIV in British Columbia, Canada</b>	09:00 - 09:00
	Christina Wiesmann (Simon Fraser University, Canada)	
eP395	<b>Epidemiological Profile of Pregnant Women Living with HIV in Brazil: A Cross-Sectional Analysis of National Surveillance Data</b>	09:00 - 09:00
	Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED), Brazil)	
eP396	<b>Epidemiology of Human Immunodeficiency Virus HIV in Tunisia in 2024</b>	09:00 - 09:00
	Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	
eP397	<b>Estimating HIV incidence and associated risk factors using longitudinal community-based testing data across the WHO European Region: Insights from the COBATEST Network</b>	09:00 - 09:00

	Laura Fernàndez-López (Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain)	
eP398	<b>HIV seropositivity in Key or Vulnerable Population at higher risk: results of rapid testing program in the Russian Federation during 2020-2024</b> Alexander Chuykov (AHF Russia, Russian Federation)	09:00 - 09:00
eP399	<b>Impact of the COVID-19 Pandemic on HIV Case Detection in Georgia: An Interrupted Time Series Analysis (2018-2024)</b> Otar Chokoshvili (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP400	<b>Incidence of HIV and STI After Initiating Pre-Exposure Prophylaxis, Among Men who have Sex with Men in Georgia: Findings from Routine Program Surveillance, 2020-2024</b> Otar Chokoshvili (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP401	<b>Knowledge, Attitude and Practice on HIV/AIDS among University Students in Kilimanjaro Region aged 18 to 45 years. A Cross Sectional Study</b> Simon Ernest (KCMC University, Tanzania)	09:00 - 09:00
eP402	<b>MIGRATION AND HIV IN LATIN AMERICA: A MULTICENTER REGIONAL DESCRIPTIVE STUDY</b> María Marta Greco (Hospital Español La Plata, Argentina)	09:00 - 09:00
eP403	<b>Migration-Linked Transmission of HIV-1 Subtype A6 in Europe: Evidence from Multinational Molecular Cluster Analysis</b> Karol Serwin (Pomeranian Medical University in Szczecin, Poland)	09:00 - 09:00
eP404	<b>Missed Lessons, Missed Protections: Strengthening Adolescent STI and HIV Awareness Through Targeted Educational Interventions</b> Gunda Waldmann (University Hospital, LMU Munich, Germany)	09:00 - 09:00
eP405	<b>Missed Opportunities and Factors Associated with Late Diagnosis of HIV Infection in the Era of Rapid Testing</b> Federico Daniel Cardozo (Hospital General de Agudos Jose Maria Ramos Mejia, Argentina)	09:00 - 09:00
eP406	<b>Phylogenetic analysis and transmission networks highlight the role of older adults in the transmission of HIV-1 in northern Zhejiang, China</b> xiaohong Pan (Zhejiang Provincial Center for Disease Control and Prevention, China, China)	09:00 - 09:00
eP407	<b>Pre-exposure prophylaxis (PrEP) and the reduction in new cases of HIV acquisition in men in the state of Sao Paulo, Brazil</b> Mariza Vono Tancredi (Centro de Referencia e Treinamento DST-AIDS-SP, Brazil)	09:00 - 09:00
eP408	<b>Seroprevalence of HIV, HBV and HCV Among People Who Use Drugs in Turkey</b> Ali Asan (University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Turkey)	09:00 - 09:00
eP409	<b>Seroprevalence of Toxoplasma gondii in Individuals Living with HIV/AIDS: An Epidemiological Assessment and Clinical Significance</b> Merve Kılıç Tekin (Haseki Training and Research Hospital, Turkey)	09:00 - 09:00
eP410	<b>Sex-Based Disparities in Hospitalizations due to Advance Disease among People Living with HIV in a Tertiary Center from 2003-2023 in Mexico City</b> Santiago Agraz Orozco (Instituto Nacional de Ciencias Médicas y	09:00 - 09:00

	Nutricion Salvador Zubirán, Mexico)	
eP411	<b>Structural Barriers and HIV Testing Uptake Among Female Sex Workers in Albania: Findings from Integrated Bio-Behavioral Surveillance</b> Elona Gjebrea Hoxha (Albanian Center for Population and Development, Albania)	09:00 - 09:00
eP412	<b>The Relationship Between Development Indicators and HIV Epidemiology: A Global Perspective on Social Determinants</b> Özge Eren Korkmaz (Izmir Dokuz Eylül University, Turkey)	09:00 - 09:00
eP413	<b>Trends in HIV awareness, screening practices and attitudes in Tunisia: Insights from MICS Data (2012-2023)</b> Mariem Noura (Faculty of Medicine of Tunis, Tunis El Manar University-Tunisia., Tunisia)	09:00 - 09:00
	<b>C2. HIV prevention</b>	09:00 - 09:00
eP414	<b>Addressing HIV-Related Morbidity and Mortality Through Community-Based Adolescent Prevention and Linkage to Care in Muyuka Subdivision, Southwest Region, Cameroon</b> TEZETE EVET ADEOLA ADEOLA (Alliance for Community Initiative, Cameroon)	09:00 - 09:00
eP415	<b>Clinic vs. Self HIV Testing in Southern Africa: A Systematic Review on Progress Towards UNAIDS Targets</b> David Flynn (Imperial College London, United Kingdom)	09:00 - 09:00
eP416	<b>Effectiveness of the HIV Testing Month campaign in promoting testing in the general public in Hong Kong</b> Tsz Ho Kwan (The Chinese University of Hong Kong, Hong Kong)	09:00 - 09:00
eP417	<b>EPIDEMIOLOGICAL CHARACTERISTICS OF new HIV cases IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL.</b> Alexis Rebollo Curbelo (University Hospital of Bellvitge, Spain)	09:00 - 09:00
eP418	<b>Estimating the health impact and cost-effectiveness of emergency department opt-out testing for blood-borne viruses in Germany</b> Jürgen K Rockstroh (University Hospital Bonn, Germany)	09:00 - 09:00
eP419	<b>Expanding HIV Screening Beyond Hospital Walls in Milan: 18 years of the "EasyTest" project</b> Angelo Roberto Raccagni (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP421	<b>HIV Screening Practices and Knowledge of Indicator Conditions Among Resident Doctors: A Cross-Sectional Study</b> Mehmet Buğra Özkara (Ege University, Turkey)	09:00 - 09:00
eP422	<b>Individuals newly diagnosed with HIV in London, UK: characteristics of previous attenders and 'never-attenders'</b> Gary Whitlock (Chelsea & Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP423	<b>Involvement of key populations in HIV testing through social networks, Odesa, Ukraine</b> Nataliia Kitsenko (NGO "Way Home", Odesa, Ukraine, Ukraine)	09:00 - 09:00
eP424	<b>Medical-Driven HIV Testing Persists Over Time in Central and Eastern Europe: Evidence from the Go Holistic Go Beyond Project</b> Ivana Gmizic (Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Serbia)	09:00 - 09:00
eP425	<b>Missed Opportunities for HIV Testing in Newly Diagnosed Patients at a Tertiary Care Hospital: A Retrospective Analysis</b>	09:00 - 09:00

	Bircan Kayaaslan (Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Turkey)	
eP426	<b>NEW OPPORTUNITIES FOR COVERING THE POPULATION WITH HIV TESTING IN LVIV, UKRAINE</b> Olena Pavlyshyn (Communal Non-Profit Enterprise "Lviv Territorial Medical Association 2", Lviv, Ukraine, Ukraine)	09:00 - 09:00
eP427	<b>Overview on community-based screening in Tunisia in 2024</b> Samir Mokrani (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP428	<b>Use of Regional Mentors to Optimize Maternal Retesting Services for Prevention of Vertical Transmission of HIV: A case of Mwanza, Tabora, and Morogoro in Tanzania</b> Neema Makyao (Amref Health Africa, Tanzania)	09:00 - 09:00
eP429	<b>Wedge-shaped clustered randomized trial to evaluate two tools for identifying individuals at risk for or already infected with HIV: Atenea Study Interim Analysis</b> María Jesús Pérez- Elías (Ramon y Cajal University Hospital, Spain)	09:00 - 09:00
eP430	<b>Female Patients on HIV Post-Exposure Prophylaxis: Clinical outcomes and prevention opportunities</b> Natalia Sánchez-Ocaña Martín (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP431	<b>HIV post-exposure prophylaxis in the integrase inhibitor era: experience in a low-middle income country</b> Julián Vega (Hospital General de Agudos "Juan A. Fernández", Argentina)	09:00 - 09:00
eP432	<b>Rapid assessment of access to HIV Post-Exposure Prophylaxis (PEP) in EU/EEA countries</b> Ferenc Bagyinszky (AIDS Action Europe, Germany)	09:00 - 09:00
eP433	<b>A Multidisciplinary Approach to Promoting Accessibility and Adherence to Pre-Exposure Prophylaxis (PrEP) in a Portuguese Hospital in Lisbon</b> Bárbara Cardoso (Hospital de Santa Maria, Portugal)	09:00 - 09:00
eP434	<b>Assessing the Interest and Willingness of Nigerian Community Pharmacists to Deliver Pharmacy-Based Pre-Exposure Prophylaxis (PrEP) Services</b> Theodora Chioma Omenoba (Veritas University Nigeria Abuja, Nigeria)	09:00 - 09:00
eP435	<b>Assessment of healthcare access and knowledge of HIV pre-exposure prophylaxis in women sex workers in Lille, Northern France.</b> Emmanuelle Bontemps (Tourcoing Hospital, France)	09:00 - 09:00
eP436	<b>Automated Data Solutions for PrEP Monitoring and Planning in Ukraine</b> Diana Shevchenko (SI Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
eP437	<b>Awareness and Uptake of Pre-Exposure Prophylaxis among Pregnant women at risk of HIV in Mid-Western and Central Uganda: A Population-Based Study</b> Bashiri Magada (Africa Medical and Behavioral Sciences Organization (AMBSO), Uganda)	09:00 - 09:00
eP438	<b>Characteristics of PrEP Users at First Counseling Visit: Persistent Gaps in Reaching High-Risk Populations</b> Drieda Zace (Tor Vergata University of Rome, Italy)	09:00 - 09:00
eP439	<b>Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)</b> Sandro Mattioli (PrEP Point Plus, Italy)	09:00 - 09:00

eP440	<b>Comparison of users accessing PrEP in hospital-based or community-based setting: first picture from the PrIDE cohort</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP441	<b>Engagement of Women of Color in HIV Prevention through PrEP at a Clinic Serving LGBTQ+ Communities</b> Darya Fridman (The LGBTQ Center, United States)	09:00 - 09:00
eP442	<b>Evaluation of a multidisciplinary reach-out program, facilitating HIV pre-exposure prophylaxis (PrEP) prescription and retention in care, in a group of trans women (TW) at high risk of HIV infection. Preliminary results from the PrEP à porter study</b> VALENTINA ISERNIA (Bichât - Claude Bernard Hospital, France)	09:00 - 09:00
eP443	<b>Examining the real-world population-level impact of Scotland's national HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men</b> Claudia Estcourt (Glasgow Caledonian University, United Kingdom)	09:00 - 09:00
eP444	<b>Experience of Implementing PrEP in a Health Insurance in Buenos Aires, Argentina: Lessons Learned and Challenges</b> Iael Altclas (IPTEI Medica, Argentina)	09:00 - 09:00
eP445	<b>Frequency of Enteric Pathogens in Austrian PrEP Users</b> Nikolaus Urban (Medical University of Vienna, Austria)	09:00 - 09:00
eP446	<b>HIV infection in PrEP users: incidence, epidemiological, clinical and virological characteristics. A multicenter ambispective Cohort in Spain (SCOPE Study)</b> Juan Ambrosioni (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain)	09:00 - 09:00
eP447	<b>Impact of COVID-19 lockdown on HIV pre-exposure prophylaxis (PrEP) service delivery in Uganda: Challenges and coping strategies</b> Sylvia Namanda (Infectious Diseases Institute, College of Health Sciences, Makerere University, Uganda)	09:00 - 09:00
eP448	<b>Impact of Pre-Exposure Prophylaxis (PrEP) Introduction on Homosexual HIV Transmission in Kazakhstan: An Interrupted Time Series Analysis</b> Indira Karibayeva ("Kazakh Scientific Center for Dermatology and Infectious Diseases" of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan)	09:00 - 09:00
eP449	<b>Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey</b> Silvia Nozza (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP450	<b>Inequality in the Distribution of PrEP in Brazil: An Analysis of Coverage in Relation to HIV Incidence by Age Group, Sexual Orientation, and Race</b> Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED), Brazil)	09:00 - 09:00
eP451	<b>Interest in and intention to use long-acting PrEP among PrEP-naïve MSM and MSM currently using PrEP in Thailand</b> Natthakhet Yaemim Deyn (PULSE Clinic Plc, Thailand)	09:00 - 09:00
eP452	<b>Introducing community-based PrEP delivery in Romania</b> Raluca Pătraşcu (National Institute for Infectious Diseases "Prof dr Matei Balş", Romania)	09:00 - 09:00
eP453	<b>Introduction of Pre-Exposure Prophylaxis (PrEP) in Kazakhstan: Its Impact on HIV Testing and Diagnosis Rates among People Who Inject Drugs</b>	09:00 - 09:00

	Botagoz Turdaliyeva ("Kazakh Scientific Center for Dermatology and Infectious Diseases" of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan)	
eP454	<b>Mental Health, Stigma and Risk Perception Among CAB-LA PrEP Initiators: a cross-sectional study</b> Davide Moschese (Luigi Sacco University Hospital, Italy)	09:00 - 09:00
eP455	<b>Mind the Gap: transition from HIV PEP with B/F/TAF to oral PrEP in real-world setting</b> Flavia Passini (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP456	<b>Opportunities to Prevent Human Immunodeficiency Virus (HIV) Acquisition: Global Survey Results on Sexual Health Engagement in Newly Diagnosed People Living With HIV From the VOLITION Study</b> Cassidy A Gutner (ViiV Healthcare, United States)	09:00 - 09:00
eP457	<b>Pre-Exposure prophylaxis to prevent HIV transmission among migrant men who have sex with men in Georgia</b> Maia Tsintsadze (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP458	<b>Prevalence and Correlates of Intimate Partner Violence among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) Using PrEP in Pre-War Ukraine</b> Nikolay Lunchenkov (Technical University of Munich, Germany)	09:00 - 09:00
eP459	<b>Real-World Experience with Oral PrEP in Italy: A Descriptive Study from a Single-Center Cohort (2018-2024)</b> Andrea Carbone (Catholic University of Sacred Heart, Italy)	09:00 - 09:00
eP460	<b>Reasons for HIV-Preexposure Prophylaxis (PrEP) discontinuation and its predictors in people still at risk for HIV acquisition</b> Virginia Barchi (National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, Italy)	09:00 - 09:00
eP461	<b>Sexual health knowledge, interest and acceptability of PrEP in migrant women: the MIMOSA study</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP462	<b>Social Media Communication for Recruitment and Adherence to Combined HIV/STI Prevention with a Focus on the Trans Population at a Research Center, São Paulo, Brazil</b> Vinicius Francisco da Silva (Centro de Referência e Treinamento DST/AIDS, Brazil)	09:00 - 09:00
eP463	<b>Systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men</b> David Comer (University of Galway, Ireland)	09:00 - 09:00
eP464	<b>Use of whole blood capillary samples to estimate glomerular filtration rate using enzymatic analysis of creatinine among HIV PrEP users</b> Maurice Pelsers (Dr. Stein & Collegae Maastricht, Germany)	09:00 - 09:00
eP465	<b>Would infant lamivudine prophylaxis during breastfeeding be an option to prevent from vertical transmission of HIV ?</b> Laetitia Gay (Inserm, France)	09:00 - 09:00
eP466	<b>Durable viral load suppression and viral load rebound among people living with HIV in North America and Europe. A systematic review and meta-analysis</b> Mariam Salim Mbwana (Primary Health Care Institute, Tanzania)	09:00 - 09:00

eP467	<b>HIV Self-Testing by Mail Among Sex Workers: A Virtual Harm Reduction Initiative in Montpellier, France</b> Victor Duperret (Médecins du Monde, France)	09:00 - 09:00
eP468	<b>MEASURING HIV PREVENTION KNOWLEDGE (U=U, PEP, PrEP) AND ATTITUDES IN THE HEALTHCARE SETTING: SERBIAN RESULTS FROM AN ECDC/EACS SURVEY</b> Gordana Dragović (Faculty of Medicine, University of Belgrade, Serbia)	09:00 - 09:00
eP469	<b>Treatment as Prevention: The Impact of the National Care and Support Program for People Living with HIV Amid Russia's Full-Scale Military Invasion of Ukraine</b> Nataliia Zapolska (Nataliia Zapolska, Ukraine)	09:00 - 09:00
	<b>C3. Social Sciences</b>	09:00 - 09:00
eP470	<b>Advancing HIV Cure Research in Latin America and the Caribbean: Perspectives, Priorities, and Advocacy Needs of Civil Society</b> Luciana Kamel (Fundação Oswaldo Cruz (Fiocruz), Brazil)	09:00 - 09:00
eP471	<b>Behavioral Change Related to Stigma and Discrimination Among People Living with HIV</b> Monica Pudaruth (PILS (Prévention Information et Lutte contre le SIDA), Mauritius)	09:00 - 09:00
eP472	<b>Evaluation of Health-Related Quality of Life Over a Six-Month Period in Newly Diagnosed People Living with HIV</b> Hakki Meric Turkkan (Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey, Turkey)	09:00 - 09:00
eP473	<b>Evolving Influences on HIV Knowledge in Young Filipino Women: Education, Media, and Stigma</b> Sophia Palma (University of Debrecen, Hungary)	09:00 - 09:00
eP474	<b>Memory rehabilitation for HIV-Associated Neurocognitive Disorders (HAND) : A review of the literature</b> Signe Andersen (Centre Hospitalier Universitaire, France)	09:00 - 09:00
eP475	<b>Multi-dimensional impulsivity in people living with HIV on effective cART</b> Chloe Knox (University Hospitals Sussex NHS Trust, United Kingdom)	09:00 - 09:00
eP476	<b>Preliminary findings from a new group-based memory rehabilitation program, <i>Coaching Memory</i>, for HIV-Associated Neurocognitive Disorders (HAND)</b> Signe Andersen (Centre Hospitalier Universitaire, France)	09:00 - 09:00
eP477	<b>Reframing HIV: How Personal Growth and Acceptance Could Improve ART Adherence</b> Andrea Norcini-Pala (SUNY Downstate Health Sciences University, United States)	09:00 - 09:00
eP478	<b>Time to Suboptimal Treatment Patterns Among People With HIV on Antiretroviral Therapy in the United States</b> Travis Lim (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP479	<b>A Telegram Bot as a Digital Tool for Transgender People in Ukraine: Access to HIV Services and Gender-Affirmative Support</b> Vitalii Apanasenko (Youth Public Movement "Partner", Ukraine)	09:00 - 09:00
eP480	<b>Bimonthly long acting cabotegravir and rilpivirine in transgender women with HIV: evidence from the Spanish RELATIVITY cohort.</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP481	<b>Integrated biobehavioral survey among transgender and non-binary people in Ukraine, 2024</b>	09:00 - 09:00

	Sofiia Ohorodnik (Public Health Center of the MOH of Ukraine, Ukraine)	
eP482	<b>Effect of SARS-CoV-2 vaccination on HIV viral load in patients under BIC/TAF/FTC therapy: a retrospective observational study</b> Giuseppe Pipitone (ARNAS Civico Hospital, Italy)	09:00 - 09:00
eP483	<b>Gamified Education: Utilizing Interactive Play to Enhance HIV/AIDS Awareness and Prevention</b> Olga Feger (State University «Uzhhorod National University», Ukraine)	09:00 - 09:00
eP484	<b>Loneliness and HIV in Adults 50+: Voices on Needed Interventions</b> Rosa De Miguel Buckley (La Paz- Carlos III University Hospital, Spain)	09:00 - 09:00
eP485	<b>More than just a drink: Identifying and intervening on silent risk profiles for alcohol misuse in People Living With HIV</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP486	<b>Perspectives on HIV Cure-Related Trials with Analytical Treatment Interruption among People Living with HIV and Healthcare Practitioners</b> Kwanza Price (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP487	<b>Reasons for interrupting antiretroviral therapy, results of the study</b> Yaroslava Lopatina (AHF Ukraine, Ukraine)	09:00 - 09:00
eP488	<b>Silent Crisis: Loneliness in Older Adults Living with HIV</b> Joanna Cano-Smith (La Paz- Carlos III University Hospital, Spain)	09:00 - 09:00
eP489	<b>Stigma and Quality of Life in People Living with HIV: Psychosocial vulnerability and clinical implications</b> Carolina Olmos Mata (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP490	<b>Cost analysis and diagnostic yield of asymptomatic sexually transmitted infections (STIs) screening in a high-risk cohort of men who have sex with men (MSM)</b> Pierluigi Francesco Salvo (Università Cattolica del Sacro Cuore, Italy)	09:00 - 09:00
eP491	<b>Feelings, experiences and coping strategies after HIV diagnosis amongst people with recently acquired HIV in Europe</b> Inés Suárez-García (Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, Spain)	09:00 - 09:00
eP492	<b>Leveraging Interactive SMS Training to Equip Health Workers for Inclusive HIV Services Amid Uganda's Anti-Gay Law Implementation</b> Christine Nabukera Rwabyogamu (Infectious Diseases Initiative, Uganda)	09:00 - 09:00
eP493	<b>Navigating Sexual Dysfunction with HIV: Experiences of Gay, Bisexual, and Other Men Who Have Sex with Men in Montreal, Canada</b> Francesco Avallone (McGill University, Canada)	09:00 - 09:00
eP494	<b>Risk reduction strategies for HIV transmission during time among men who have sex with men in Slovenia: Qualitative study</b> Miran Solinc (University of Ljubljana, Slovenia)	09:00 - 09:00
eP495	<b>"Even Me Myself, I Don't See Myself as a Human Being": Migration, Violence, and HIV Exposure Among African Refugee Male Sex Workers in Transit to Italy</b> Marco Barracchia (Maastricht University, Netherlands)	09:00 - 09:00
eP496	<b>Assessing Mental Health in an Immigrant-Dominated HIV Cohort Using PHQ-9: A Pilot Analysis from a Greek HIV Unit</b> Vissaria Sakka (National Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP497	<b>Characterisation of migrant PLWHIV from sub-Saharan Africa in a</b>	09:00 - 09:00



	<b>hospital in Europe - mixed-methods study in the Lisbon region, Portugal</b> Rita Patrocínio de Jesus (Hospital Prof. Doutor Fernando Fonseca, Portugal)	
eP498	<b>Where Health Begins: Mobile Health as a Tool for HIV/STI Access Among LGBTQI+ Migrants in Italy</b> Marco Barracchia (Maastricht University, Netherlands)	09:00 - 09:00
eP499	<b>Attitudes towards PrEP among women engaged in sex work who use drugs (WESW-UD) in Kazakhstan</b> Tara McCrimmon (Columbia University Mailman School of Public Health, United States)	09:00 - 09:00
eP500	<b>Barriers to STI Prevention among Female Sex Workers in Türkiye: A Qualitative Study</b> Ismail Orbay (Hacettepe University, Turkey)	09:00 - 09:00
eP501	<b>Did the AEGIDA Intervention Reduce Sexual Behaviors Associated with HIV Acquisition among Women who Exchange Sex and/or Use Substances in Kazakhstan?</b> Victoria Frye (Columbia University School of Social Work, United States)	09:00 - 09:00
eP502	<b>Health issues in sex workers attending a sexual health clinic in Paris: an observational cohort</b> Sarah Gaston-Dreyfus (Saint Antoine hospital, France)	09:00 - 09:00
eP503	<b>Internalized Stigma and Mental Health Symptoms among females who engage in sex work and use drugs in Kazakhstan: Baseline insights from the AEGIDA Study</b> Assel Terlikbayeva (Center for Scientific and Practical Initiatives, Kazakhstan)	09:00 - 09:00
eP504	<b>Intersectional identities and barriers</b> Trajche Janushev (Regional Network Sex Workers' Rights Advocacy Network (SWAN), Hungary)	09:00 - 09:00
eP505	<b>Retention Cascade and Predictors in a Sexual Health Program for Sex Workers: Expanded Access Through NGO Collaboration</b> Diana Corona-Mata (Hospital Universitario Reina Sofía, Spain)	09:00 - 09:00
eP506	<b>Associations Between Marijuana Use Patterns and HIV Care Continuum Outcomes Among Adults with HIV in Florida</b> Robert Cook (University of Florida, United States)	09:00 - 09:00
eP507	<b>Chemsex Trajectories among GBMSM in Almaty, Kazakhstan: A Reflexive Thematic Analysis Using a Life Course Framework</b> Nikolay Lunchenkov (Technical University of Munich, Germany)	09:00 - 09:00
eP508	<b>Co-designing community-led, comprehensive chemsex harm reduction services for young men who have sex with men in Thailand: sexual health-focused, legal/rights-focused, and on-the-spot models</b> Sudarat Thongsuksangcharoen (Institute of HIV Research and Innovation, Thailand)	09:00 - 09:00
eP509	<b>Describing substance use related to sex (chemsex) among individuals newly diagnosed with HIV at a sexual health clinic in Spain</b> Inés Armenteros (Centro Sanitario Sandoval - Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP510	<b>Peer-to-peer needle and syringe programmes (P2PNSP) as a way of engaging PWID in HIV prevention: 7 case studies</b> Alexei Lakhov (European Network of People who Use Drugs, Germany)	09:00 - 09:00

eP511	<b>The Silent Epidemic: Chemsex Practices and Their Implications in Turkiye</b> Gökhan Vatansever (Ege University, Turkey)	09:00 - 09:00
eP512	<b>Trends in HIV prevalence among key populations between 2009 and 2021</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP513	<b>AEGIDA: A Behavioral HIV Intervention Associated with Reduced Partner Violence Among Women Who Exchange Sex and Use Substances (WESUS) in Kazakhstan</b> Sholpan Primbetova (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP514	<b>Barriers to HIV Services for LGBT+ People in Armenia: Legal Gaps, Stigma, and Human Rights Concerns</b> Vaghinak Ter-Hovhannisyanyan (Gavar State University, Armenia)	09:00 - 09:00
eP515	<b>Community and provider-driven strategies to reduce HIV-related stigma in Kazakhstan: opportunities for change</b> Meruyert Darisheva (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP516	<b>Empowering High-Risk Communities: Peer Educators as Catalysts for HIV Prevention in Kumba, Cameroon</b> Alemju Fontu (Alliance for Community Initiative, Cameroon)	09:00 - 09:00
eP517	<b>From Tokenism to Transformation: Tackling Structural Inequities in HIV Grant Revisions</b> Gayane Arustamyan (Advancing Global Health Solutions, Portugal)	09:00 - 09:00
eP518	<b>HIV and STIs Prevention in Women in Italy: the importance of the educational setting in WomanIST project</b> Dario Bernacchia (ASST Ovest Milanese - Legnano Hospital, Italy)	09:00 - 09:00
eP519	<b>HIV-RELATED STIGMA AND DISCRIMINATION IN ARGENTINA'S POPULATION: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY</b> José A. E. Barletta (Hospital Fernández, Argentina)	09:00 - 09:00
eP520	<b>Medical Mistrust as a Barrier to Healthcare Access Among Women Vulnerable to HIV</b> Meruyert Darisheva (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP521	<b>Overview on the epidemiology of HIV/AIDS among key populations in Tunisia, 2024</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP522	<b>Prison: An Essential Piece in the 'Towards Zero' Puzzle</b> Pankaj Sethi (Positive East, United Kingdom)	09:00 - 09:00
eP523	<b>Reaching neglected Vulnerable Populations: Addressing the HIV Knowledge Gap in UK prisons</b> Sophie Strachan (Sophia Forum, United Kingdom)	09:00 - 09:00
eP524	<b>Religiosity and Perceived Stress Among Filipino People Living with HIV: Evidence from a Community-Led Treatment Hub in Metro Manila, Philippines</b> Emmanuel S. Baja (Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Philippines)	09:00 - 09:00
eP525	<b>Understanding HIV and Key Population Stigma in Kazakhstan's Healthcare Workforce: A Cross-Sectional Analysis</b> Gaukhar Mergenova (Asfendiyarov Kazakh National Medical University, Kazakhstan)	09:00 - 09:00

eP526	<b>HIV/AIDS IN LVIV (UKRAINE) IN WAR CONDITIONS: EPIDEMIOLOGICAL CHANGES</b> Olena Mysano (Communal Non-Profit Enterprise "Lviv Territorial Medical Association 2", Lviv, Ukraine (CNE "Lviv TMO 2"), Ukraine)	09:00 - 09:00
eP527	<b>Impact of the War on HIV Diagnosis Timeliness: CD4 Level Dynamics Among Newly Registered PLHIV in Ukraine</b> Larysa Hetman (Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
eP528	<b>Resilience of Harm Reduction and HIV Prevention Services for People Who Inject Drugs in Ukraine Amid War: Insights from 2021-2023</b> Liudmyla Legkostup (Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
	<b>Clinical Cases</b>	09:00 - 09:00
eP.C001	<b>Possible CNS Compartmentalization and Lenacapavir Resistance in Multidrug-Resistant HIV</b> Annalisa Marinosci (University Hospitals of Geneva, Switzerland)	09:00 - 09:00
eP.C002	<b>Virological failure with NNRTI resistance on CAB+RPV-LA in a man with subtherapeutic cabotegravir levels</b> Nian Li (North Middlesex University Hospital, United Kingdom)	09:00 - 09:00
eP.C003	<b>Bictegravir in Aging Adults Living with HIV: Sustained Virologic Control and Age-Appropriate Safety Profile</b> Marcello Trizzino (University of Palermo, Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight Against AIDS, Palermo, Italy, Italy)	09:00 - 09:00
eP.C004	<b>Central nervous system lesions in late-presenting person living with HIV - opportunistic infection or a brain tumour?</b> Filip Glavac (University Hospital for Infectious Diseases, Zagreb, Croatia, Croatia)	09:00 - 09:00
eP.C005	<b>Case Report: Late Diagnosis of HIV at Clinical Stage 4 With Pulmonary and CNS Tuberculosis</b> Oleksandra Bezrodna (Bogomolets National Medical University, Ukraine)	09:00 - 09:00
eP.C006	<b>Evolving Genital Lesions of Unusual Etiology in a Man Who Have Sex with Man: Case Report</b> Carlo Bienkowski (Medical University of Warsaw, Poland)	09:00 - 09:00
eP.C007	<b>CMV-related cholangiopathy as part of IRIS in an HIV-infected patient with invasive pulmonary aspergillosis</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C008	<b>Bacillary Angiomatosis in a HIV Patient with High CD4 Count: An Unexpected Manifestation of IRIS?</b> Hayat Kumbasar Karaosmanoğlu (Taksim Training and Research Hospital, Turkey)	09:00 - 09:00
eP.C009	<b>Disseminated Whipple's Disease and Kaposi's Sarcoma with IRIS-PML in an individual with Advanced HIV</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C010	<b>Disseminated MAC, Leishmaniasis, and CMV in a patient with advanced HIV: A complex case of IRIS</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C011	<b>A case of AIDS-associated Progressive Multifocal Leukoencephalopathy with significant improvement in higher brain function following glucocorticoid therapy</b> Motoki Kon (NHO Sendai Medical Center, Japan)	09:00 - 09:00

eP.C012	<b>Fatal Case of KSHV-Associated Diseases with Airway Involvement: Kaposi Sarcoma, Multicentric Castleman Disease, and Diffuse Large B-Cell Lymphoma in a Person living with HIV</b> Vitor José da Silva Classmann (Evandro Chagas National Institute of Infectious Diseases (INI-Fiocruz), Brazil)	09:00 - 09:00
eP.C013	<b>When the Fever Won't Break: A Case of Disseminated MAC in Advanced HIV</b> ilkay akbulut (Health Sciences University Tepecik Training and Research Hospital, Turkey)	09:00 - 09:00
eP.C014	<b>Visceral Leishmaniasis and HIV coinfection: unusual clinical presentation</b> Lorenzo Albertini (Università degli Studi di Milano, Italy)	09:00 - 09:00
eP.C015	<b>A Rare and Fatal Case of Cerebral and Renal Toxoplasmosis in a Non-adherent Person Living with Advanced HIV</b> Büşra Akmaz (Izmir Katip Celebi University, Atatürk Educational Research Hospital, Turkey)	09:00 - 09:00
eP.C016	<b>Encephalitis caused by ganciclovir-resistant cytomegalovirus in a late-presenting person living with HIV, diffuse large B-cell lymphoma, and multiple opportunistic infections</b> Marija Santini (University Hospital for Infectious Diseases, Croatia)	09:00 - 09:00
eP.C017	<b>Disseminated Mycobacterium Avium Complex (dMAC) and Ophthalmoplegia - a diagnostic challenge</b> Niroshan Dayalan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP.C018	<b>The first case of lung abscess and bacteremia caused by Rhodococcus hoagii in a patient with advanced HIV Infection in Croatia - a therapeutic challenge</b> Nikola Kudoić (University Hospital for Infectious Diseases Dr. Fran Mihaljevic, Croatia)	09:00 - 09:00
eP.C019	<b>First reported case of <i>Trichophyton mentagrophytes</i> genotype VII infection in a Portuguese HIV-positive patient</b> Fábio Reis (Hospital Pedro Hispano, Portugal)	09:00 - 09:00
eP.C020	<b>Maribavir Salvage Therapy for ganciclovir-resistant cytomegalovirus in two women with HIV-related lymphoma</b> Guillaume THIZY (Saint Louis Hospital, APHP, France)	09:00 - 09:00
eP.C021	<b>Paradoxical Immune Reconstitution Inflammatory Syndrome associated with <i>Pneumocystis jirovecii</i> pneumonia in a person living with HIV: a case report</b> Dara Mbanze (Unidade Local de Saúde Gaia e Espinho, Portugal)	09:00 - 09:00
eP.C022	<b>Treatment of refractory Giardiasis with quinacrine in a young refugee with HIV and HCV coinfection</b> Alberto Diaz De Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C023	<b>HIV-associated chronic inflammatory demyelinating polyneuropathy successfully managed with immunoadsorption</b> Yuanmei Che (Jiangxi Provincial People's Hospital/The First Affiliated Hospital of Nanchang Medical College, China)	09:00 - 09:00
eP.C024	<b>Polymorphic Kaposi Sarcoma in the shadows of isolation and migration</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP.C025	<b><i>Mycobacterium avium</i> Complex Infection Following Immune Reconstitution Inflammatory Syndrome: A Diagnostic Journey</b> Daniela Rodrigues Nogueira (Unidade Local de Saúde de Santo António, Portugal)	09:00 - 09:00


eP.C026	<b>Oral ulcerations associated with Epstein-Barr virus in a severely immunocompromised person living with HIV-1</b> Márcia Daniela Silva (Unidade Local de Saúde de Santo António, Portugal)	09:00 - 09:00
eP.C027	<b>Genital and Oral Ulcerative Vasculitis in a Recently Diagnosed PWH with Negative Microbiological Workup</b> Alberto Foncillas (Hospital Clínic de Barcelona, Universitat de Barcelona, Spain)	09:00 - 09:00
eP.C028	<b>An atypical presentation of psychosis in Progressive Multifocal Leukoencephalopathy</b> Natasha Somani (Chelsea and Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP.C029	<b>Fatal Overlapping CMV Encephalitis, Adrenal Insufficiency, and IRIS in an Individual with Advanced HIV and Disseminated MAI</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C030	<b>Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution</b> Maria Felipe Medeiros (Casa da Pesquisa CRT DST AIDS São Paulo, Brazil)	09:00 - 09:00
eP.C031	<b>Emergence of Maribavir Resistance in an AIDS Patient with Refractory Cytomegalovirus Viremia and Retinitis</b> Vissaria Sakka (National Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP.C032	<b>Severe disseminated cryptococcosis, with asymptomatic central nervous system involvement, in a very late presenter</b> Sever Membulat (National Institute for Infectious Diseases "Matei Bals", Romania)	09:00 - 09:00
eP.C033	<b>A case of an AIDS related multifocal cryptococcus infection</b> Sergei Rakovich (Belarusian State Medical University, Belarus)	09:00 - 09:00
eP.C034	<b>Unmasking IRIS due to <i>Toxoplasma gondii</i> in a new HIV-positive individual with CD4 <math>\geq 200</math> cells/mm<sup>3</sup> and disseminated tuberculosis</b> Francisco Vale (Unidade Local de Saúde Almada-Seixal, Hospital Garcia de Orta, Portugal)	09:00 - 09:00
eP.C035	<b>Cryptococcal meningitis in a 34-Year-Old Man with Advanced HIV and Left insular Astrocytoma.</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C036	<b>Nocardia Abscessus diagnosis in a cis gender woman living with HIV</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP.C037	<b>Clinical Case of Advanced HIV With Multiple Opportunistic Diseases: Pneumocystis Pneumonia, CMV Chorioretinitis, and Kaposi's Sarcoma</b> Olena Vinnytska (Bogomolets National Medical University, Ukraine)	09:00 - 09:00
eP.C038	<b>Immune reconstitution inflammatory syndrome with atypical presentation of varicella zoster virus encephalitis</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP.C039	<b>Diagnostic and therapeutic challenges in a case of cerebral mass lesions in a person living with HIV</b> Emma Rubenstein (Hôpital Saint Louis, France)	09:00 - 09:00
eP.C040	<b>Spondylodiscitis caused by <i>M. avium</i> complex in a man living with HIV and poor immunological - recovery after HAART</b> Luca Baldassari (ASST Ospedale papa Giovanni XXIII, Italy)	09:00 - 09:00

eP.C041	<b>Multiple concurrent opportunistic infections in newly diagnosed HIV-positive patient</b> GRACIANA LUCIA CARDENAS (Francisco J. Muñoz Hospital, Argentina)	09:00 - 09:00
eP.C042	<b>Disseminated <i>Talaromyces Marneffei</i> Infection Presenting as Pulmonary Cavitary Nodules: A Case Report</b> Xiaoying Qin (The Second Affiliated Hospital of Guangxi Medical University, China)	09:00 - 09:00
eP.C043	<b>A case of Disseminated <i>Trichosporon asahii</i> Infection in a Patient with Advanced Human Immunodeficiency Virus Disease and Kaposi Sarcoma</b> Eleni Papantoniou (Aristotle University of Thessaloniki, Greece)	09:00 - 09:00
eP.C044	<b>Coexistence of Multicentric Castleman Disease and Visceral Kaposi Sarcoma : A Case-Report</b> Su Jung Choi (Hospital Español, Mexico)	09:00 - 09:00
eP.C045	<b>Multicentric Castleman Disease as a Cause of Fever of Unknown Origin: A Case Report</b> Su Jung Choi (Hospital Español, Mexico)	09:00 - 09:00
eP.C046	<b>Overcoming Barriers in Care: Managing HIV in people with Disabilities</b> Thyago César da Silva Pires (State University of Ponta Grossa, Brazil)	09:00 - 09:00
eP.C047	<b>Advanced Coronary Artery Disease in a Low-Risk HIV Patient - A Case for Early Statin Intervention</b> Aishriah Kalearasu (Maidstone Hospital, United Kingdom)	09:00 - 09:00
eP.C048	<b>Diffuse Large B-Cell Lymphoma in a Person Living with HIV and a History of Leprosy: A Diagnostic Challenge</b> UMUT OZGUR (Sisli Hamidiye Etfal Training and Research Hospital, Turkey)	09:00 - 09:00
eP.C049	<b>Use of PCSK9 Inhibitor Evolocumab in PLWH with persistent hyperlipidemia despite statin therapy: two case reports</b> Layla Pagnucco (Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo- University of Pavia - Italy, Italy)	09:00 - 09:00
eP.C050	<b>Complete remission of a Large B-cell Lymphoma in a person living with HIV: a case report with a 16 year follow-up</b> Kateryna Lytvyn (Dnipro State Medical University, Ukraine)	09:00 - 09:00
eP.C051	<b>Interaction between GLP-1 receptor agonists and cART in PLWH and Obesity: A case report</b> Raffaele Ferri (Università degli Studi "G.D'Annunzio", Italy)	09:00 - 09:00

*Plenary lecture*

09:15 - 09:45

Grand Amphitheatre

**PL1 - Are we prepared for pandemics?**Live broadcasted session 

Sanjay Bhagani (Royal Free London NHST Trust, United Kingdom)

**Are we prepared for pandemics?**

09:15 - 09:45

Yazdan Yazdanpanah (ANRS MIE, France)

*Plenary lecture*

09:45 - 10:15

Grand Amphitheatre

**PL2 - ART now & near: how far have we come & how much further must we go?**Live broadcasted session 

Alexandra Calmy (Geneva University Hospital, University of Geneva, Switzerland)

**ART now & near: how far have we come & how much further must we go?**

09:45 - 10:15

Laura Waters (Central &amp; North West London NHS Trust, United Kingdom)

*Breaks*

10:15 - 11:00

Grand Amphitheatre

**Coffee break***Oral presentations*

10:45 - 12:00

Room 252 AB

**O1 - Oral cross track session**

Nicola Mackie (Imperial College Healthcare NHS Trust, United Kingdom)

Michaela Müller-Trutwin (Institut Pasteur, Paris, France, France)

- |      |   |               |
|------|---|---------------|
| O1.1 | <b>T-cell modulation following therapeutic vaccination in people living with HIV (PLWH)</b><br>Yunjoo Lee (Ragon Institute of Mass General Brigham, MIT, and Harvard, United States)  | 10:45 - 10:54 |
| O1.2 | <b>Lymph nodes play a central role in SIV persistence compared to gut (P-VISCONTI study)</b><br>Véronique AVETTAND-FENOEL (Université d'Orléans, France)  | 10:54 - 11:03 |
| O1.3 | <b>Mapping patterns of resistance to 2<sup>nd</sup> generation INSTI in clinical practice: results from the ROSETTA-registry</b><br>Mafalda N.S. Miranda (University Medical Center Utrecht, Netherlands)   | 11:03 - 11:12 |
| O1.4 | <b>Association of Injection Site with Trough Concentrations of Cabotegravir and Rilpivirine Q2M</b><br>Thierry Prazuck (Centre Hospitalier Universitaire d'Orléans, France)   | 11:12 - 11:21 |
| O1.5 | <b>Beyond COVID-19 in People with HIV: specific miRNA Expression Profile persists after SARS-CoV-2 clearance</b><br>Sergio Grande Garcia (Instituto de Salud Carlos III, Spain)   | 11:21 - 11:30 |
| O1.6 | <b>HIV is Associated with CT Measures of Interstitial Lung Disease: Analyses from the Multicenter AIDS Cohort Study</b><br>Sarath Raju (Johns Hopkins School of Medicine, United States)  | 11:30 - 11:39 |
| O1.7 | <b>Health-related quality of life in ageing people with HIV is not different to that of well-matched controls without HIV: an 8-year longitudinal analysis from the AGE<sub>HIV</sub> cohort study on ageing and comorbidities</b><br>Kevin Moody (Amsterdam University Medical Center, University of Amsterdam, Netherlands) | 11:39 - 11:48 |

*Parallel session*

11:00 - 12:00

Grand Amphitheatre

**PS01 - Integrase inhibitors everywhere: Good or bad?**

Antonios Papadopoulos (MEDICAL SCHOOL, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, UNIVERSITY GENERAL HOSPITAL "ATTIKON", Greece)

Christine Katlama (Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, France)

	<b>It always starts from scratch: Integrase resistance and its global implications</b>	11:00 - 11:10
	Jonathan Schapiro (National Hemophilia Center, Sheba Medical Center, Israel)	
PS01.1	<b>Potential treatment options following virological failure with long-acting injectable cabotegravir and rilpivirine: an analysis based on reported cases</b>	11:10 - 11:19
PS01.2	<b>Weight and Body Composition After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily from BIC/FTC/TAF in Adults Living With HIV-1: Week 48 Results From a Randomized, Double-Blind Phase 3 Study</b>	11:19 - 11:28
	Chloe Orkin (Queen Mary University of London, United Kingdom)	
PS01.3	<b>Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO Study)</b>	11:28 - 11:37
	Arnau Monforte (Hospital Universitari Vall d'Hebron, Spain)	
PS01.4	<b>Hepatitis B Virus Reactivation in People Living with HIV Switching to Long Acting-Cabotegravir/Rilpivirine therapy: A Cohort Study Analysis</b>	11:37 - 11:46
	Alberto Foncillas (Hospital Clínic de Barcelona, Universitat de Barcelona, Spain)	
<i>Parallel session</i>		
11:00 - 12:00		Amphithéâtre Bordeaux
	<b>PS02 - Scaling up PrEP to meet the needs of everyone</b>	
	Magdalena Ankiersztejn-Bartczak (Foundation for Social Education, Poland)	
	Claudia Estcourt (Glasgow Caledonian University, United Kingdom)	
	<b>The Why and the How of addressing PrEP equity across Europe</b>	11:00 - 11:10
	Oana Sandulescu (Carol Davila University of Medicine and Pharmacy Bucharest, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania)	
	<b>Meeting the PrEP needs of women</b>	11:10 - 11:20
	Sinead Delany (University of the Witwatersrand, South Africa)	
PS02.1	<b>Extended PrEP cascades and determinants of long-acting PrEP intention and unmet PrEP needs among transgender women, transgender men, and non-binary individuals in 20 European countries</b>	11:20 - 11:29
	Haoyi Wang (Maastricht University, Netherlands)	
PS02.2	<b>Gaps and Gains in PrEP Continuity: Clinical and Programmatic Insights from Nigeria's 2024 National Rollout</b>	11:29 - 11:38
	Ramatu Aliyu Magaji (National Agency for the Control of HIV/AIDS, Nigeria)	
PS02.3	<b>Strengthening Community-Based Integrated HIV/STI/VH Prevention, Testing, and Linkage-to-Care: First-Year Outcomes of the CORE Project</b>	11:38 - 11:47
	Laura Fernández-López (Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain)	
PS02.4	<b>Recruitment of Disproportionately Affected Populations in the PURPOSE 5 Study Evaluating Lenacapavir for PrEP in France and the UK</b>	11:47 - 11:56
	Jean-Michel Molina (University of Paris Cité, France)	



*Parallel session*

11:00 - 12:00

Salle Maillot

**PS03 - Senescence, inflammation and ageing in HIV. What is all the fuss about?**

Cristina Mussini (University of Modena and Reggio Emilia, Italy)

Paddy Mallon (UCD School of Medicine, Ireland)

**Ageing with HIV: from basic science to clinical research**

11:00 - 11:15

Georg Behrens (Hannover Medical School, Germany)

PS03.1

**Associations between gut microbiome, kynurenine pathway of tryptophan metabolism, and symptoms of depression in people with HIV**

11:15 - 11:24

Xiangning Bai (Oslo University Hospital, Norway)

PS03.2

**Immune-inflammatory profile with inflammation, innate activation, and endothelial dysfunction in people with HIV is associated with obstructive coronary artery disease**

11:24 - 11:33

Moises Alberto Suarez-Zdunek (Copenhagen University Hospital - Rigshospitalet, Denmark)

PS03.3

**A Randomized, Multi-Center, Double-Blind, Placebo-Controlled ACTG Study to Evaluate the Effects of Cenicriviroc on Arterial Inflammation in People with HIV**

11:33 - 11:42

Janet Lo (Harvard Medical School / Massachusetts General Hospital, United States)

*Breaks*

12:00 - 14:30

Grand Amphitheatre

**Lunch break***Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP04 - Antiviral drugs: viral escape and immunological failure**

Antonella Castagna (Vita-Salute San Raffaele University, Italy)

MeP04.1

**HIV persistence in deep tissues on dolutegravir based antiretroviral therapy is not associated with the selection of drug resistance mutations to second generation INSTI (ANRS DOLUVOIR)**

12:05 - 12:10

Gilbert Mchantaf (INSERM U1016, CNRS UMR8104, Université Paris Cité, Institut Cochin, France)

MeP04.2

**HIV-1 cell-to-cell Transmission to macrophages escapes type I interferon and host restriction factors, and is resistant to antiretroviral drugs**

12:10 - 12:15

Sen Yan (Institut Cochin, France)

MeP04.3

**DOLUTEGRAVIR IMPACT IN CARDIOVASCULAR GENES USING ZEBRAFISH EMBRYO MODEL**

12:15 - 12:20

Gorgio Tiecco (University of Brescia, Italy)

MeP04.4

**Dysregulated Neutrophil Apoptosis and Emergence of Inflammatory Subsets in people living with HIV: Mechanisms of Immunological Failure**

12:20 - 12:25

Aiwei Zhu (Beijing Youan Hospital, Capital Medical University, China)

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**Moderated ePoster Sessions 1 - 4**

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP03 - Sexual health among people living with HIV**

Robert Hejzák (European AIDS Treatment Group (EATG) / Czech AIDS Help Association, Czech Republic)

- |         |  |               |
|---------|--|---------------|
| MeP03.1 | <b>Sexual Dissatisfaction in People Living With HIV, results from the Vive+ project</b>  | 12:05 - 12:10 |
|         | Beatriz Julieta Blanco Rojas (Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Spain)   |               |
| MeP03.2 | <b>Navigating the sexual well-being and partner relationships among women living with HIV/AIDS in India</b>  | 12:10 - 12:15 |
| MeP03.3 | <b>From Pilot to Practice: Strengthening Sexual Health Care Counseling in HIV clinical practice through Education and Training</b>   | 12:15 - 12:20 |
|         | Suzanne de Munnik (Catharina hospital, Netherlands)  |               |
| MeP03.4 | <b>"I didn't think it was serious": Understanding Sexual Dysfunction Care Needs of Gay, Bisexual and Other Men who Have Sex with Men Living with HIV in Montreal, Canada</b> | 12:20 - 12:25 |

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP02 - Biomarkers and Inflammation**

Casper Rokx (Erasmus MC University Medical Center, Netherlands)

- |         |  |               |
|---------|--|---------------|
| MeP02.1 | <b>Temporal multi-omics approach in well treated PHIV youth and healthy controls: insights into soluble factors that could lead to accelerated inflammaging</b>        | 12:05 - 12:08 |
|         | Julie van der Post (Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Netherlands)   |               |
| MeP02.2 | <b>Exploring Impact of Inflammation and Body Composition on Frailty Dynamics Among Older People with HIV</b>   | 12:08 - 12:11 |
|         | Win Min Han (HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand; The Kirby Institute, Sydney, Australia, Thailand)                |               |
| MeP02.3 | <b>Plasma proteomic assessment of mitochondrial protein degradation in people aging with HIV and elite controllers</b>   | 12:11 - 12:14 |
|         | Brian Epling (National Institute of Allergy and Infectious Diseases, United States)  |               |
| MeP02.4 | <b>Neurocognitive and Plasma Biomarker Changes Following Antiretroviral Therapy Initiation in Treatment-Naïve People Living with HIV: A Prospective 18-Month Study</b> | 12:14 - 12:17 |
|         | Charalampos D. Moschopoulos (4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Greece)                 |               |
| MeP02.5 | <b>Metformin prevents weight gain in non-diabetic adults with HIV: results from a randomized, placebo-controlled trial</b>   | 12:17 - 12:20 |
|         | Cristina Marcelo Calvo (Hospital Universitario la Paz - idiPAZ, Spain)   |               |
|         | <b>Discussion</b>  | 12:20 - 12:25 |


*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP01- From Diagnosis to Retention**

- |         |   |               |
|---------|---|---------------|
| MeP01.1 | <b>Trends in late diagnosis of HIV and its association with education and income: a nationwide cohort study from 2003 to 2023 in Sweden</b> | 12:05 - 12:10 |
|---------|---|---------------|

	Sara Falk (Karolinska Institutet, Sweden)	
MeP01.2	<b>Factors associated with loss to follow-up among PWH-1: Analysis through linkage of the ANRS PRIMO, CODEX, and COPANA to the ANRS CO4 FHDH: the PDVCOH study</b> Charlène Mafuta (Université Paris-Saclay, CESP - INSERM U1018, France)	12:10 - 12:15
MeP01.3	<b>Personalized dynamic predictions of the time-to-next visit: identifying individuals more prone to disengage from care</b> Giota Touloumi (Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Greece)	12:15 - 12:20
MeP01.4	<b>Understanding drivers of HIV-related stigma in Romanian healthcare settings</b> OANA MIHAELA INESCU (Carol Davila University of Medicine and Pharmacy and National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Romania)	12:20 - 12:25
<i>Industry sponsored session</i> 12:30 - 14:00		
<b>Industry sponsored session</b> Live broadcasted session 		Amphithéâtre Bleu
<i>Special session</i> 12:30 - 13:30		
<b>SPS1 - WHO</b>		Amphithéâtre Bordeaux
<i>Special session</i> 12:30 - 13:30		
<b>SPS2 - NEAT ID</b>		Salle Maillot
<i>Moderated ePosters</i> 14:05 - 14:25		
<b>MeP08 - Pregnancy, children and adolescents</b> Nicolas Nagot (University of Montpellier, France)		ePoster Exhibition
MeP08.1	<b>Socio-demographic and socio-economic characteristics of women diagnosed with HIV during the pregnancy, using registry data from Statistic Netherlands</b> Colette Smit (Stichting HIV Monitoring, Netherlands)	14:05 - 14:10
MeP08.2	<b>Breastfeeding and HIV in High-Income Settings: Exploring Women living with HIV and Health-care Providers' Perspectives in Belgium</b> H'ava Masquelier (Université Libre de Bruxelles, Belgium)	14:10 - 14:15
MeP08.3	<b>Semi-structured interviews with women living with HIV and their health care professionals to determine factors influencing counseling on infant feeding options: a qualitative study</b> Lena van der Wekken-Pas (Radboudumc, Netherlands)	14:15 - 14:20
MeP08.4	<b>Transition experiences of young adults with perinatal HIV in the Netherlands</b> Annouschka Weijsenfeld (Amsterdam UMC, Netherlands)	14:20 - 14:25

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP07 - How to optimize patient-provider relationship: stigma and understanding**

Robert Hejzák (European AIDS Treatment Group (EATG) / Czech AIDS Help Association, Czech Republic)

- |         |   |               |
|---------|---|---------------|
| MeP07.1 | <b>Developing, delivering and evaluating a bespoke HIV Knowledge and Stigma training program for healthcare workers; changes in knowledge and attitudes towards people with HIV</b><br>Linda Cheyenne Vaccari (Royal Free London NHS Foundation Trust, United Kingdom)  | 14:05 - 14:10 |
| MeP07.2 | <b>HIV-RELATED STIGMA AND DISCRIMINATION AMONGST HEALTH CARE PROVIDERS IN ARGENTINA: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY</b><br>José A. E. Barletta (Hospital Fernández, Argentina)   | 14:10 - 14:15 |
| MeP07.3 | <b>Implementation of Mobile Clinics in Ukraine During Wartime: Early Outcomes of a Nationwide Program</b><br>Svitlana Vynohradova (Державна установа «Центр громадського здоров'я МОЗ України», Ukraine)  | 14:15 - 14:20 |
| MeP07.4 | <b>Structural factors associated with viral suppression among transgender women living with HIV in France, ANRS-Trans&amp;HIV: a nationwide retrospective life-event survey</b><br>Margot Annequin (Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, France) | 14:20 - 14:25 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP06 - Sex, bugs and prevention**

Gilles Wandeler (Bern University Hospital, Switzerland)

- |         |  |               |
|---------|--|---------------|
| MeP06.1 | <b>The Impact of 4CMenB Vaccination and Doxycycline post-exposure prophylaxis on Pharyngeal Meningococcal Carriage among MSM using HIV PrEP</b><br>Ala-Eddine Deghmane (Institut Pasteur, Invasive Bacteria Infections Unit, Université Paris Cité, Paris, France)                                   | 14:05 - 14:10 |
| MeP06.2 | <b>Pharmacokinetics and efficacy of a single dose of 200 mg of doxycycline in men who have sex with men using PrEP</b><br>Lauriane Goldwirt (APHP, Saint-Louis Hospital; U976 University of Paris Cité, France)  | 14:10 - 14:15 |
| MeP06.3 | <b>Modeling DoxyPEP impact amongst PrEP users: an opportunity for prevention in low-middle income countries</b><br>Julián Vega (Hospital General de Agudos "Juan A. Fernández", Argentina)   | 14:15 - 14:20 |
| MeP06.4 | <b>Risk Factors Associated with Bacterial Sexually Transmitted Infections (STIs) Among Men Who Have Sex with Men (MSM) During the Pre-Exposure Prophylaxis (PrEP) era: a Systematic Review and Meta-Analysis in High-Income Countries</b><br>Mathieu Castry (INSERM - Université Paris Cité, France) | 14:20 - 14:25 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP05 - Triple therapy forever**

Silvia Nozza (Vita-Salute San Raffaele University, Italy)

- |         |  |               |
|---------|--|---------------|
| MeP05.1 | <b>Real-World Effectiveness of Bictegravir- versus Dolutegravir-Based Triple regimens in High-Viremia HIV Infection: The BicDol Study</b><br>Antoine Chéret (University of French West Indies, France) | 14:05 - 14:05 |
| MeP05.2 | <b>Long-term viral suppression, and cardiometabolic benefits of</b>  | 14:05 - 14:05 |

	<b>switch to ainoovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open-label results from the SPRINT post-study</b> Hong Qin (Aidea Pharma, China)	
MeP05.3	<b>Five-year extended follow-up of the observational BICSTaR cohort: Final analysis in people with HIV (PWH) receiving bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice</b> Benoit Trottier (Clinique de Médecine Urbaine du Quartier Latin, Canada)	14:05 - 14:05
MeP05.4	<b>ART persistence among treatment-experienced people with HIV and mental health disorders in the US</b> James Jarrett (Gilead Sciences, United Kingdom)	14:05 - 14:05
<i>Moderated ePosters</i> 14:05 - 14:25		
<b>Moderated ePoster Sessions 5 - 8</b>		ePoster Exhibition
<i>Parallel session</i> 14:30 - 15:30		
<b>PS04 - Social and gender inequities in accessing care and prevention</b> Grzegorz Jezierski (Lambda Warszawa Association, Poland) Harriet Langanke (GSSG - Gemeinnützige Stiftung Sexualität und Gesundheit, Germany)		Grand Amphitheatre
	<b>Gender inequities</b> Nathalie Bajos (INSERM, France)	14:30 - 14:40
	<b>Intersectional stigma</b> Bülent Turan (Koc University, Turkey)	14:40 - 14:50
PS04.1	<b>Exploring Mental Health Burden in Adults who Acquired HIV during Childhood and Adolescence</b> Beatriz Julieta Blanco Rojas (Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya, Spain)	14:50 - 14:59
PS04.2	<b>Economic Drivers of HIV Vulnerability Among African Refugee Male Sex Workers in Italy: A Mixed-Methods Study</b> Marco Barracchia (Maastricht University, Netherlands)	14:59 - 15:08
PS04.3	<b>Multidimensional gender affirmation among transgender women living with HIV: an indicator of engaging in transactional sex?</b> Raymond Van Huizen (Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, France)	15:08 - 15:17
PS04.4	<b>Chemsex Substance Use among gbMSM in Switzerland, a Cohort Collaboration Study between the Swiss HIV Cohort Study and the SwissPrEPared Study</b> Bashkim Jaha (University Hospital Zurich, Switzerland)	15:17 - 15:26
<i>Parallel session</i> 14:30 - 15:30		
<b>PS05 - Hepatitis and TB Co-Infection</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain) Aisuluu Bolotbaevaa (European AIDS Treatment Group, Kyrgyzstan)		Amphithéâtre Bleu
	<b>Risk and screening for Hepatocellular carcinoma in people with HIV</b> Jürgen K Rockstroh (University Hospital Bonn, Germany)	14:30 - 14:45
PS05.1	<b>Hepatocellular Carcinoma Screening in HIV/HBV Coinfected</b>	14:45 - 14:54

**Individuals: Insights from Spain, Germany, and Poland**

Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)

- |        |   |               |
|--------|---|---------------|
| PS05.2 | <b>Kinetics of occult hepatitis B infection in people with HIV switching from HBV-active ART to long-acting cabotegravir/rilpivirine</b><br>Alessia Magnapera (University of Rome Tor Vergata, Italy) | 14:54 - 15:03 |
| PS05.3 | <b>Analysis of tuberculosis preventive treatment cascade among people living with HIV in the country of Georgia: a mixed methods study</b>  | 15:03 - 15:12 |
| PS05.4 | <b>Evaluating Plasma Proteome Signatures for Active Tuberculosis Prediction and Immune Profiling in People With HIV</b><br>Katharina Kusejko (University Hospital Zurich, Switzerland)                | 15:12 - 15:21 |

*Parallel session*

14:30 - 15:30

Amphithéâtre Bordeaux

**PS06 - Cancer screening in people living with HIV: What's new?**

Botond Lakatos (National Institute of Hematology and Infectious Diseases, National Center of HIV, Hungary)

Lene Ryom (CHIP, Rigshospitalet, University of Copenhagen, Denmark)

- |        |   |               |
|--------|---|---------------|
|        | <b>Lung cancer screening</b><br>Alain Makinson (CHU de Montpellier, France)   | 14:30 - 14:40 |
|        | <b>Cervical and anal cancer screening</b><br>Mar Masià (Hospital General Universitario de Elche, Spain)   | 14:40 - 14:50 |
| PS06.1 | <b>Outcomes of cervical cancer screening among women with HIV in the Netherlands</b><br>Vita Jongen (Stichting hiv monitoring, Netherlands)   | 14:50 - 14:59 |
| PS06.2 | <b>Anal cancer screening in a cohort of women with HIV: uptake and outcome from a prospective study</b>   | 14:59 - 15:08 |
| PS06.3 | <b>Prostate Cancer in People Living with HIV (PLWH): Results from a Large Retrospective Multicentre Analysis in Germany</b><br>Malte Benedikt Monin (University Medical Center Hamburg-Eppendorf, II. Department of Medicine, Germany)                              | 15:08 - 15:17 |
| PS06.4 | <b>Evolving cancer incidence in persons with HIV in France between 2014-2023: A nationwide study using the French National Health Data System</b><br>Elhadji Leye (Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, France) | 15:17 - 15:26 |

*Parallel session*

14:30 - 15:30

Salle Maillot

**PS07 - Innovative mechanisms shifting the paradigm of treatment and prevention**

Elena Bruzzesi (IRCCS Ospedale San Raffaele, Italy)

François Dabis (University of Bordeaux, France)

- |        |  |               |
|--------|--|---------------|
|        | <b>HIV Capsid Dynamics and Lenacapavir's Role in Remodeling Viral Replication</b><br>Francesca Di Nunzio (Institut Pasteur, France)  | 14:30 - 14:40 |
|        | <b>Perspectives of bNAbs and vaccine research</b><br>Florian Klein (University Hospital, Germany)  | 14:40 - 14:50 |
| PS07.1 | <b>Safety and Analytical Treatment Interruption Outcomes in a Clinical Trial of 2 Broadly Neutralizing Antibodies Plus Vesatolimod in Early-Treated South African Women With Clade C HIV-1</b> | 14:50 - 14:59 |

	Daina Lim (Gilead Sciences, Inc., United Kingdom)	
PS07.2	<b>Lenacapavir Directs Specific Immunoproteasome-Mediated Degradation of Gag Proteins and Increases the killing of HIV-Infected Cells</b> Pierre Gantner (strasbourg university, France)	14:59 - 15:08
PS07.3	<b>Dasatinib enhances NK cell cytotoxicity and reverses functional exhaustion in HIV infection</b> María José Muñoz-Gómez (National Center of Microbiology, Instituto de Salud Carlos III, Spain)	15:08 - 15:17
PS07.4	<b>Germline-Targeting HIV-1 Env Ferritin Nanoparticles Elicit V2-Apex-Directed Antibodies in Rhesus Macaques</b>	15:17 - 15:26
<i>Breaks</i>		
15:30 - 16:15		Grand Amphitheatre
<b>Coffee break</b>		
<i>Moderated ePosters</i>		
15:35 - 16:10		ePoster Exhibition
<b>MeP09 - Late Breaking Science</b>		
<i>Moderated ePosters</i>		
15:35 - 16:10		ePoster Exhibition
<b>MeP12 - Co-infections and vaccination</b>		
Gilles Wandeler (Bern University Hospital, Switzerland)		
MeP12.1	<b>Prevalence, Incidence, and Clearance of Anal HPV Infection Among MSM in Japan: A Longitudinal Cohort Study</b> Naokatsu Ando (National Center for Global Health and Medicine, Japan Institute for Health Security, Japan)	15:35 - 15:40
MeP12.2	<b>The Impact of COVID-19 on HIV Care Disruption and Return to Treatment in Mauritius: Findings from the COVIH-OI Qualitative Study</b> Kenny Emmanuel Eleonore (PILS (Prévention Information et Lutte contre le SIDA), Mauritius)	15:40 - 15:45
MeP12.3	<b>A case series of acute hepatitis B among PLWH switched to long acting (LA) Cabotegravir (CAB)/ Rilpivirine (RPV)</b>	15:45 - 15:50
MeP12.4	<b>Prevalence and Factors Associated with Liver Cirrhosis in People with HIV and Chronic Hepatitis B: A Cross-sectional Study in Spain, Germany, and Poland</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)	15:50 - 15:55
MeP12.5	<b>Understanding why modelling studies by the Center for Disease Analysis Foundation fail to provide reliable estimates of Hepatitis C prevalence in Northern and Western Europe</b> Barbara Bertisch (Checkin Zollhaus, Switzerland)	15:55 - 16:00
MeP12.6	<b>Significantly More HIV-Seropositive Adults(PLWHA) Lack Detectable Anti-Measles IgG After Childhood Measles, Mumps, Rubella (MMR) Vaccinations When Compared to HIV-Seronegative Controls</b> Gary Blick (Health Care Advocates International, United States)	16:00 - 16:05
MeP12.7	<b>Impact of Antimicrobial Prophylaxis on AIDS-Defining Events in People with HIV: a Multicenter Experience</b> Chiara Fusetti (Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Italy)	16:05 - 16:10

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP10 - Drug-resistance and defective virus**

Silvia Nozza (Vita-Salute San Raffaele University, Italy)

- |         |   |               |
|---------|---|---------------|
| MeP10.1 | <b>Population Pharmacokinetics, Antidrug Antibodies and Exposure-Response of VH3810109 (N6LS) in Virologically Suppressed Adults Living With HIV From the Phase 2b EMBRACE Study</b><br>A. Yin Edwards (Certara, United States)           | 15:35 - 15:40 |
| MeP10.2 | <b>High <i>in vitro</i> resistance barrier for the bictegravir/lenacapavir combination</b><br>Michelle L. D'Antoni (Gilead Sciences, Inc., United States)   | 15:40 - 15:45 |
| MeP10.3 | <b>Genotypic susceptibility to broadly neutralizing antibodies and fostemsavir of transmitted viruses, and evolution over time in the French acute HIV infection PRIMO cohort</b><br>Hegger Machado Fritsch (Université de Tours, France) | 15:45 - 15:50 |
| MeP10.4 | <b>Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial</b><br>Jose Arribas (Hospital La Paz, Spain)   | 15:50 - 15:55 |
| MeP10.5 | <b>How Should APOBEC3-induced Resistance Mutations be Considered in the Management of Antiretroviral Therapy?</b><br>Marie Gilbert (Bichat Claude Bernard - APHP, France)   | 15:55 - 16:00 |
| MeP10.6 | <b>Nucleocapsid mutations at time of virological failure with an integrase inhibitor</b><br>Quentin Le Hingrat (AP-HP, France)  | 16:00 - 16:05 |
| MeP10.7 | <b>Defects in the 5' Long Terminal Repeat of HIV-1 May Help Differentiate Active Replication From Non-Suppressible Low-Level Viremia</b>  | 16:05 - 16:10 |

*Moderated ePosters*

15:35 - 16:10





ePoster Exhibition

**MeP11 - Cardiovascular and metabolic diseases**

Casper Rokx (Erasmus MC University Medical Center, Netherlands)

- |         |  |               |
|---------|--|---------------|
| MeP11.1 | <b>HIV infection is strongly associated with acute myocardial infarction, independently of age, gender, and comorbidities: a population-based cohort study</b><br>Robert Güerri-Fernández (Hospital del Mar, Spain)  | 15:35 - 15:40 |
| MeP11.2 | <b>Systolic inter-arm blood pressure difference and coronary artery disease in people with HIV</b><br>Sávio Amaral (Federal University of Bahia, Brazil)   | 15:40 - 15:45 |
| MeP11.3 | <b>Healthcare Utilization and Costs in People Living with HIV With and Without Hypertension and Type 2 Diabetes Mellitus in the United States</b><br>Sean P. Fleming (Merck & Co., Inc., United States)  | 15:45 - 15:50 |
| MeP11.4 | <b>Rethinking obesity: applying the Lancet Commission framework on clinical obesity to people living with HIV in South Africa</b><br>Joana Woods (University of Witwatersrand, South Africa)   | 15:50 - 15:55 |
| MeP11.5 | <b>Comparable gut microbiome composition and diversity in people living with HIV with and without metabolic dysfunction-associated steatotic liver disease</b><br>Magnus Søltøft Lindhardt (Copenhagen University Hospital - Amager and Hvidovre, Denmark) | 15:55 - 16:00 |
| MeP11.6 | <b>Prevalence and associated risk factors for MASLD in people living</b>   | 16:00 - 16:05 |



	<b>with HIV: highlighting metabolic syndrome components</b> Adrian Rodriguez (Hospital Universitari Son Llatzer, Spain)	
MeP11.7	<b>Prevalence of Addictive behaviours in MSM practicing Chemsex, and impact on their sexuality: results of the PACmen study</b> Thomas L'yavanc ("Le 190" Sexual Health Center, France)	16:05 - 16:10
<i>Moderated ePosters</i> 15:35 - 16:10		
<b>Moderated ePoster Sessions 9 - 12</b>		ePoster Exhibition
<i>Industry sponsored session</i> 16:15 - 17:15		
<b>Industry sponsored session</b> Live broadcasted session 		Amphithéâtre Bleu
<i>Industry sponsored session</i> 16:15 - 17:15		
<b>Industry sponsored session</b> Live broadcasted session 		Amphithéâtre Bordeaux
<i>Roundtable Discussion</i> 16:15 - 17:15		
<b>RT2 - HBV reactivation in people living with HIV</b> Live broadcasted session 		Salle Maillot
Christoph Boesecke (Department of Medicine I, Bonn University Hospital, Germany)		
	<b>Risk of HBV reactivation in people living with HIV receiving NRTI sparing dual therapy</b> Tetiana Melnyk (Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, INSERM, France)	16:15 - 16:25
	<b>Roundtable Discussion on HBV reactivation in people living with HIV</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain) Sanjay Bhagani (Royal Free London NHST Trust, United Kingdom) Karine Lacombe (Sorbonne Université, France)	16:25 - 17:15
<i>Special session</i> 16:15 - 17:15		
<b>SPS3 - EATG</b>		Room 252 AB
<i>Special session</i> 16:15 - 17:15		
<b>SPS4 - SFLS</b>		Room 242 AB
<i>Special session</i> 17:30 - 18:30		
<b>EACS Guidelines session</b> Live broadcasted session 		Grand Amphitheatre
Jürgen K Rockstroh (University Hospital Bonn, Germany) Juan Ambrosioni (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain)		


<b>Part I</b>	17:30 - 17:30
<b>Antiretrovirals for treatment and prevention</b>	17:30 - 17:40
Laura Levi (Hôpital Bicêtre, France)	
<b>Pediatric HIV</b>	17:40 - 17:50
Paolo Paioni (Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Switzerland)	
<b>HIV Co-infections</b>	17:50 - 18:00
Andrea Mastrangelo (Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland, Switzerland)	
<b>Part II</b>	18:00 - 18:00
<b>Co-morbidities</b>	18:00 - 18:15
Abiu Sempere (Hospital Clinic, Spain)	
Jasmini Alagaratnam (Chelsea and Westminster Hospital, United Kingdom)	
<b>Discussion</b>	18:15 - 18:30
Alexandra Calmy (Geneva University Hospital, University of Geneva, Switzerland)	
Catia Marzolini (University Hospital Lausanne and University Hospital Basel, Switzerland)	
Steven Welch (University Hospitals Birmingham NHS Foundation Trust, UK, United Kingdom)	
Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)	

*Industry sponsored session*

18:45 - 20:15

Amphithéâtre Bleu

**Industry sponsored session**

Live broadcasted session 

Friday, October 17, 2025

*Industry sponsored session*


08:00 - 09:00

Amphithéâtre Bleu

**Industry sponsored session**Live broadcasted session *Meet-the-expert*

08:00 - 09:00

Amphithéâtre Bordeaux

**MTE3 - Invisible Battles: Mental and Neurological Health**Live broadcasted session **HIV-Related Brain Injury in 2025: Evolving Diagnosis and Treatment**

08:00 - 08:10

Paola Cinque (San Raffaele Scientific Institute, Milano, Italy, Italy)

**Mental health challenges in people living with HIV**


08:10 - 08:20

Jordi Blanch (Hospital Universitari Santa Maria de Lleida, Hospital Clínic de Barcelona, Spain)

*Meet-the-expert*

08:00 - 09:00

Salle Maillot

**MTE4 - Should we have ATI trials and how?**Live broadcasted session 

Sarah Fidler (Imperial College London UK, United Kingdom)

Beatriz Mothe (Department of Infectious Diseases and IrsiCaixa, Spain)

**RIO trial participant testimony**

08:00 - 08:05

MTE4.1

**Qualitative Insights into the Lived Experiences of People living with HIV who Participated in an Analytical Treatment Interruption in the RIO Randomised-Controlled Trial**


08:05 - 08:05

Jesal Gohil (Imperial College London, United Kingdom)

*Meet-the-expert*

08:00 - 09:00

Room 242 AB

**MTE5 - Weighing in on weight gain**Live broadcasted session 

Esteban Martínez (Hospital Clínic &amp; University of Barcelona, Spain)

**What does the data really tell us on weight gain in people living with HIV?**

08:00 - 08:10

Dominique Costagliola (Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, France)

**Therapeutic options for losing weight: GLP -1 receptor agonists and what else?**

08:10 - 08:20

Paddy Mallon (UCD School of Medicine, Ireland)

*ePosters*

09:00 - 18:00

ePoster on Display

**ePosters on Display****A. Basic and Translational Science**

09:00 - 09:00

eP001

**Refining the resistance landscape of lenacapavir in HIV-1 through**

09:00 - 09:00

	<b>cell-based selection</b> Jolieke A. T. van Osch (Erasmus University Medical Center, Netherlands)	
eP002	<b>Dasatinib enhances innate macrophage restriction and limits HIV-1 replication</b> Clara Sánchez Menéndez (National Center of Microbiology, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP003	<b>HIV persistence in cisgender women after long periods on ART: could be shaped by the route and moment of HIV acquisition?</b> Lucia Baquero (CONICET-Universidad de Buenos Aires. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Argentina)	09:00 - 09:00
eP004	<b>HIV-specific CD8+ T-cell response drives viral selection and integration site in silent regions in individuals treated during the acute phase of HIV acquisition</b> Pien van Paassen (Amsterdam UMC, Netherlands)	09:00 - 09:00
eP005	<b>HIV-specific T-cell immune response in elite controllers</b> Leonel Cruces (Institute for Biomedical Research on Retrovirus and Aids (INBIRS), Argentina)	09:00 - 09:00
eP006	<b>Linking Gut Microbiome to HIV Reservoir Size in People Living with HIV</b> Oscar Kieri (Karolinska Institutet, Sweden)	09:00 - 09:00
eP007	<b>Longitudinal dynamics of virology, immunity, and HIV-1 reservoir in people living with HIV and cancer: impact of antitumor therapy and immune checkpoint inhibitors</b> Jingchun Mao (Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, China)	09:00 - 09:00
eP008	<b>Machine learning identified genetic features associated with HIV Sequences in the Monocytes</b> Xiaorong Peng (Zhejiang University, China)	09:00 - 09:00
eP009	<b>Variations in sero-biomarkers of gut barrier dysfunction and sCD14 in ART-naïve PWH initiating ART</b> Valentina Iannone (Università Cattolica del Sacro Cuore, Roma, Italy)	09:00 - 09:00
eP010	<b>Decoding HIV: Two Technologies, One Genome</b> Federica Stefanelli (IRCCS San Martino Hospital, Italy)	09:00 - 09:00
eP011	<b>False Positivity in HIV Screening Using Fourth-Generation Assay: Performance and Potential Influencing Factors in a Low Prevalence Population</b> Lily Shui-kuen Cheng (United Christian Hospital, Hong Kong)	09:00 - 09:00
eP012	<b>Feasibility and reliability of decentralized HIV-1 viral load monitoring on self-sampled blood</b> Kyra Mendes de Leon (Amsterdam UMC, Netherlands)	09:00 - 09:00
eP013	<b>Limited Performance of FIB-4 and NAFLD Fibrosis Score for Detecting Liver Fibrosis in People Living with HIV</b> Rahma Mohamed (Cairo University, Egypt)	09:00 - 09:00
eP014	<b>Whole-Genome Sequencing for HIV-1 drug resistance testing: are we ready?</b> Federica Stefanelli (IRCCS San Martino Hospital, Italy)	09:00 - 09:00
eP015	<b>Dynamic Crosstalk Between MAIT Cells and NK Cells in Incomplete Immune Reconstitution of Individuals acquiring HIV</b> Zhuoya Deng (Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00

eP016	<b>Dynamics and Immunological Signature of <math>\gamma\delta</math> T Cells Following Antiretroviral Therapy Initiation in Acute HIV-1 Infection</b> Zhen Li (Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP017	<b>Extracellular Acyl-CoA-Binding Protein prevents autophagy and T-cell function in people with HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP018	<b>Immune checkpoint patterns in cerebrospinal fluid after ART initiation related to neurocognitive decline among PWH</b> ANA JOY LOZANO (UNIVERSITY OF THE PHILIPPINES MANILA, Philippines)	09:00 - 09:00
eP019	<b>Modulation of TLR-Driven Monocyte Activation by JAK-STAT Inhibitors in People With HIV</b> Marion Camard (Université Paris-Saclay, Inserm, CEA, France)	09:00 - 09:00
eP020	<b>Reduction of immune- senescence in People with HIV (PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine</b> Mariasilvia Guardiani (Sapienza University of Rome, Italy)	09:00 - 09:00
eP021	<b>Tenascin-C Bridges Biomarker Discovery and Immune Modulation in Incomplete Immune Reconstitution Among People Living with HIV</b> Zhuoya Deng (Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP022	<b>Type I Interferon Drives Myeloid-Mediated T-Cell Activation in People Living with HIV Under Antiretroviral Therapy</b> Léo Plaçais (Unité INSERM U1184, laboratoire IDMIT, Commissariat à l'énergie atomique, France)	09:00 - 09:00
eP023	<b>ANTIOXIDANT CAPACITY IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY</b> Radoslava Emilova (National Center of Infectious and Parasitic Diseases, Bulgaria)	09:00 - 09:00
eP024	<b>Differential expression of ER-TR7 following challenge with more recent antiretroviral drugs: an <i>in vitro</i> model</b> Maria Aurora Carleo (AO dei Colli - PO "D. Cotugno", Italy)	09:00 - 09:00
eP026	<b>Functional characterization of the HIV-2 V3 loop: Insights into host interaction and viral tropism</b> Paloma Gonçalves (Research Institute for Medicines, Faculty of pharmacy, Universidade de Lisboa, Portugal)	09:00 - 09:00
eP027	<b>High levels of anti-HHV-8 IgG binding capacity are linked with low HHV-8 viremia in people with and without HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP028	<b>Identification of transcriptional active SIV-infected cells in Rhesus Macaques</b> Jerome Estaquier (Université Laval, Canada)	09:00 - 09:00
eP029	<b>Impaired Immune Reconstitution in PLWH: the Role of CD4<sup>+</sup>T-Cell-Associated NKG2D Ligands and CD4<sup>+</sup>T-Cell Subsets Imbalance</b> Peng Xu (Beijing Youan Hospital, Capital Medical University, China)	09:00 - 09:00
eP030	<b>Markers of astroglial/monocyte activation and inflammation are associated with neurocognitive impairment in people with HIV on suppressive ART</b> Matteo Augello (University of Milan, Italy)	09:00 - 09:00

eP031	<b>Microglia cause HIV-induced transcriptional and metabolomic changes in human brain organoids leading to neurological impairment</b> Pamela E. Capendale (OrganoVIR Labs, Emma Children's Hospital, Department of Pediatric Infectious Diseases, Amsterdam UMC, location Academic Medical Center,, Netherlands)	09:00 - 09:00
eP032	<b>Myeloid production of the mitokine GDF15 is associated with HIV reservoir size and non-AIDS comorbidity marker in ART-treated people with HIV</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP033	<b>Single-Cell Transcriptomic Analysis Reveals Nef-Induced Dysregulation of Hematopoietic Stem Cell Development and Aging-Associated Pathways in HIV Infection</b> Wei Zou (Nanchang University/the 1st affiliated hospital, China)	09:00 - 09:00
eP034	<b>A Systematic Analysis of Immune Responses Following BCG Vaccination in People with HIV</b> Johannes Nemeth (University Hospital Zurich, Switzerland)	09:00 - 09:00
eP035	<b>Optimized Expression of CD4-Inducible (CD4i) Epitopes in HIV-1 Vaccine Prototypes Based on Virus-Like Particles (VLPs)</b> ALMUDENA RUBIO-PEREZ (CENTRO NACIONAL DE MICROBIOLOGÍA, INSTITUTO DE SALUD CARLOS III, Spain)	09:00 - 09:00
eP036	<b>Development of diagnostic/prognostic marker and therapeutic target for HCV-mono- and HIV/HCV-co-infection-mediated liver diseases</b> IN-WOO PARK (University of North Texas Health Science Center, United States)	09:00 - 09:00
eP037	<b>Low-level viraemia (LLV) in people living with HIV and its management at an HIV centre in London</b> Matthew Valentino (Mater Dei Hospital, Malta)	09:00 - 09:00
eP038	<b>Novel NGS-based Pipeline for HIV-1 pol Region Analysis</b> Arina Syrkina (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP039	<b>Proviral DNA genotyping among patients living with HIV with Undetectable Viral Load or Low-Level Viral Load</b> Dan Turner (Tel Aviv Sourasky Medical Center/ Faculty of Medicine, Tel Aviv University, Israel)	09:00 - 09:00
eP040	<b>Exploration of the genetic diversity and the evolution of HIV-1 non-B subtypes in Serbia: phylogenetic information beyond viral spread</b> Marina Siljic (University of Belgrade, Faculty of Medicine, Institute of Microbiology and Immunology, Serbia)	09:00 - 09:00
eP041	<b>Using Nanopore sequence data to analyse drug resistance profile and its association with phylodynamics from HIV quasispecies</b> Tsz Ho Kwan (The Chinese University of Hong Kong, Hong Kong)	09:00 - 09:00
	<b>B1. Clinical Science - Antiretroviral therapy</b>	09:00 - 09:00
eP042	<b>A Clinical Pathway for the Use of Long-Acting Injectable antiretroviral therapy (LAI-ART) in Adherence Challenged People Living with HIV</b> Siobhan Quirke (GUIDe Clinic, Ireland)	09:00 - 09:00
eP043	<b>A combined dolutegravir-rilpivirine oral regimen as lead-in therapy for long-acting injectable antiretroviral treatment in people living with HIV</b> Mayda Rahi (Assistance Publique – Hôpitaux de Paris, Nord. Hôpital	09:00 - 09:00

	Bichat-Claude Bernard, France)	
eP044	<b>Adverse events and treatment discontinuation in a large, observational cohort of PLHIV starting Dolutegravir or non-Dolutegravir-based antiretroviral therapy (ART) in Brazil: The CODE cohort</b> Carlos Brites (FEDERAL UNIVERSITY OF BAHIA, Brazil)	09:00 - 09:00
eP045	<b>Analysis of viral load and INSTI resistance in people with HIV-1A6 receiving oral second generation INSTI</b> Maarten van de Klundert (Karolinska institutet, Sweden)	09:00 - 09:00
eP046	<b>Antiviral exposure and risk of Metabolic Dysfunction-Associated Steatotic Liver Disease</b> Magnus Søltø Lindhardt (Copenhagen University Hospital - Amager and Hvidovre, Denmark)	09:00 - 09:00
eP047	<b>B/F/TAF in Latin American Elderly PLWH: A 96-Week Analysis of Effectiveness, Safety, and Metabolic Outcomes from the BICTARG Cohort</b> Cinthia Lamaizon (Helios Salud, Argentina)	09:00 - 09:00
eP048	<b>Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV Aged ≥50: Low Discontinuation Rates and Favorable Metabolic Outcomes Over 36 Months</b> Andrea De Vito (University of Sassari, Italy)	09:00 - 09:00
eP049	<b>CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France</b> Patrick Philibert (Hôpital Européen Marseille, France)	09:00 - 09:00
eP050	<b>Changes in Neuronal Injury and Inflammation Biomarkers in CSF of People Switching to Doravirine plus Raltegravir</b> Analuz Fernández (Hospital Universitari de Bellvitge, Spain)	09:00 - 09:00
eP051	<b>CHANGES IN QUALITY OF LIFE IN PEOPLE LIVING WITH HIV SWITCHING TO DOLUTEGRAVIR-BASED REGIMENS, FROM STABLE OR FAILING CURRENT ANTIRETROVIRAL REGIMENS IN THE CODE COHORT</b> Liliane Lins-Kusterer (FEDERAL UNIVERSITY OF BAHIA, Brazil)	09:00 - 09:00
eP052	<b>Changes in weight and BMI associated with switching to doravirine/lamivudine/tenofovir disoproxil fumarate vs. continuing an integrase inhibitor- or protease inhibitor-based regimen- an observational prospective case-control study</b> Charlotte-Paige Rolle (Orlando Immunology Center, United States)	09:00 - 09:00
eP053	<b>Characteristics and Outcomes of People with HIV (PWH) Virally Suppressed on Complex Regimens</b> Richard Elion (Trio Health, United States)	09:00 - 09:00
eP054	<b>Clinical and immunovirological outcomes in advanced people living with HIV receiving dual versus triple drug regimens: a real-world cohort study</b> Emanuela Zappulo (University of Naples Federico II, Naples, Italy, Italy)	09:00 - 09:00
eP055	<b>Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2-drug or continuing 3-drug therapy over 18-months of follow-up</b> Lia Fiaschi (University of Siena, Italy)	09:00 - 09:00
eP056	<b>Comparative Dynamics of Inflammatory Biomarkers in Antiretroviral-Naïve MSM with HIV initiating DTG/3TC versus BIC/FTC/TAF</b>	09:00 - 09:00

	Ran Wang (Beijing Youan Hospital, Capital Medical University, China)	
eP057	<b>Comparison of HIV diagnosis and treatment features in cis- and trans-gender women in two different European Centres (London and Padua)</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP058	<b>COMPARISON OF THE RESPONSE TO ANTIRETROVIRAL TREATMENT BETWEEN LATE PRESENTING AND OTHER ADULT PEOPLE LIVING WITH HIV: A 13- YEAR SINGLE-CENTER EXPERIENCE</b> Narmin Huseynova (Izmir Katip Celebi University, Atatürk Education Research Hospital, Turkey)	09:00 - 09:00
eP059	<b>Differences on Clinical and Virological Outcomes of Cabotegravir + Rilpivirine Long Acting between Men and Women in the Dat'AIDS Cohort</b> Clotilde Allavena (CHU Nantes, France)	09:00 - 09:00
eP060	<b>Discontinuations of long-acting injectable cabotegravir and rilpivirine in observational cohorts</b> Chloe Pasin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP061	<b>Does adherence to CAB + RPV decrease over time in real world? A substudy from the RELATIVITY cohort</b> Luis Buzon Martín (Hospital Universitario de Burgos, Spain)	09:00 - 09:00
eP062	<b>DOLAM-500: 48 and 96-Week Real-World Efficacy and Safety of Dolutegravir Plus Lamivudine in ART-Naïve Individuals with Baseline HIV-1 RNA <math>\geq 500,000</math> copies/mL</b> Asuman İnan (Saglik Bilimleri University, Turkey)	09:00 - 09:00
eP063	<b>DOLANKA: Real World Data on the use of two drug regimen Dolutegravir (DTG) + Lamivudine (3TC) in treatment-naïve people living with HIV in Ankara-Turkey: Interim analysis results</b> MELIHA CAGLA SONMEZER (Hacettepe University Faculty Of Medicine, Turkey)	09:00 - 09:00
eP064	<b>DTG/3TC AS INITIAL THERAPY IN PEOPLE LIVING WITH HIV AND VIRAL LOAD <math>&gt;500,000</math> COPIES/ML AND CD4 CELL COUNT <math>\geq 200/\text{mm}^3</math></b> Juan Martin-Torres (Hospital Universitario 12 de Octubre, Spain)	09:00 - 09:00
eP065	<b>Dual Antiretroviral Therapy Is More Commonly Used in Men than in Women Living with HIV - Findings from the German North-Rhine Cohort</b> Heribert Knechten (PZB Aachen, Germany)	09:00 - 09:00
eP066	<b>Durability and reasons for treatment discontinuation of BIC/FTC/TAF in real life: data from 927 Persons With HIV in charge to "D. Cotugno" hospital, Naples, Southern Italy</b> Francesco Maria Fusco ("D. Cotugno" hospital, Azienda Ospedaliera dei Colli, Italy)	09:00 - 09:00
eP067	<b>Durability of Long-Acting Cabotegravir + Rilpivirine in virologically suppressed adults living with HIV: A Multicenter Observational Study in Tuscany (LAHIV)</b> Filippo Lagi (Azienda Ospedaliero Universitaria Careggi, Italy)	09:00 - 09:00
eP068	<b>Durability of viral suppression following antiretroviral therapy optimization to TLD among treatment-experienced adults living with HIV in Tajikistan</b> Aziz Nabidzhonov (U.S. Centers for Disease Control and Prevention, Tajikistan)	09:00 - 09:00
eP069	<b>Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir</b>	09:00 - 09:00



	<b>alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV TR cohort</b> Halis Akalın (Bursa Uludağ University Faculty of Medicine, Turkey)	
eP070	<b>Effectiveness of switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from NNRTI-based ART in virologically suppressed people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH Study)</b> Roberta Gagliardini (INMI L. Spallanzani IRCCS, Italy)	09:00 - 09:00
eP071	<b>Epidemiological situation of HIV treatment in Tunisia, 2024</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP072	<b>Equal risk of confirmed virological failure among individuals using long-acting injectable cabotegravir/rilpivirine during first and second year of follow-up: results from the Dutch ATHENA national observational cohort</b> Ferdinand W. N. M. Wit (Stichting hiv monitoring, Netherlands)	09:00 - 09:00
eP073	<b>High Uptake of Intermittent Drug-Reduced ART Strategies Among Virally Suppressed People Living with HIV (PWH) at an HIV Clinic in Paris, France</b> Christine Katlama (Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, France)	09:00 - 09:00
eP074	<b>HIV-2: Viraemias in the course of untreated and treated "People Living With HIV-2" (PLWH2) in an observational cohort ("H2O") from Hamburg</b> Dirk Berzow (Praxis Eimsbüttel, Germany)	09:00 - 09:00
eP075	<b>Impact of Antiretroviral Therapy (ART) Regimen Initiation or Switch in Virologically Suppressed People With Human Immunodeficiency Virus-1 (HIV-1) on Lipid Profile at 48 weeks: A Systematic Literature Review</b> Julián Olalla (Hospital Costa del Sol, Spain)	09:00 - 09:00
eP076	<b>Impact of bictegravir/emtricitabin/tenofovir alafenamid (BIC/TAF/FTC) and Dolutegravir/Lamivudine on Depression Symptoms in People Living with HIV: A Retrospective Analysis of Beck Depression Inventory Scores</b> Oguz Karabay (Sakarya University, Turkey)	09:00 - 09:00
eP077	<b>Impact of nucleoside reverse transcriptase inhibitor resistance-associated mutations on long-term virologic suppression of bictegravir/emtricitabine/tenofovir alafenamide: real-world evidence</b> Cinthia Lamaizon (Helios Salud, Argentina)	09:00 - 09:00
eP078	<b>IMPACT OF PREEXISTING K103N ON THE EFFECTIVINES OF LA-CAB+RPV: REAL-LIFE RELATIVITY COHORT</b> Luz Martín Carbonero (Hospital Universitario La Paz, Spain)	09:00 - 09:00
eP079	<b>Impact of treatment simplification in people living with HIV-2 - a retrospective study conducted in Hospital Beatriz Ângelo</b> Beatriz Adragão Fernandes (Faculdade de Medicina da Universidade de Lisboa, Portugal)	09:00 - 09:00
eP080	<b>Implementation of a same-day ART start model in a real-life setting in Italy</b> Giulia Micheli (National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP081	<b>Implementation Outcomes and Preliminary Effectiveness of Digitally Administering an Electronic Patient-Reported Outcome Measure of Barriers to Adherence to Antiretrovirals (the I-Score) in</b>	09:00 - 09:00

	<b>HIV Care</b> David LESSARD (Research Institute of the McGill University Health Centre, Canada)	
eP082	<b>Increasing CD4/CD8 Ratio Confirmed after Two Years of Long-Acting Cabotegravir and Rilpivirine in the SCoholART Study</b> Gabriele Loi (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP083	<b>Living with HIV-2: Clinical and Therapeutic Profile of a Cohort Followed in a Portuguese Local Health Unit</b> Diana Briosa Reis (Unidade Local de Saúde do Algarve, Portugal)	09:00 - 09:00
eP084	<b>Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV</b> Júlia Calvo (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP085	<b>Long-Acting CAB + RPV: Safety, Efficacy, and Discontinuation Risks in ODOACRE Cohort</b> Andrea De Vito (University of Sassari, Italy)	09:00 - 09:00
eP086	<b>Long-Acting Cabotegravir-Rilpivirine in Real-Life: Sex-based Characteristics and Effectiveness</b> Ana González-Cordón (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP087	<b>Long-Acting Cabotegravir-Rilpivirine in Vulnerable Population: Chemsex Practices-based Analysis</b> Maria Martínez-Rebollar (HIV Unit, Infectious Diseases Service, Hospital Clínic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Spain)	09:00 - 09:00
eP088	<b>Long-Acting HIV Treatment in Practice: Promising Outcomes and Real-World Challenges from the CACTUZ Cohort</b> Caroline Matthys (Ghent University Hospital, Belgium)	09:00 - 09:00
eP089	<b>Long-acting injectable cabotegravir and rilpivirine outcomes in HIV individuals with stable treatment with dolutegravir and rilpivirine</b> María José Galindo Puerto (Hospital Clínico Universitario of Valencia, Spain)	09:00 - 09:00
eP090	<b>LONG-TERM BIC/TAF/FTC DURABILITY AND IMPACT OF DTG/3TC OR LONG-ACTING CABO/RPV</b> Ana Moreno Zamora (Hospital Ramón y Cajal, Spain)	09:00 - 09:00
eP091	<b>Long-term effectiveness of bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed people with HIV across age strata: observational data from the ICONA-BIC Study</b> Alessandro Tavelli (Icona Foundation, Italy)	09:00 - 09:00
eP092	<b>Long-Term Metabolic and Safety Profiles of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in HIV Treatment: A Multicenter Retrospective Study Using Mixed-Effects Modeling</b> Oguz Karabay (Sakarya University, Turkey)	09:00 - 09:00
eP093	<b>Modulation of biomarkers of CNS inflammation, immune activation and neuronal injury in PWH switching to long-acting injectable cabotegravir/rilpivirine therapy: 12 months of follow-up</b> Maria Antonella Zingaropoli (Sapienza University of Rome, Italy)	09:00 - 09:00
eP094	<b>One-Year Clinical Outcomes of Second-generation Integrase Inhibitors Therapy in Late HIV Presenters in Egypt and Saudi Arabia</b> Hanan Hamdy (Cairo university, Egypt)	09:00 - 09:00

eP095	<b>PAtient Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis</b> Eva Fernvik (ViiV Healthcare, Sweden)	09:00 - 09:00
eP096	<b>Patient-Reported Health and Virological Outcomes Among People with HIV Switching to Long-Acting Injectable Cabotegravir and Rilpivirine (LANTERN)</b> CHIEN-YU Cheng (Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan)	09:00 - 09:00
eP097	<b>Patient-Reported Outcomes and Experiences in a Diverse HIV Cohort Initiating Rapid B/F/TAF: The ASAP Study</b> Dominic Chu (McGill University, Canada)	09:00 - 09:00
eP098	<b>Profile of comorbidities in individuals who are receiving Long-Acting Cabotegravir and Rilpivirine: Real-World Insights from the RELATIVITY Cohort</b> María José Galindo Puerto (Hospital Clinico Universitario of Valencia, Spain)	09:00 - 09:00
eP099	<b>Real life data of people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide with baseline CD4+ count below 200 cells/mL (BicAdvance study)</b> Diego Ripamonti (ASST Papa Giovanni XXIII, Italy)	09:00 - 09:00
eP100	<b>Real life experience with Doravirine-based treatment: therapeutic efficacy and influence on lipid and T-cell immune profile</b> Riccardo Nardo (Università degli Studi di Milano, Italy)	09:00 - 09:00
eP101	<b>Real world use of lenacapavir in France: a national, observational study</b> Romain Palich (Pitié-Salpêtrière University Hospital, AP-HP, France)	09:00 - 09:00
eP102	<b>Real-Life Effectiveness, Safety, and Patient-Reported Outcomes of Long-Acting Cabotegravir-Rilpivirine: Results from a large single center cohort</b> Ana González-Cordón (Hospital Clínic de Barcelona - IDIBAPS - Universitat de Barcelona, Spain)	09:00 - 09:00
eP103	<b>Real-World Effectiveness and Tolerability of Cabotegravir + Rilpivirine Long-Acting in People Living with HIV-1: A Meta-Analysis of Real-World Evidence</b> Chloe Orkin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP104	<b>Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The "AReTi" Study Results</b> Dimitrios Athanasopoulos (GSK & ViiV Healthcare, Greece)	09:00 - 09:00
eP105	<b>Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations</b> Chloe Pasin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP106	<b>Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada</b> Jean-Francois Fortin (ViiV Healthcare, Canada)	09:00 - 09:00
eP107	<b>Reasons for switching to long-acting injectable antiretroviral therapy with cabotegravir/rilpivirine among adult people living with HIV: the real-life PANTER study</b> Martin Duracinsky (Patient-Reported Outcomes Research (PROQOL), Health Economics Clinical Trial Center (URC-ECO), Hôtel-Dieu Hospital, AP-HP, 75004, France)	09:00 - 09:00

eP108	<b>Results at month 12 of CABO-CHANCE study: real-world-evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every two months in viral suppressed people with HIV (PWH)</b> Carmen Hidalgo Tenorio (Hospital Universitario Virgen de las Nieves, Spain)	09:00 - 09:00
eP109	<b>Risk of virological failure after switch to a tenofovir-sparing dual therapy in virologically suppressed people with HIV and past HBV infection</b> Alberto Borghetti (Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Istituto Malattie Infettive, Italy)	09:00 - 09:00
eP110	<b>Risk of virological rebound is similar in people with HIV switching to long-acting cabotegravir/rilpivirine or integrase inhibitor-based oral therapy</b> Flavia Badalucco Ciotta (Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP111	<b>Subtype-Dependent Clinical and Immunological Patterns of Acute HIV-1 Acquisition: A Retrospective Analysis from Southern China</b> Qiuyue Zhang (Third People's Hospital of Shenzhen, National Clinical Research Center for infectious Diseases, China)	09:00 - 09:00
eP112	<b>Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting and impact of tenofovir resistance</b> Alain Makinson (CHU de Montpellier, France)	09:00 - 09:00
eP113	<b>Switching to Generic Dolutegravir: Sustained Gains in Immunity, Viral Control, and Metabolic Stability</b> Ahmed M. Kamel (Cairo University, Egypt)	09:00 - 09:00
eP114	<b>Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort</b> Gianmaria Baldin (Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Italy)	09:00 - 09:00
eP115	<b>The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV</b> Maria Jesus Perez Elías (Hospital Universitario Ramón y Cajal, Spain)	09:00 - 09:00
eP116	<b>The Increasing Use of Two-Drug HIV Regimens</b> Sarah Brown (Research Partnership, United Kingdom)	09:00 - 09:00
eP117	<b>TR-DOLA: Real-world data on the use of Dolutegravir (DTG) + Lamivudine (3TC) in treatment-experienced people living with HIV in TURKIYE</b> Ayse Deniz Gokengin (Ege University Faculty of Medicine Hospital, Turkey)	09:00 - 09:00
eP118	<b>Treatment switch among US Medicare beneficiaries with HIV</b> James Jarrett (Gilead Sciences, United Kingdom)	09:00 - 09:00
eP119	<b>Trends in opportunistic diseases at antiretroviral therapy initiation, Croatia 2009-2023</b> Šime Zekan (University Hospital for Infectious Diseases, Croatia)	09:00 - 09:00
eP120	<b>Two versus three-drug Doravirine based regimens in real life: a multicentric observational study</b> Adriana Cervo (Infectious Diseases Unit, University Hospital of Modena, Italy)	09:00 - 09:00
eP121	<b>Two-year efficacy and durability of cabotegravir and rilpivirine in</b>	09:00 - 09:00

	<b>the SCohoLART study</b> Camilla Muccini (IRCCS San Raffaele Scientific Institute, Italy)	
eP122	<b>Unconventional DORAVIRINE antiretroviral regime: a single-center experience</b> Francesco Giovanni Genderini (Centre Hospitalier Universitaire Saint-Pierre-Université Libre de Bruxelles, Brussels, Belgium, Belgium)	09:00 - 09:00
eP123	<b>Variability in Laboratory Monitoring After Switching to Long-Acting CAB/RPV: Patterns and Associations with Virological Outcomes</b> Maria de Lagarde Sebastian (Hospital Universitario 12 de Octubre, imas12, CIBERINFEC, Spain)	09:00 - 09:00
eP124	<b>Virological Failure on Long-Acting Cabotegravir + Rilpivirine: Associated Factors and Remaining Options in the Real-World Dat'AIDS Cohort</b> Colin Deschanvres (Nantes University Hospital, France)	09:00 - 09:00
eP125	<b>7-Year Sustained Efficacy, Safety, and Immunological Improvement With Fostemsavir-Based Regimens in Individuals With HIV and Limited Treatment Options</b> Judith A. Aberg (Icahn School of Medicine, Mount Sinai Health System, United States)	09:00 - 09:00
eP126	<b>Comparable efficacy but greater discontinuations due to adverse events with dolutegravir-containing two-drug versus three-drug antiretroviral therapy: a systematic review and meta-analysis</b> Cassandra Fairhead (Royal Free London NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP127	<b>Cutoff for Baseline Phenotypic Sensitivity to VH3810109 (N6LS) Did Not Impact Occurrence of Confirmed Virologic Failure in the Phase 2b EMBRACE Study</b> Margaret Gartland (ViiV Healthcare, United States)	09:00 - 09:00
eP128	<b>Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a bictegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens</b> Chloe Orkin (Queen Mary University of London, United Kingdom)	09:00 - 09:00
eP129	<b>Efficacy, and safety of ainoovirine plus lamivudine, and tenofovir DF in young people with HIV-1: pooled analyses of RACER, and SPRINT studies, two randomized, active-controlled phase 3 trials</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP130	<b>Efficacy, and safety of ainoovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP131	<b>Evaluation of VH3810109 (N6LS) and Cabotegravir Long-Acting, Dual Modality, Injections for HIV Treatment: People With HIV and Staff Perspectives</b> Cassidy A Gutner (ViiV Healthcare, United States)	09:00 - 09:00
eP132	<b>Impact of switching from a bictegravir- or dolutegravir-based regimen with emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine on weight and metabolic profiles: a randomized, open-label, multicenter, parallel-group trial</b> Kensuke Minami (Jichi Medical University, Japan)	09:00 - 09:00
eP133	<b>Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results</b>	09:00 - 09:00

	Arman Papadakis Sali (Gilead Sciences, Inc., United States)	
eP134	<b>Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study</b> Carlos Brites (Fundação Bahiana de Infectologia, Brazil)	09:00 - 09:00
eP135	<b>Switch to DOR/TDF/3TC in People With Controlled HIV and history of RNA genotype M184V/I mutation: Interim Results of the DRIVE OFF-ROAD Multicenter Single-Arm Phase II trial</b> Jean-Jacques Parienti (Caen University Hospital, France)	09:00 - 09:00
eP136	<b>Treatment outcomes in people with a late HIV diagnosis: A pooled analysis of participants with advanced HIV disease at diagnosis randomized to receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)</b> Jürgen K Rockstroh (University Hospital Bonn, Germany)	09:00 - 09:00
eP137	<b>LONG-ACTING INJECTABLE ANTIRITROVIRAL TREATMENT</b> Kaddu Muhamed yahya (Abacus parenteral drugs limited, Uganda)	09:00 - 09:00
eP138	<b>Physician specialties involved in prescribing BIC/F/TAF and concomitant drugs in people with HIV (PWH) in Germany: implications for potential drug to drug interaction (DDI)</b> Guido Schäfer (ICH MVZ Grindel, Germany)	09:00 - 09:00
eP139	<b>Virological Outcomes in People Living With HIV on INSTI-based cART Receiving Paclitaxel for Kaposi Sarcoma: A Retrospective Cohort Study</b> Niroshan Dayalan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP140	<b>A French national real-world survey of people with multi-resistant HIV-1 viruses treated with an antiretroviral regimen including fostemsavir</b> Charlotte Charpentier (Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, France)	09:00 - 09:00
eP141	<b>APOBEC-associated mutations in proviral HIV-DNA: assessing their impact on long-acting cabotegravir/rilpivirine treatment suitability</b> Giovanni Massobrio (University of Genoa/IRCCS Ospedale Policlinico San Martino, Italy)	09:00 - 09:00
eP142	<b>Applications and Clinical Utility of Proviral HIV DNA Resistance Testing in Routine Practice: A Real-World Analysis</b> Neva Braccialarghe (University of Rome Tor Vergata, Italy)	09:00 - 09:00
eP143	<b>Distribution of HIV-1 Subtypes and Genotypic Resistance Analysis in People Living with HIV: A 9-Year Retrospective Evaluation</b> Ashhan Candevir (Çukurova University, Turkey)	09:00 - 09:00
eP144	<b>Drug resistance analysis of HIV-1 variants circulated in migrants MSM and transgender women living in Moscow, Russia in 2020-2025</b> Ilya Lapovok (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP145	<b>Dual Validation through Trend Analysis and Spatiotemporal Profiling: A Decade-Long Roadmap for HIV Genotypic Resistance Testing Scale-Up in China's Universal Free ART Programs (2014-2023)</b> Defu Yuan (Department of Epidemiology and Health Statistics, Key Laboratory of Environmental Medicine Engineering of Ministry of Education, School of Public Health, Southeast University, China)	09:00 - 09:00
eP146	<b>Durability of lenacapavir in viremic HTE PWH: real-world data from the PRESTIGIO Registry</b>	09:00 - 09:00

	Tommaso Clemente (IRCCS San Raffaele Scientific Institute, Italy)	
eP147	<b>Evidence of transmitted resistance to integrase strand transfer inhibitors (INSTIs) within local transmission clusters among antiretroviral therapy-naïve PLHIV in Greece</b> Evangelia Georgia Kostaki (National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP148	<b>Factors associated with maintenance of high CD4 counts in heavily treatment experienced multidrug resistance PWH: data from PRESTIGIO Registry</b> Maria Santoro (University of Rome "Tor Vergata", Italy)	09:00 - 09:00
eP149	<b>High virologic suppression in treatment-naïve people with HIV-1 on ainoovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP150	<b>HIV Drug Resistance in People Living with HIV (PLWH) in Congo: Implications for Optimizing Therapy in Resource-Limited Settings</b> Dominic Rauschnig (University Hospital Cologne, Germany)	09:00 - 09:00
eP151	<b>HIV-1 genetic diversity and transmitted drug resistance among newly diagnosed HIV-positive individuals in Eastern European and Central Asian countries</b> Alina Kirichenko (Central Research Institute of Epidemiology, Russian Federation)	09:00 - 09:00
eP152	<b>HIV-2 Drug Resistance in Portugal: NGS data from 2023-2024</b> Fátima Gonçalves (Hospital de Egas Moniz- Unidade Local de Saúde de Lisboa Ocidental, Portugal)	09:00 - 09:00
eP153	<b>HIVANKA: Temporal Trends of Transmitted Drug Resistance and Subtype Distribution in Newly Diagnosed People in Ankara, Turkey (2016-2024)</b> MELIHA CAGLA SONMEZER (Hacettepe University Faculty Of Medicine, Turkey)	09:00 - 09:00
eP154	<b>Impact of PrEP on HIV-1 Diversity and Drug-Resistance Mutations in Newly Diagnosed HIV-1 Individuals in Málaga (Southern Spain) from 2016 to 2023</b> María López Jódar (Biomedical Research Institute of Malaga. Hospital Universitario Virgen de la Victoria, Spain)	09:00 - 09:00
eP155	<b>Integrase Resistance Mutations in Treatment-Naive Persons with Advanced Immunodeficiency Initiating Dual Therapy with Dolutegravir and Lamivudine</b> Maria Figueroa (Fundacion Huesped, Argentina)	09:00 - 09:00
eP156	<b>Potential for replacing the boosted-PI with doravirine in ART-experienced subjects successfully treated with darunavir-cobicistat plus dolutegravir dual regimen</b> Diego Ripamonti (ASST Papa Giovanni XXIII, Italy)	09:00 - 09:00
eP157	<b>Proviral DNA as a Reliable Tool for Resistance Testing in HIV-2: Long-Term Outcomes in a Portuguese Cohort</b> Inês Lopes (Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Portugal)	09:00 - 09:00
eP158	<b>Selection of antiretroviral resistance in treatment-experienced PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study</b> Anne-Genevieve Marcelin (Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, France)	09:00 - 09:00

eP159	<b>Selection rate of resistance to Long-Acting CAB/RPV in a real life French cohort with strict inclusion and monitoring criteria</b> Sidonie LAMBERT-NICLOT (Santé Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique APHP, Hôpital Saint-Antoine, France)	09:00 - 09:00
eP160	<b>Switching to bicittegravir/emtricitabine/tenofovir alafenamide in highly treatment experienced people living with multidrug-resistant HIV</b> Jose Luis Casado Osorio (Ramon y Cajal Hospital, Spain)	09:00 - 09:00
eP161	<b>The profile of surveillance HIV resistance mutations in the migrant population of a tertiary hospital: a 4-year analysis</b> Gonçalo Cruz (ULS Coimbra, Portugal)	09:00 - 09:00
eP162	<b>The role of doravirine in the treatment of multidrug-resistant HIV: data from the PRESTIGIO Registry</b> Tommaso Clemente (IRCCS San Raffaele Scientific Institute, Italy)	09:00 - 09:00
eP163	<b>Trends of HIV drug resistance and associated factors: an analysis of the Uganda national HIV drug resistance program data, 2021-2024</b> Bridget Ainembabazi (Uganda National Institute of Public Health, Uganda)	09:00 - 09:00
eP164	<b>CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF DORAVIRINE: IMPLICATIONS IN NEUROCOGNITIVE IMPAIRMENT</b> Qing Ma (University at Buffalo, United States)	09:00 - 09:00
eP165	<b>Pharmacogenetics of Dolutegravir and Bicittegravir Plasma and Intracellular Pharmacokinetics</b> Leïla Belkhir (Cliniques universitaires Saint-Luc, Belgium)	09:00 - 09:00
eP166	<b>Pharmacokinetics and Safety of MK-8527 in Adults With Moderate or Severe Renal Impairment</b> Jesse C. Nussbaum (Merck & Co., Inc., United States)	09:00 - 09:00
eP167	<b>Real-life switch to long-acting Cabotegravir/Rilpivirine ensures adequate drug levels without short-term impact on viral reservoir or inflammation: the Long-Icona Study</b> Roberta Gagliardini (INMI L. Spallanzani IRCCS, Italy)	09:00 - 09:00
eP168	<b>An audit of antiretroviral regimens in people living with HIV attending an HIV/sexual health clinic in Sydney's Inner West in response to the REPRIEVE study</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP169	<b>Effect of dolutegravir transition in HIV-positive adults at a university-based tertiary care hospital in Thailand</b> Rujipas Sirijatuphat (Mahidol University, Thailand)	09:00 - 09:00
eP170	<b>Safety and durability of treatment with Bicittegravir/Emtricitabine/Tenofovir Alafenamide in a real-life cohort</b> Nicola Squillace (Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Italy)	09:00 - 09:00
eP171	<b>Virologic Outcomes of Dolutegravir-Based ART Among Thai people with HIV Previously Treated with Lopinavir/ritonavir based Second-line regimens: A National Program Analysis</b> Anchalee Avihingsanon (HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Thailand)	09:00 - 09:00
	<b>B2. Clinical Science - Co-infection</b>	09:00 - 09:00
eP172	<b>Immune correlates of protection vs vaccine hesitancy in people living with HIV: to be or not to be (vaccinated)</b>	09:00 - 09:00



	Alejandro Vallejo (Ramon y Cajal Hospital, Spain)	
eP173	<b>Comparative Analysis of Mpox Cases in People Living with HIV in Lisbon and Rio de Janeiro During the 2022 Outbreak</b> Raffaele Junior Aliberti (Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Portugal)	09:00 - 09:00
eP174	<b>Enhanced immune response against mpox clade Ib and IIb after a booster dose of MVA-BN vaccine in a high-risk population</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP175	<b>Estimating Hard-to-reach Populations in South Korea Using Mpox Mathematical Modeling</b> Sol Kim (School of Mathematics and Computing (Mathematics), Yonsei University, Korea, Republic of)	09:00 - 09:00
eP176	<b>HIV and mpox co-infection in Israel: a cross-sectional comparative study</b> Zohar Mor (Ministry of Health, Israel)	09:00 - 09:00
eP177	<b>Mpox infection alters HIV-1 reservoir dynamics in ART-treated people with HIV</b> Guiomar Casado Fernández (Centro Nacional de Microbiología, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP178	<b>Mpox infection elicits stronger and more sustained T-cell responses than vaccination in people with HIV and PrEP users</b> Olivia de la Calle-Jiménez (National Center of Microbiology, Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP179	<b>Mpox-Specific Humoral and Cellular Immune Responses up to two years from natural infection or MVA-BN vaccination</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP180	<b>Asymptomatic CMV Suppression with Letemovir Reduces Plasma Secondary Bile Acid Levels in Individuals with HIV on Long-term Antiretroviral Therapy: ACTG Study A5383</b> John Koethe (Vanderbilt University Medical Center, United States)	09:00 - 09:00
eP181	<b>Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections in People Living (PLWH) with HIV Who Engage in Chemsex: A Descriptive Ambispective Study in Barcelona</b> Maria Martínez-Rebollar (HIV Unit, Infectious Diseases Service, Hospital Clínic, IDIBAPS, AIDS and HIV Research Group, University of Barcelona, Spain)	09:00 - 09:00
eP182	<b>Experience using a Portable Fundus Camera to Prevention of Blindness in people living with HIV in Ukraine</b> Maryna Sira (L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of the National Academy of Medical Science of Ukraine, Ukraine)	09:00 - 09:00
eP183	<b>Influence of a 3-month letemovir treatment on gut permeability and inflammation in people living with HIV on antiretroviral therapy</b> Stephane Isnard (Research Institute of the McGill University Health Centre, Canada)	09:00 - 09:00
eP184	<b>Measles in People Living with HIV: A Comparative Analysis with HIV-Negative Patients</b> David Valentin Mangaloiu (Carol Davila University of Medicine and Pharmacy Bucharest, Romania, Romania)	09:00 - 09:00
eP185	<b>Missed opportunities for early HIV diagnosis in people living with HIV in a Romanian tertiary care center</b>	09:00 - 09:00

	Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)	
eP186	<b>Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis</b> Asta Maria Blom Nielsen (Copenhagen University Hospital - Rigshospitalet, Denmark)	09:00 - 09:00
eP187	<b>Resistance profiles and therapeutic approach of <i>Klebsiella pneumoniae</i> strains identified in people living with HIV and other hospitalized individuals</b> Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)	09:00 - 09:00
eP188	<b>Risk of Pneumocystis Pneumonia by CD4 Level in Ukrainian Adults Living With HIV: A Retrospective Analysis</b> Diana Shevchenko (Public Health Center of the Ministry of Health of Ukraine, Ukraine)	09:00 - 09:00
eP189	<b>Severe <i>Rhodococcus equi</i> in Late Presenters With HIV: A Case Series and Therapeutic Challenges</b> Ivana Gmizic (Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Serbia)	09:00 - 09:00
eP190	<b>Systematic Review and Meta-Analysis of Human Papilloma Virus Prevalence and Geno-type Disparity among HIV-positive Women in Africa</b> Yirga Wondu Amare (Pecs University, Hungary)	09:00 - 09:00
eP191	<b>Asociation between plasma inflammatory profile and sexually transmitted infections recurrence in PrEP users and people with HIV</b> Yolanda Campanero Núñez (Hospital Clínico San Carlos-IdISSC, Spain)	09:00 - 09:00
eP192	<b>Assessing the Impact of PrEP on STI Rates: a Real-World Multicenter Cohort from Milan</b> Donatella Maddalena (Luigi Sacco University Hospital, Italy)	09:00 - 09:00
eP193	<b>Awareness and attitudes toward Doxycycline Post-Exposure Prophylaxis (DoxyPEP) among MSM in Greece: A cross-sectional study</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP194	<b>Comparative effectiveness of 250 mg vs 500 mg ceftriaxone in treating uncomplicated gonorrhea in a country of a low prevalence of ceftriaxone-nonsusceptible <i>Neisseria gonorrhoeae</i></b> Tzong-Yow Wu (National Taiwan University Hospital Yunlin Branch, Taiwan)	09:00 - 09:00
eP195	<b>Doxycycline prophylaxis use among MSM attending a reference center for STI and HIV treatment in Rome</b> Alessandra Latini (San Gallicano Dermatological Institute IRCCS, Italy)	09:00 - 09:00
eP196	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Kyrgyz Republic</b> Anastasia Pokrovskaya (Central Research Institute of Epidemiology of Rospotrebnadzor, Russian Federation)	09:00 - 09:00
eP197	<b>Prevalence of human papilloma virus in tree loci among women with various HIV status in the Republic of Belarus</b> Anastasia Pokrovskaya (Central Research Institute of Epidemiology of Rospotrebnadzor, Russian Federation)	09:00 - 09:00
eP198	<b>Real-world effectiveness of doxycycline Post-Exposure Prophylaxis (DoxyPEP) in at-risk MSM in Greece</b>	09:00 - 09:00

	Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	
eP199	<b>Sexually transmitted infections at the time of HIV diagnosis in a sexual health clinic in Spain</b> Inés Armenteros (Centro Sanitario Sandoval - Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP200	<b>AIDS patients with Talaromycosis Marneffeii exhibit inflammatory activation and depletion in their peripheral blood monocytes</b> Pengle Guo (Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou Medical Research Institute of Infectious Diseases, China)	09:00 - 09:00
eP201	<b>Antiretroviral therapy in people with HIV and TB in France: a nationwide retrospective study between 2010 and 2023</b> Hugo Law-Koune (EPI-PHARE (GIS ANSM-CNAM), France)	09:00 - 09:00
eP202	<b>Characterisation of Cryptococcal meningitis - a 12-year retrospective study in a hospital in Lisbon, Portugal</b> Daniel Toscano (Hospital Professor Dr. Fernando Fonseca, Portugal)	09:00 - 09:00
eP203	<b>Epidemiological and Clinical Analysis and Outcomes of Tuberculosis Co-infection Among People Living with HIV in the Turkey ClinSurv HIV Cohort: A Large Case Series</b> Okan Derin (İstanbul Şişli Hamidiye Etfal Training and Research Hospital, Turkey)	09:00 - 09:00
eP204	<b>Factors associated with positive baseline Toxoplasma Gondii IgG antibodies among people living with HIV in recent years</b> Carlo Bienkowski (Medical University of Warsaw, Poland)	09:00 - 09:00
eP205	<b>Health Outcomes of Individuals Living with HIV Affected by Chronic Neuroinfections in Sub-Saharan Africa: Early Insights from Mozambique</b> Helena Buque (Maputo Central Hospital, Mozambique)	09:00 - 09:00
eP206	<b>Incidence of opportunistic infections among people living with HIV in Rwanda. Does Differentiated care delivery matters?</b> Mariam Salim Mbwana (Primary Health Care Institute, Tanzania)	09:00 - 09:00
eP207	<b>Multivariate predictive model for predicting in-hospital mortality in HIV-associated talaromycosis: a multicenter retrospective study</b> Biao Zhu (The First Affiliated Hospital, School of Medicine, Zhejiang University, China)	09:00 - 09:00
eP208	<b>Neuromeningeal tuberculosis in eighteen PLWHIV</b> NASSIMA BELABAS (UNIVERSITY - ALGERIA 1 - FACULTY OF MEDECINE ZIANIA ALGIERS, ALGERIA, Algeria)	09:00 - 09:00
eP209	<b>Plasma IL-6 level predict the risk of in-hospital mortality in HIV-associated Pneumocystis Pneumonia</b> Huan Xia (Tianjin Second People's Hospital, China)	09:00 - 09:00
eP210	<b>Predictors of Recurrence and Survival in HIV-Associated Nontuberculous Mycobacterial Infections: A 20-Year Retrospective Cohort Study</b> Johannes Zielke (Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Germany)	09:00 - 09:00
eP211	<b>Dynamic Sequential Organ Failure Assessment (SOFA) Score and quick SOFA (qSOFA) predict 30-day mortality in patients with HIV-associated Talaromycosis: a multicenter cohort study</b> Guanjing Lang (The First Affiliated Hospital, Zhejiang University School of Medicine, China)	09:00 - 09:00

eP212	<b>The most common nontuberculous mycobacteria species and their antibiotic resistance among people with HIV</b> Dagny Krankowska (Medical University of Warsaw and Hospital for Infectious Diseases, Poland)	09:00 - 09:00
eP213	<b>Tuberculosis Meningitis and Other Opportunistic Infections of the Central Nervous System in Persons Living with HIV: An Observational Cohort Study in Brazil</b> Mona Gardet (Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Brazil)	09:00 - 09:00
eP214	<b>Tuberculosis profile in a cohort of people living with HIV hospitalized at the National Institute for Infectious Diseases "Prof. Dr. Matei Bals" in Bucharest, Romania</b> Anca Negru (National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Romania)	09:00 - 09:00
eP215	<b>Determinants of Influenza, HBV, and Pneumococcal Vaccination Uptake in People Living with HIV: A Multilevel and Expert Survey Study</b> Hye Seong (Yonsei University College of Medicine, Korea, Republic of)	09:00 - 09:00
eP216	<b>Evaluating Immunization Rates in People Living with HIV based on Influenza Uptake</b> Lee Nguyen (University of California, Irvine School of Pharmacy and Pharmaceutical Sciences, United States)	09:00 - 09:00
eP217	<b>Hepatitis A and B immunization rates among MSM who are at high-risk sees potential for improvement</b> Sven Breitschwerdt (University Hospital Bonn, Germany)	09:00 - 09:00
eP218	<b>Immunity Gaps to Vaccine Preventable Diseases in People with HIV: Real-World Evidence from Japan</b> Michiko Koga (The University of Tokyo, Japan)	09:00 - 09:00
eP219	<b>Serological response to Engerix®-B vaccination in PLWHIV</b> Rita Patrocínio de Jesus (Hospital Prof. Doutor Fernando Fonseca, Portugal)	09:00 - 09:00
eP220	<b>Seropositivity and Vaccination Coverage of HBV, HAV, VZV, Measles, Rubella, and Mumps in People Living with HIV</b> Eunmi Yang (Hallym University Sacred Heart Hospital, Korea, Republic of)	09:00 - 09:00
eP221	<b>Extracellular Vesicle DNA cargo Mirrors Systemic Immune and Microbial Perturbations in People with HIV and HCV Coinfected Individuals</b> Sergio Grande Garcia (Instituto de Salud Carlos III, Spain)	09:00 - 09:00
eP222	<b>Factors Associated with HBs Antigen Seroclearance in People Living with HIV and Chronic Hepatitis B</b> Takashi Muramatsu (Tokyo Medical University Hospital, Japan)	09:00 - 09:00
eP223	<b>Impact of intravenous methamphetamine use on Direct-acting Antiviral Agents (DAAs) treatment in people living with HIV and hepatitis C in Mexico</b> Corazón Barrientos-Flores (Clinica Especializada Condesa, Mexico)	09:00 - 09:00
eP224	<b>Lipid dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV co-acquired clients: a retrospective study</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)	09:00 - 09:00
eP225	<b>Lipidomic Profiles After HCV Cure in People with HIV Reflect Changes Linked to Significant Liver Stiffness</b> Juan Berenguer (Hospital General Universitario Gregorio Marañón, Spain)	09:00 - 09:00
eP226	<b>Long-term persistence alterations in CD4 and CD8 T-cell profile</b>	09:00 - 09:00

	<b>after HCV elimination in people living with HIV</b> Manuel Llamas Adán (Carlos III Institute of Health, Spain)	
eP227	<b>Low HCV Prevalence Among PLWH in Türkiye: Risk Factors and Treatment Gaps</b> Bilge Caglar (Haseki Training and Research Hospital, Turkey)	09:00 - 09:00
eP228	<b>Overt and Occult Hepatitis B Virus Infection among People Living with HIV/AIDS in Bulgaria</b> Radka Komitova (Medical University of Plovdiv, Bulgaria)	09:00 - 09:00
	<b>B3. Clinical Science - Co-morbidities and ageing</b>	09:00 - 09:00
eP230	<b>“The Platinum clinic”, a collaborative HIV and Geriatric Medicine clinic for older people living with HIV in Dublin, Ireland</b> Clara O'Flaherty (St. James' Hospital Dublin, Ireland)	09:00 - 09:00
eP231	<b>A Cross-Sectional Comparison of Use of Frailty Assessment Tools in Older People Living with HIV</b> Chloe Knox (University Hospitals Sussex NHS Trust, United Kingdom)	09:00 - 09:00
eP232	<b>A retrospective review of referrals to specialist secondary care HIV-led and Gynaecology-led menopause clinics</b> Kimberley Forbes (St Stephen's Centre, Chelsea and Westminster Hospital, London, United Kingdom)	09:00 - 09:00
eP233	<b>Assessing health risks in ageing adults with HIV and stratifying outcomes thru the use of scores and scales</b> Michael Virata (Yale School of Medicine, United States)	09:00 - 09:00
eP234	<b>Cognitive and locomotor disorders in people living with HIV between 2007 and 2023: outcomes of the ANRS CO3 AQUIVIH-NA cohort</b> Fabrice Bonnet (CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, France)	09:00 - 09:00
eP235	<b>Evaluation of a Healthy Aging Score in a Cohort of Older Adults Living with HIV in Canada</b> Sharon Walmsley (University of Toronto, Canada)	09:00 - 09:00
eP236	<b>Four years frailty transitions in elderly adults living with HIV: Results from the SEPTAVIH Study</b> Clotilde Allavena (CHU Nantes, France)	09:00 - 09:00
eP237	<b>Frailty Screening in People Living with HIV Aged Over 65: Clinical Characteristics and Predictive Factors from a Real-World Cohort in a University Hospital in Florence, Italy</b> Gasparro Giuseppe (University of Florence, Italy, Italy)	09:00 - 09:00
eP238	<b>Gut microbiome and healthy aging in HIV: a sub-analysis of the CHANGE HIV cohort</b> Sharon Walmsley (University of Toronto, Canada)	09:00 - 09:00
eP239	<b>Neurocognitive Impairment in Older People Living with HIV: Preliminary Findings from a Geriatric Care Program</b> Liesbeth Delesie (Ghent University Hospital, Belgium)	09:00 - 09:00
eP240	<b>One score to rule them all? Or maybe not quite ...</b> Beatrice Barda (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00
eP241	<b>Predicting Frailty in Older People Living with HIV Using Machine Learning</b> Jaime Vera (Brighton and Sussex Medical School, United Kingdom)	09:00 - 09:00
eP242	<b>The Prevalence and Predictors of elevated HOMA-IR in People Living with HIV (PLWH)</b>	09:00 - 09:00

	Shu-Ying Chang (Taoyuan General Hospital, Ministry of Health and Welfare, Taiwan)	
eP243	<b>Understanding Frailty and Aging in People Living with HIV in Kazakhstan: A Pilot Investigation</b> Balnur Iskakova (Asfendiyarov Kazakh National Medical University, Kazakhstan)	09:00 - 09:00
eP244	<b>A Comparative Analysis of Echocardiographic Findings in People Living With HIV and Healthy Volunteers</b> AYTAN SEYDALIYEVA (Koç University Hospital, Turkey)	09:00 - 09:00
eP245	<b>A Comparative Analysis of HbA1c, Glycated Albumin, and Fasting Plasma Glucose for Glycemic Assessment in People Living with HIV</b> Tun-Chieh Chen (Kaohsiung Medical University, Taiwan)	09:00 - 09:00
eP246	<b>A rapid scoping review of tools and approaches for medication adherence screening and assessment</b> Nicola Galbraith (Gilead Sciences Ltd, United Kingdom)	09:00 - 09:00
eP247	<b>Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway</b> Kate Alford (Brighton and Sussex Medical School, United Kingdom)	09:00 - 09:00
eP248	<b>Association of Biomarker Clusters With Lung Disease and Mortality in People With HIV</b> Ioannis Konstantinidis (University of Pittsburgh School of Medicine, United States)	09:00 - 09:00
eP249	<b>Association of Cytomegalovirus Immunoglobulin G Antibodies with Prevalent and Incident Hypertension in People With HIV</b> Josefine Loft (Copenhagen University Hospital - Rigshospitalet, Denmark)	09:00 - 09:00
eP250	<b>Bempedoic Acid and Evolocumab Use in People Living with HIV: A Real-World Snapshot of Lipid-Lowering Strategies in Statin-Intolerant or Reluctant individuals</b> Marianna Menozzi (University Hospital of Modena, Italy)	09:00 - 09:00
eP251	<b>Changes in Metabolic Parameters after Switching from Efavirenz to Dolutegravir-based Regimen: A Cohort Study in Thai People Living with HIV</b> Pitchaporn Chongyangyuenvong (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP252	<b>Clinical Features of Transgender People Living with HIV Throughout Europe: multimorbidity and polypharmacy</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP253	<b>Confusion in the sky: to score or not to score?</b> Beatrice Barda (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00
eP254	<b>Determinants of Weight Change in HIV-Positive Individuals Receiving Antiretroviral Therapy</b> EMİNE İLAY DUMAN (University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Turkey)	09:00 - 09:00
eP255	<b>Eating habits and possible effects of Mediterranean diet on body composition in ageing people living with HIV</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP256	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident cardiovascular events</b> Stefan Esser (University Hospital Essen, University Duisburg Essen, Germany)	09:00 - 09:00

eP257	<b>Effect of extreme weight gain within 5 years in people with HIV on upcoming incident diabetes mellitus</b> Stefan Esser (University Hospital Essen, University Duisburg Essen, Germany)	09:00 - 09:00
eP258	<b>Effects of high-dose probiotic supplementation on immune activation and neurocognitive disorders in people living with HIV on successful antiretroviral treatment: the ProCog study</b> Matteo Vassallo (Centre hospitalier de Cannes, France)	09:00 - 09:00
eP259	<b>Enhancing Transplant Access for People with HIV: A Comparative Study of Liver and Kidney Transplant Outcomes from donors with or without HIV</b> Adriana Cervo (Infectious Diseases Unit, University Hospital of Modena, Italy)	09:00 - 09:00
eP260	<b>Epicardial adipose tissue thickness and cardiometabolic risk in people living with HIV: A comparative study of TAF- and TDF-based regimens</b> Beyza Erol (Katip Celebi University Ataturk Training and Research Hospital, Turkey)	09:00 - 09:00
eP261	<b>From wasting to gaining: The impact of BMI changes on dyslipidemia risk in people living with HIV</b> Jisun Chung (The catholic university of korea, Korea, Republic of)	09:00 - 09:00
eP262	<b>Genetic influence of TM6SF2 rs58542926 genotype on significant liver fibrosis in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD)</b> Win Min Han (HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand; The Kirby Institute, Sydney, Australia, Thailand)	09:00 - 09:00
eP263	<b>How do people living with HIV sleep?</b> Macha Tetart (Tourcoing Hospital, France)	09:00 - 09:00
eP264	<b>Hypertension in People with HIV Starting ART: Association with Regimen Class</b> Jose I Bernardino (Hospital Universitario La Paz. IdiPAZ, Spain)	09:00 - 09:00
eP265	<b>Impact of a Mediterranean Diet-Based Nutritional Intervention on Lipid Profile in People Living with HIV: Interim Results at Week 24 from a Randomized Controlled Clinical Trial</b> Esperanza Cañas-Ruano (Hospital del Mar, Spain)	09:00 - 09:00
eP266	<b>Implementation of FIB-4 Screening and Determinants of Liver Fibrosis Among People Living with HIV: A Real-World Cohort Study</b> Olivier Robineau (Centre Hospitalier Gustave Dron, France)	09:00 - 09:00
eP267	<b>Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to a nucleos(t)ide-based antiretroviral regimen: week 144 results from SPRINT, a randomized phase 3 trial</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP268	<b>Improved body weight, lipid and immune profile and adipose tissue gene expression after a 48-week switch from an INSTI regimen to DOR/3TC/TDF in persons with HIV with INSTI-associated weight gain: The ADDORE study</b> J Capeau (Sorbonne Université, Inserm UMR_S938, CRSA, ICAN, France)	09:00 - 09:00
eP269	<b>Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort</b> Ana Luz Cano Díaz (Instituto Mexicano Del Seguro Social, Mexico)	09:00 - 09:00

eP270	<b>Incidental Detection of Gynecomastia and Adipomastia on Chest CT in Male People Living with HIV: An Opportunistic Imaging Assessment</b> Veysel Akca (Mugla Sitki Kocman University Faculty of Medicine, Turkey)	09:00 - 09:00
eP271	<b>Influence of HIV status on organ procurement and allocation: A Discrete Choice Experiment among Australian Transplant Providers</b> David WJ Griffin (Alfred Health, Australia)	09:00 - 09:00
eP272	<b>Insights from Gut Microbiome Profiling: <i>Evtepia spp.</i> as a Distinctive Marker of Leanness in People with HIV</b> Mackenzie Joe (McGovern Medical School at UTHealth Houston, United States)	09:00 - 09:00
eP273	<b>Longitudinal changes of coronary artery calcium score (CACS) in persons with HIV</b> Maithili Varadarajan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP274	<b>Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to ainoovirine coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP275	<b>Long-term Lipid Metabolism Benefits of Switching to Ainoovirine-based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study</b> Hong Qin (Aidea Pharma, China)	09:00 - 09:00
eP276	<b>Medication Optimization in Older People Living with HIV: A Multidisciplinary Approach</b> Fatma Nisa Ballı Turhan (Gazi University Faculty of Pharmacy, Department of Clinical Pharmacy, Turkey)	09:00 - 09:00
eP277	<b>Metabolic Liver Disease in Newly Diagnosed People Living with HIV: MASHIV-TR COHORT</b> Mustafa Kemal Celen (Dicle University, Turkey)	09:00 - 09:00
eP279	<b>Monocyte polarization is related to Atherosclerosis in People Living with HIV on Suppressive ART</b> Javier Lozano-Gerona (John A. Burns School of Medicine, University of Hawaii, United States)	09:00 - 09:00
eP280	<b>Neurocognitive Screening in people living with HIV: 5-year referral and outcomes review</b> Shimu Allan (Royal Free NHS Foundation Trust, Royal Free Hospital, United Kingdom)	09:00 - 09:00
eP281	<b>Non-linear relationships between inflammatory markers and erectile dysfunction in a group of young men living with HIV</b> Federico Cesanelli (University of Brescia, Italy)	09:00 - 09:00
eP282	<b>Obesity in People Living with HIV: A Retrospective Analysis of a cardiovascular disease Risk Clinic Cohort</b> Alice Alicerces (Garcia de Orta Hospital, Portugal)	09:00 - 09:00
eP283	<b>People with HIV at high cardiovascular risk were undertreated with statins independent of gender</b> Maximilian Platte (University Hospital Duisburg-Essen, Germany)	09:00 - 09:00
eP284	<b>Physical inactivity is associated with persistent steatotic liver disease in people with HIV</b> Eloïse Magnenat (Inselspital, Bern University Hospital, Switzerland)	09:00 - 09:00
eP285	<b>Preserved renal function in PWH on ainoovirine-based antiretroviral regimen: week 144 results from SPRINT study, a</b>	09:00 - 09:00



	<b>randomized phase 3 trial</b> Hong Qin (Aidea Pharma, China)	
eP286	<b>Prevalence and Predictors of Obesity and Metabolic Syndrome in HIV-Positive Individuals: A Cross-Sectional Study from Türkiye</b> EMİNE İLAY DUMAN (University of Health Sciences, Izmir Bozyaka Education and Research Hospital, Turkey)	09:00 - 09:00
eP287	<b>Prevalence and risk factors of liver fibrosis in metabolic associated fatty liver disease (MAFLD) among people living with HIV(PLWH) in Shanghai</b> Wei Xu (Shanghai Public Health Clinical Center, China)	09:00 - 09:00
eP288	<b>Prevalence of Steatotic Liver Disease Phenotypes and Clinically Significant Fibrosis Predictors Among People With HIV in The Middle East Region: A Multicenter Study</b> Ahmed Cordie (Cairo University Hospitals HIV Clinic, Endemic Medicine Department, Cairo University, Egypt)	09:00 - 09:00
eP289	<b>Progressive Pulmonary Artery Enlargement in Aging, Virologically Suppressed People With HIV: A 7-Year CT Imaging Study</b> Napon Hiranburana (The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand)	09:00 - 09:00
eP290	<b>Prospective evaluation of cardiovascular risk in PLWH receiving LA-cabotegravir/rilpivirine</b> Marco Bongiovanni (Ente Ospedaliero Cantonale, Switzerland)	09:00 - 09:00
eP291	<b>Relationships Between Lung Health Indicators and Depressive Symptoms, Anxiety, Resilience, and Social Support among Women with HIV</b> Jun Y. Byun (University of Alabama at Birmingham, United States)	09:00 - 09:00
eP292	<b>Research on the Diagnostic Value in Cerebrospinal Fluid and Blood Biomarkers of HIV-Associated Neurocognitive Disorders</b> Jiaqi Wei (Capital Medical University, China)	09:00 - 09:00
eP293	<b>Same Patients, Different Risks: A Head-to-Head of ESC and EACS CVD Guidelines in PLWH</b> Katia Falasca (University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy, Italy)	09:00 - 09:00
eP294	<b>Semaglutide Improves Markers of Cardiovascular Risk in People With HIV: The SLIM LIVER Study</b> Jordan Lake (UTHealth Houston, United States)	09:00 - 09:00
eP295	<b>Serum Uric Acid Dynamics in Chinese HIV Patients: A 20-Year Cohort Study</b> Xin Huang (Peking Union Medical College Hospital, China)	09:00 - 09:00
eP296	<b>Severe Acute Chemsex Intoxications in People Living With HIV: Clinical Insights from a Tertiary-Care ID-ICU</b> Ana Sofia Santos (Centro Hospitalar de São João / ULS São João, Portugal)	09:00 - 09:00
eP297	<b>Statin initiation following the REPRIEVE Trial: Results of a clinical audit at an urban sexual health clinic in Sydney, Australia</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP298	<b>Study on the impact and mechanisms of R-CHOP-Based immunochemotherapy on immune status in ARL people</b> Biao Zhu (The First Affiliated Hospital, School of Medicine, Zhejiang University, China)	09:00 - 09:00
eP299	<b>The FIB-4 is a marker of macrophage activation independently from hepatic disease in people living with HIV on stable and successful treatment</b>	09:00 - 09:00

	Matteo Vassallo (Centre hospitalier de Cannes, France)	
eP300	<b>Understanding hospitalization among people living with HIV (PLWH) in the combination antiretroviral therapy (cART) era: a single-centre retrospective study</b> Antonella Gallicchio (Ospedali dei colli - Cotugno, Italy)	09:00 - 09:00
eP301	<b>Use of statins mitigates the impact of smoking on frailty trajectories in people with HIV: a longitudinal cohort study</b> Jovana Milic (University of Modena and Reggio Emilia, Italy)	09:00 - 09:00
eP302	<b>Weight gain and metabolic complications in a large prospective cohort of overweight and obese people with HIV</b> Lucia Taramasso (Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy, Italy)	09:00 - 09:00
eP303	<b>Women living with HIV in Australia: Development of a clinical monitoring tool to address gender-specific care gaps and standardize care</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP304	<b>A Multidisciplinary Approach to Enhance Quality of Life in Older People Living with HIV: A Comparative Study</b> Fatma Nisa Ballı Turhan (Gazi University Faculty of Pharmacy, Department of Clinical Pharmacy, Turkey)	09:00 - 09:00
eP305	<b>Addressing patient-reported outcome measures (PROMs) in routine care does not improve patient's perspective on the receipt of patient-centered care and self-management behavior</b> Roos D Klungers (University of Amsterdam, Netherlands)	09:00 - 09:00
eP306	<b>Ageing with HIV in France: When PLHIV Needs and Clinical Practice Diverge</b> Daniela Rojas Castro (MoiPatient, France)	09:00 - 09:00
eP307	<b>Assessment of Neurocognitive Functions and Intellectual Capacity in People Living with HIV: A Case-Control Study</b> Yasemin Çakır Kıymaz (Sivas Cumhuriyet University, Turkey)	09:00 - 09:00
eP308	<b>Disability and Physical Activity among Adults Living with HIV in the United Kingdom, Ireland, United States and Canada: A Structural Equation Model Using the Episodic Disability Questionnaire</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP309	<b>Effectiveness of Aerobic Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP310	<b>Effectiveness of Progressive Resistive Exercise among Adults Living with HIV: An Updated Systematic Review and Meta-Analysis using the Cochrane Collaboration Protocol</b> Kelly O'Brien (University of Toronto, Canada)	09:00 - 09:00
eP311	<b>Factors Influencing the Quality of Life Among Men Who Have Sex with Men Living with HIV at an STD Center in Northern Taiwan</b> HsinHao Lai (Division of Infectious Diseases, Taipei City Hospital, Yang-Ming Branch, Taiwan)	09:00 - 09:00
eP312	<b>Integrating HIV and Mental Health Care in Prison: A Complex but Achievable Goal</b> Frederico Duarte (Hospital Pedro Hispano, Portugal)	09:00 - 09:00
eP313	<b>Internalized HIV Stigma and Its Influence on Reproductive Intentions of Women Living with HIV in Kazakhstan</b> Batyrbek Assembekov (Asfendiyarov Kazakh National Medical University,	09:00 - 09:00

	Kazakhstan)	
eP314	<b>Internalized Stigma and Its Impact on Mental Health and Quality of Life among People Living with HIV in Mauritius</b> Monica Pudaruth (PILS (Prévention Information et Lutte contre le SIDA), Mauritius)	09:00 - 09:00
eP315	<b>Mental health in PLWH: psychopathological variables and personality traits in patients compared with non-clinical subjects</b> Francesco Romano (Sapienza University of Rome, Policlinico Umberto I, Italy)	09:00 - 09:00
eP316	<b>Neurocognitive impairment is associated with functional performance deficits and compromised adherence during follow up in people living with HIV</b> Jose Luis Casado Osorio (Ramon y Cajal Hospital, Spain)	09:00 - 09:00
eP317	<b>Oral Lesions in People Living with HIV (LINING HIV)</b> Emmanouil Angelos Rigopoulos (University General Hospital of Patras, Greece)	09:00 - 09:00
eP318	<b>Outcomes of a mental health screening in a cohort of people with HIV</b> Peacchaima Purusothman (Hospital Tengku Ampuan Rahimah, Klang, Malaysia)	09:00 - 09:00
eP319	<b>Poor Sleep and MASLD are Common in People with HIV and Contribute to Poor Health-Related Quality of Life</b> Ana N Hyatt (UTHealth Houston, United States)	09:00 - 09:00
eP320	<b>Sexual satisfaction in men with HIV aged ≤50 years explored with standardized validated questionnaires: prevalence and patterns of various sexual dysfunction, and association with psychosocial factors</b> Nicola Squillace (Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Italy)	09:00 - 09:00
eP321	<b>Social support and mental health in People Living with HIV: A cross-sectional analysis from a Greek cohort</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP322	<b>KS evolution in HIV aviremic PLWH: a prospective cohort of the French CancerVIH Network</b> Alain Makinson (CHU de Montpellier, France)	09:00 - 09:00
eP323	<b>Prevalence of high-risk human papillomavirus and anal precancerous lesions among men who have sex with men living with HIV in Hong Kong</b> T S Kwong (Queen Elizabeth Hospital, Hong Kong)	09:00 - 09:00
eP324	<b>Real-World Clinical Insights into Underrecognized Differences in Prostate Cancer Among People Living with HIV</b> Kyoko Yoshida (Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Japan)	09:00 - 09:00
eP326	<b>Update on German-Austrian Guideline on Screening for Anal Dysplasia and Anal Carcinoma in People Living with HIV</b> David Chromy (Medical University of Vienna, Austria)	09:00 - 09:00
	<b>B4. Clinical Science - Pregnancy, children and adolescents</b>	09:00 - 09:00
eP327	<b>Unintended Pregnancy Among Adolescents Living with HIV in Africa: A Systematic Review</b> Mackline Hope (Infectious Diseases Institute, Uganda)	09:00 - 09:00
eP328	<b>HIV diagnosis in pregnancy accounts for 18% of all diagnoses and</b>	09:00 - 09:00

	<b>may reduce advanced stage HIV diagnosis in women over 30 years in the Netherlands</b> Colette Smit (Stichting HIV Monitoring, Netherlands)	
eP329	<b>Life expectancy of premature babies born to HIV-positive mothers</b> Fatima zohra Bensadoun (Faculté de médecine d'Oran, Algeria)	09:00 - 09:00
eP330	<b>cART use in pregnancy: a real-life experience in Italy</b> Elena Zaninetta (Clinica Malattie Infettive, Università di Milano, ASST Santi Paolo e Carlo, Italy)	09:00 - 09:00
eP331	<b>MISSED OPPORTUNITY: HIV-1 TRANSMISSION CHAIN ACROSS THREE GENERATIONS</b> Ulrike Elisabeth Haars (Infektiologie Krefeld, Germany)	09:00 - 09:00
eP332	<b>Pregnancy monitoring in HIV-serodifferent couples: Support and medical monitoring</b> Fatima zohra Bensadoun (Faculté de médecine d'Oran, Algeria)	09:00 - 09:00
	<b>C1. Epidemiology/ public health / models of care</b>	09:00 - 09:00
eP333	<b>A Multidisciplinary Offer to Support Emerging Practices: Feedback from the Lounge in Toulouse Dedicated to People Engaging in Chemsex</b> Ali Fendri (AIDES, Occitanie, France)	09:00 - 09:00
eP334	<b>Acceptability, feasibility, and systemic challenges of community-based antiretroviral therapy delivery model in Cambodia: A qualitative evaluation using the Framework Method</b> Ziya Tian (National University of Singapore, Singapore)	09:00 - 09:00
eP335	<b>Adaptation and preliminary outcomes of the Community Health Worker Optimization of Antihypertensive Care in HIV (COACH) program: an intervention to address hypertension among people with HIV (PWH) in Tanzania</b> Preeti Manavalan (University of Florida, United States)	09:00 - 09:00
eP336	<b>AI-ntiretroviral preferences</b> Rachel Burdon (Sydney Local Health District, Australia)	09:00 - 09:00
eP337	<b>ANALYSIS OF THE CLINICAL COMPLEXITY OF PEOPLE LIVING WITH HIV BASED ON THE GESIDA STRATIFICATION SYSTEM</b> Carolina Olmos Mata (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP338	<b>ARE WE STILL TOO LATE? MISSED OPPORTUNITIES IN THE DETECTION OF HIV</b> Sara Gómez García (Hospital Clínico Universitario de Valladolid, Spain)	09:00 - 09:00
eP339	<b>Closing the HIV Testing Gap: Readiness of Pharmacy staff Providing Other Prevention Screenings</b> Natalie Crawford (Emory University, United States)	09:00 - 09:00
eP340	<b>Costs Associated With People With HIV in France</b> Alexandre Vimont (Public Health Expertise, France)	09:00 - 09:00
eP341	<b>Decentralization of Care? A Comparison of Primary Care Services and Specialized Services in the Care of People Living with HIV in a State in Southern Brazil</b> Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED), Brazil)	09:00 - 09:00
eP342	<b>Demographic and Risk Profile Analysis of Users Accessing PrEP Through a Paid Digital Service in the Netherlands: Exploring PrEP Uptake Patterns Beyond Traditional Settings</b> John White (Preventx, United Kingdom)	09:00 - 09:00

eP343	<b>Enhancing HIV Self-Testing Uptake through Syringe Vending Machines: A Case Study in Tbilisi, Georgia</b> Irma Kirtadze (Ilia State University, Georgia)	09:00 - 09:00
eP344	<b>EXPERIENCE OF STRUCTURING A TRANSGENDER-SPECIFIC HIV OUTPATIENT CLINIC AT INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS: AN INTEGRATED CARE PATHWAY MODEL</b> Pisci Bruja Garcia de Oliveira (Instituto de Infectologia Emílio Ribas, Brazil)	09:00 - 09:00
eP345	<b>Exploring barriers to pre-exposure prophylaxis among HIV people initiating antiretroviral therapy in Portugal: the POSITIVE CARE study</b> Laura Paixão (MSD Portugal, Portugal)	09:00 - 09:00
eP346	<b>Exploring the Awareness, Attitudes, and Preferences of People Living with HIV Toward Long-Acting Injectable Treatments</b> Berna Karaismailoğlu (Basaksehir Cam and Sakura City Hospital, Turkey)	09:00 - 09:00
eP347	<b>General and Family Doctors' perspectives regarding their knowledge, preparedness level and challenges in preventing the Human Immunodeficiency Virus transmission</b> José Ganicho (ULS São José, Portugal)	09:00 - 09:00
eP348	<b>Health care perspectives of People Living with HIV in Central and Eastern Europe (CEE): Results from a Multi-Country Survey</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP349	<b>HIV PrEP Need, Availability, and Potential Pharmacy Integration: A Rural-Urban Analysis in the Southern US</b> Siena Senn (Rollins School of Public Health at Emory University, United States)	09:00 - 09:00
eP350	<b>HIV Viewpoints: Survey on the Treatment Experiences of People Living with HIV in Europe</b> Megan Dunbar (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP351	<b>Impact of COVID-19 Pandemic on Treatment Outcomes among People Living with HIV in Thailand: A Nested Case-control Study</b> Arnon Techapongsatorn (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP352	<b>Increase PrEP uptake to reduce HIV incidence in Italy: the case for simplified and differentiated PrEP delivery</b> Nicoletta Frattini (Milano Check Point ETS, Italy)	09:00 - 09:00
eP353	<b>Inpatient burden and diagnosis-specific trends in a dedicated HIV department (2011-2024): a thirteen-year review</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP354	<b>Introducing late HIV diagnosis cohort reviews in Wales: Exploring missed opportunities for testing</b> Sophie Harker (Public Health Wales, United Kingdom)	09:00 - 09:00
eP355	<b>Linkage to Care and ART initiation: A Retrospective Analysis to guide implementation of rapid ART initiation in outpatient setting</b> Bonnie Chun Kwan Wong (Department of Health, Hong Kong)	09:00 - 09:00
eP356	<b>Mental Well-being and the Work Environment among Healthcare Workers Taking Care of PLWH - Data from the Euroguidelines in Central and Eastern Europe Network Group</b> Agata Skrzat-Klapaczyńska (Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Poland, Poland)	09:00 - 09:00

eP357	<b>Navigating PrEP prescription: An exploratory study on barriers and facilitators among healthcare providers in North Louisiana</b> Camila Castro (Unichristus, Brazil)	09:00 - 09:00
eP358	<b>Outcomes of rapid anti-retroviral therapy (ART) initiation in London, UK</b> Gary Whitlock (Chelsea & Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP359	<b>Prevalence of HIV Indicator Conditions in People with Late Diagnosis of HIV, 25 years on: Are we still missing opportunities for earlier care?</b> Ella Spear (Monash Health, Australia)	09:00 - 09:00
eP360	<b>Provider willingness to discuss and prescribe pre-exposure prophylaxis (PrEP) with women at risk of HIV in Kazakhstan</b> Tara McCrimmon (Columbia University Mailman School of Public Health, United States)	09:00 - 09:00
eP361	<b>Quality improvement project aimed at reducing costs of unnecessary investigations in HIV outpatient clinics</b> Aarzo Bhatia (Manchester University Foundation Trust, United Kingdom)	09:00 - 09:00
eP362	<b>Reasons for ART interruption related to the war in Ukraine</b> Kseniia Voronova (AIDS Healthcare Foundation, Ukraine)	09:00 - 09:00
eP363	<b>Reorganizing a HIV clinic in northern Italy for the implementation of Long-Acting Cabotegravir/Rilpivirine for HIV Treatment with limited resources</b> Layla Pagnucco (Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo- University of Pavia - Italy, Italy)	09:00 - 09:00
eP364	<b>Response patterns to a patient-reported outcomes assessment (MyPRO) among racialized women living with and without HIV in a community health clinic in Toronto, Canada</b> Duncan Short (ViiV Healthcare, United Kingdom)	09:00 - 09:00
eP365	<b>Retention of clients diagnosed through Secondary HIV self-testing: A longitudinal analysis over 12 months in Johannesburg, South Africa</b> Mabjala Rosemary Letsoalo (Sefako Makgatho University, South Africa)	09:00 - 09:00
eP366	<b>Risk factors for sexually transmitted infections in men attending clinics in Jerusalem compared with Tel Aviv</b> Karen Olshtain Pops (Hebrew University Medical Center, Israel)	09:00 - 09:00
eP367	<b>Serum cryptococcal antigen titer as predictor of disseminated Cryptococcosis in people living with HIV</b> Victoria Pinto (Hospital General de Agudos Dr. Juan A. Fernández, Argentina)	09:00 - 09:00
eP368	<b>Significant discrepancies Between Clinical Practice and Medical Guidelines for HPV management in HIV - data from ECEE Network Group</b> Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP369	<b>Stigma in the Healthcare Environment: Invisible Barriers</b> Azucena Bautista Hernández (Fundación de investigación biomédica Hospital de la Princesa. CIBERINFECC., Spain)	09:00 - 09:00
eP370	<b>Telehealth as a tool for expanding PrEP in Argentina</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP371	<b>Tunisian women living with HIV: assessing characteristics and vulnerabilities</b>	09:00 - 09:00

	Rajah Rezgui (La Rabta Hospital, Tunisia)	
eP372	<b>Clinical characteristics and treatment patterns among people living with HIV by ART use in the US, 2021-2024</b> Arlene Nugent (AbbVie Inc., United States)	09:00 - 09:00
eP373	<b>Evaluation of Compliance with EACS Guidelines: Analysis of Error Rates at Baseline, 3, 6, and 12 Months</b> Ece Demirkirkan (Basaksehir Cam and Sakura City Hospital, Turkey)	09:00 - 09:00
eP374	<b>Factors associated with advanced HIV presentation among individuals referred for inpatient rehabilitation: A continuum of care perspective</b> Divyan Moodley (Mildmay Hospital, United Kingdom)	09:00 - 09:00
eP375	<b>HIV COINFECTION AMONG INDIVIDUALS BELONGING TO KEY GROUPS IN UKRAINE</b> Olena Hridasova (AIDS Healthcare Foundation, Ukraine)	09:00 - 09:00
eP376	<b>Outcomes of Rapid Initiation of Antiretroviral Therapy Among People Living with HIV: Real-world Experience from A Tertiary Care Hospital in Thailand</b> Niti Aueaphongkarun (Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand)	09:00 - 09:00
eP377	<b>"Bridging the Last Mile: A Low-Cost, Gender-Responsive Model Integrating Real-Time Viral Load Dashboards and Task-Shifting in Rural Nigeria"</b> Okeoghene Akusu (National Aids & STI's Control Program, Nigeria)	09:00 - 09:00
eP378	<b>Addressing health inequities in HIV testing: Effectiveness of activation of community-based networks and use of app technology to reach and support diverse, marginalized and underserved populations to access HIV self-testing in Canada</b> Sean B. Rourke (Unity Health Toronto, Canada)	09:00 - 09:00
eP379	<b>Breaking STI Chains with <i>Con-Tacto</i>: Acceptability of an Anonymous Partner Notification App Among PrEP Users</b> Felix Straga Napolitano (Hospital Parc Tauli, Spain)	09:00 - 09:00
eP380	<b>Challenges in implementing a strategy for the triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B: the experience of the TRI-MOM project in The Gambia</b> SEYDOU DRABO (Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, France)	09:00 - 09:00
eP381	<b>Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis</b> Toshibumi Taniguchi (Chiba University Hospital, Japan)	09:00 - 09:00
eP382	<b>How Rapid is the Recommended Timing of Antiretroviral Therapy Initiation? Preliminary Findings from a Scoping Review of HIV Clinical Guidelines</b> Moustafa Laymouna (Faculty of Medicine and Health Sciences, McGill University, Canada)	09:00 - 09:00
eP383	<b>If we build it, will they come? Pharmacists' perspectives on recruiting people to a pharmacy-based sexually transmitted and bloodborne infection (STBBI) testing service</b> Deborah Kelly (Memorial University of Newfoundland, Canada)	09:00 - 09:00
eP384	<b>Introducing the CROSS framework for developing and implementing inclusive and scalable research: Insights from the co-production and delivery of a cross-country HIV survey with migrant women within EACS/WAVE's SERAY project (Strengthening health Equity Research through Active involvement of Non-Governmental</b>	09:00 - 09:00

	<b>Organisations and migrant women)</b> Melvina Woode-Owusu (University College London, United Kingdom)	
eP385	<b>Negative Beliefs About Methadone and Barriers to Opioid Agonist Therapy in Kazakhstan: Findings from a Multi-City RDS Study</b> Assel Terlikbayeva (Center for Scientific and Practical Initiatives, Kazakhstan)	09:00 - 09:00
eP386	<b>Piloting the digital distribution and implementation of the Positive Outcomes PROM in HIV Outpatients</b> Rebekah Morris (University Hospitals Sussex NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP387	<b>Psychosocial Needs in Migrants with HIV: Implications for Care</b> Joanna Cano-Smith (La Paz- Carlos III University Hospital, Spain)	09:00 - 09:00
eP388	<b>The impact of Shared Decision-Making on Long-Acting Injectable Antiretroviral Therapy in People Living with HIV in Taiwan</b> LIAN LIN (Chung Shan Medical University hospital, Taiwan)	09:00 - 09:00
eP389	<b>Using Mixed-Methods Operations Research to Evaluate Community-Led Monitoring for Improved HIV Service Delivery in Nigeria</b> Joy Egwu (National Agency for the Control of AIDS, NACA Abuja, Nigeria)	09:00 - 09:00
eP390	<b>Willingness and Ability of People Living with HIV to use Patient-Reported Outcome Measures in Routine HIV Care: Preliminary Results from the PRO-CARE Study</b> Olivia Borchmann (Copenhagen University Hospital, Hvidovre, Denmark)	09:00 - 09:00
eP391	<b>Causes of Death in People Living with Human Immunodeficiency Virus in Türkiye: A Multicentre Retrospective Study</b> Selda Sayın Kutlu (Pamukkale University, Turkey)	09:00 - 09:00
eP392	<b>Challenges in Managing People Living with HIV in Critical Care: Experience from Mexico</b> Paulina Carreño Pérez (Instituto Nacional de Enfermedades Respiratorias, Mexico)	09:00 - 09:00
eP393	<b>Unstable housing and its associations with mental health and alcohol use among persons living with HIV (PLWH): Findings from the Florida Cohort Wave 4 survey</b> Yan Wang (University of Florida, United States)	09:00 - 09:00
eP394	<b>Demographics of under-housed individuals living with HIV in British Columbia, Canada</b> Christina Wiesmann (Simon Fraser University, Canada)	09:00 - 09:00
eP395	<b>Epidemiological Profile of Pregnant Women Living with HIV in Brazil: A Cross-Sectional Analysis of National Surveillance Data</b> Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED), Brazil)	09:00 - 09:00
eP396	<b>Epidemiology of Human Immunodeficiency Virus HIV in Tunisia in 2024</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP397	<b>Estimating HIV incidence and associated risk factors using longitudinal community-based testing data across the WHO European Region: Insights from the COBATEST Network</b> Laura Fernández-López (Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Spain)	09:00 - 09:00
eP398	<b>HIV seropositivity in Key or Vulnerable Population at higher risk: results of rapid testing program in the Russian Federation during 2020-2024</b>	09:00 - 09:00



	Alexander Chuykov (AHF Russia, Russian Federation)	
eP399	<b>Impact of the COVID-19 Pandemic on HIV Case Detection in Georgia: An Interrupted Time Series Analysis (2018-2024)</b> Otar Chokoshvili (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP400	<b>Incidence of HIV and STI After Initiating Pre-Exposure Prophylaxis, Among Men who have Sex with Men in Georgia: Findings from Routine Program Surveillance, 2020-2024</b> Otar Chokoshvili (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP401	<b>Knowledge, Attitude and Practice on HIV/AIDS among University Students in Kilimanjaro Region aged 18 to 45 years. A Cross Sectional Study</b> Simon Ernest (KCMC University, Tanzania)	09:00 - 09:00
eP402	<b>MIGRATION AND HIV IN LATIN AMERICA: A MULTICENTER REGIONAL DESCRIPTIVE STUDY</b> María Marta Greco (Hospital Español La Plata, Argentina)	09:00 - 09:00
eP403	<b>Migration-Linked Transmission of HIV-1 Subtype A6 in Europe: Evidence from Multinational Molecular Cluster Analysis</b> Karol Serwin (Pomeranian Medical University in Szczecin, Poland)	09:00 - 09:00
eP404	<b>Missed Lessons, Missed Protections: Strengthening Adolescent STI and HIV Awareness Through Targeted Educational Interventions</b> Gunda Waldmann (University Hospital, LMU Munich, Germany)	09:00 - 09:00
eP405	<b>Missed Opportunities and Factors Associated with Late Diagnosis of HIV Infection in the Era of Rapid Testing</b> Federico Daniel Cardozo (Hospital General de Agudos Jose Maria Ramos Mejia, Argentina)	09:00 - 09:00
eP406	<b>Phylogenetic analysis and transmission networks highlight the role of older adults in the transmission of HIV-1 in northern Zhejiang, China</b> xiaohong Pan (Zhejiang Provincial Center for Disease Control and Prevention, China, China)	09:00 - 09:00
eP407	<b>Pre-exposure prophylaxis (PrEP) and the reduction in new cases of HIV acquisition in men in the state of Sao Paulo, Brazil</b> Mariza Vono Tancredi (Centro de Referencia e Treinamento DST-AIDS-SP, Brazil)	09:00 - 09:00
eP408	<b>Seroprevalence of HIV, HBV and HCV Among People Who Use Drugs in Turkey</b> Ali Asan (University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Turkey)	09:00 - 09:00
eP409	<b>Seroprevalence of Toxoplasma gondii in Individuals Living with HIV/AIDS: An Epidemiological Assessment and Clinical Significance</b> Merve Kılıç Tekin (Haseki Training and Research Hospital, Turkey)	09:00 - 09:00
eP410	<b>Sex-Based Disparities in Hospitalizations due to Advance Disease among People Living with HIV in a Tertiary Center from 2003-2023 in Mexico City</b> Santiago Agraz Orozco (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico)	09:00 - 09:00
eP411	<b>Structural Barriers and HIV Testing Uptake Among Female Sex Workers in Albania: Findings from Integrated Bio-Behavioral Surveillance</b> Elona Gjebrea Hoxha (Albanian Center for Population and Development, Albania)	09:00 - 09:00

eP412	<b>The Relationship Between Development Indicators and HIV Epidemiology: A Global Perspective on Social Determinants</b> Özge Eren Korkmaz (Izmir Dokuz Eylul University, Turkey)	09:00 - 09:00
eP413	<b>Trends in HIV awareness, screening practices and attitudes in Tunisia: Insights from MICS Data (2012-2023)</b> Mariem Nouira (Faculty of Medicine of Tunis, Tunis El Manar University-Tunisia., Tunisia)	09:00 - 09:00
	<b>C2. HIV prevention</b>	09:00 - 09:00
eP414	<b>Addressing HIV-Related Morbidity and Mortality Through Community-Based Adolescent Prevention and Linkage to Care in Muyuka Subdivision, Southwest Region, Cameroon</b> TEZETE EVET ADEOLA ADEOLA (Alliance for Community Initiative, Cameroon)	09:00 - 09:00
eP415	<b>Clinic vs. Self HIV Testing in Southern Africa: A Systematic Review on Progress Towards UNAIDS Targets</b> David Flynn (Imperial College London, United Kingdom)	09:00 - 09:00
eP416	<b>Effectiveness of the HIV Testing Month campaign in promoting testing in the general public in Hong Kong</b> Tsz Ho Kwan (The Chinese University of Hong Kong, Hong Kong)	09:00 - 09:00
eP417	<b>EPIDEMIOLOGICAL CHARACTERISTICS OF new HIV cases IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL.</b> Alexis Rebollo Curbelo (University Hospital of Bellvitge, Spain)	09:00 - 09:00
eP418	<b>Estimating the health impact and cost-effectiveness of emergency department opt-out testing for blood-borne viruses in Germany</b> Jürgen K Rockstroh (University Hospital Bonn, Germany)	09:00 - 09:00
eP419	<b>Expanding HIV Screening Beyond Hospital Walls in Milan: 18 years of the "EasyTest" project</b> Angelo Roberto Raccagni (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP421	<b>HIV Screening Practices and Knowledge of Indicator Conditions Among Resident Doctors: A Cross-Sectional Study</b> Mehmet Buğra Özkara (Ege University, Turkey)	09:00 - 09:00
eP422	<b>Individuals newly diagnosed with HIV in London, UK: characteristics of previous attenders and 'never-attenders'</b> Gary Whitlock (Chelsea & Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP423	<b>Involvement of key populations in HIV testing through social networks, Odesa, Ukraine</b> Nataliia Kitsenko (NGO "Way Home", Odesa, Ukraine, Ukraine)	09:00 - 09:00
eP424	<b>Medical-Driven HIV Testing Persists Over Time in Central and Eastern Europe: Evidence from the Go Holistic Go Beyond Project</b> Ivana Gmizic (Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia; Faculty of Medicine, University of Belgrade, Serbia)	09:00 - 09:00
eP425	<b>Missed Opportunities for HIV Testing in Newly Diagnosed Patients at a Tertiary Care Hospital: A Retrospective Analysis</b> Bircan Kayaaslan (Ankara Yildirim Beyazıt University, Ankara Bilkent City Hospital, Turkey)	09:00 - 09:00
eP426	<b>NEW OPPORTUNITIES FOR COVERING THE POPULATION WITH HIV TESTING IN LVIV, UKRAINE</b> Olena Pavlyshyn (Communal Non-Profit Enterprise "Lviv Territorial Medical Association 2", Lviv, Ukraine, Ukraine)	09:00 - 09:00

eP427	<b>Overview on community-based screening in Tunisia in 2024</b> Samir Mokrani (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP428	<b>Use of Regional Mentors to Optimize Maternal Retesting Services for Prevention of Vertical Transmission of HIV: A case of Mwanza, Tabora, and Morogoro in Tanzania</b> Neema Makyo (Amref Health Africa, Tanzania)	09:00 - 09:00
eP429	<b>Wedge-shaped clustered randomized trial to evaluate two tools for identifying individuals at risk for or already infected with HIV: Atenea Study Interim Analysis</b> María Jesús Pérez- Elías (Ramon y Cajal University Hospital, Spain)	09:00 - 09:00
eP430	<b>Female Patients on HIV Post-Exposure Prophylaxis: Clinical outcomes and prevention opportunities</b> Natalia Sánchez-Ocaña Martín (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP431	<b>HIV post-exposure prophylaxis in the integrase inhibitor era: experience in a low-middle income country</b> Julián Vega (Hospital General de Agudos "Juan A. Fernández", Argentina)	09:00 - 09:00
eP432	<b>Rapid assessment of access to HIV Post-Exposure Prophylaxis (PEP) in EU/EEA countries</b> Ferenc Bagyinszky (AIDS Action Europe, Germany)	09:00 - 09:00
eP433	<b>A Multidisciplinary Approach to Promoting Accessibility and Adherence to Pre-Exposure Prophylaxis (PrEP) in a Portuguese Hospital in Lisbon</b> Bárbara Cardoso (Hospital de Santa Maria, Portugal)	09:00 - 09:00
eP434	<b>Assessing the Interest and Willingness of Nigerian Community Pharmacists to Deliver Pharmacy-Based Pre-Exposure Prophylaxis (PrEP) Services</b> Theodora Chioma Omenoba (Veritas University Nigeria Abuja, Nigeria)	09:00 - 09:00
eP435	<b>Assessment of healthcare access and knowledge of HIV pre-exposure prophylaxis in women sex workers in Lille, Northern France.</b> Emmanuelle Bontemps (Tourcoing Hospital, France)	09:00 - 09:00
eP436	<b>Automated Data Solutions for PrEP Monitoring and Planning in Ukraine</b> Diana Shevchenko (SI Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
eP437	<b>Awareness and Uptake of Pre-Exposure Prophylaxis among Pregnant women at risk of HIV in Mid-Western and Central Uganda: A Population-Based Study</b> Bashiri Magada (Africa Medical and Behavioral Sciences Organization (AMBSO), Uganda)	09:00 - 09:00
eP438	<b>Characteristics of PrEP Users at First Counseling Visit: Persistent Gaps in Reaching High-Risk Populations</b> Drieda Zace (Tor Vergata University of Rome, Italy)	09:00 - 09:00
eP439	<b>Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)</b> Sandro Mattioli (PrEP Point Plus, Italy)	09:00 - 09:00
eP440	<b>Comparison of users accessing PrEP in hospital-based or community-based setting: first picture from the PRIDE cohort</b> Valentina Mazzotta (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Italy)	09:00 - 09:00
eP441	<b>Engagement of Women of Color in HIV Prevention through PrEP at a Clinic Serving LGBTQ+ Communities</b>	09:00 - 09:00

	Darya Fridman (The LGBTQ Center, United States)	
eP442	<b>Evaluation of a multidisciplinary reach-out program, facilitating HIV pre-exposure prophylaxis (PrEP) prescription and retention in care, in a group of trans women (TW) at high risk of HIV infection. Preliminary results from the PrEP à porter study</b> VALENTINA ISERNIA (Bichât - Claude Bernard Hospital, France)	09:00 - 09:00
eP443	<b>Examining the real-world population-level impact of Scotland's national HIV pre-exposure prophylaxis (PrEP) programme among gay, bisexual and other men who have sex with men</b> Claudia Estcourt (Glasgow Caledonian University, United Kingdom)	09:00 - 09:00
eP444	<b>Experience of Implementing PrEP in a Health Insurance in Buenos Aires, Argentina: Lessons Learned and Challenges</b> Iael Altclas (IPTEI Medica, Argentina)	09:00 - 09:00
eP445	<b>Frequency of Enteric Pathogens in Austrian PrEP Users</b> Nikolaus Urban (Medical University of Vienna, Austria)	09:00 - 09:00
eP446	<b>HIV infection in PrEP users: incidence, epidemiological, clinical and virological characteristics. A multicenter ambispective Cohort in Spain (SCOPE Study)</b> Juan Ambrosioni (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain)	09:00 - 09:00
eP447	<b>Impact of COVID-19 lockdown on HIV pre-exposure prophylaxis (PrEP) service delivery in Uganda: Challenges and coping strategies</b> Sylvia Namanda (Infectious Diseases Institute, College of Health Sciences, Makerere University, Uganda)	09:00 - 09:00
eP448	<b>Impact of Pre-Exposure Prophylaxis (PrEP) Introduction on Homosexual HIV Transmission in Kazakhstan: An Interrupted Time Series Analysis</b> Indira Karibayeva ("Kazakh Scientific Center for Dermatology and Infectious Diseases" of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan)	09:00 - 09:00
eP449	<b>Implementation of PrEP in Italy: Highlights and Challenges. Findings from the PrIDE Survey</b> Silvia Nozza (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP450	<b>Inequality in the Distribution of PrEP in Brazil: An Analysis of Coverage in Relation to HIV Incidence by Age Group, Sexual Orientation, and Race</b> Vinícius Gabriel Horst Soares (Institute of Medical Education (IDOMED), Brazil)	09:00 - 09:00
eP451	<b>Interest in and intention to use long-acting PrEP among PrEP-naïve MSM and MSM currently using PrEP in Thailand</b> Natthakhet Yaemim Deyn (PULSE Clinic Plc, Thailand)	09:00 - 09:00
eP452	<b>Introducing community-based PrEP delivery in Romania</b> Raluca Pătraşcu (National Institute for Infectious Diseases "Prof dr Matei Balş", Romania)	09:00 - 09:00
eP453	<b>Introduction of Pre-Exposure Prophylaxis (PrEP) in Kazakhstan: Its Impact on HIV Testing and Diagnosis Rates among People Who Inject Drugs</b> Botagoz Turdaliyeva ("Kazakh Scientific Center for Dermatology and Infectious Diseases" of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan)	09:00 - 09:00
eP454	<b>Mental Health, Stigma and Risk Perception Among CAB-LA PrEP Initiators: a cross-sectional study</b> Davide Moschese (Luigi Sacco University Hospital, Italy)	09:00 - 09:00

eP455	<b>Mind the Gap: transition from HIV PEP with B/F/TAF to oral PrEP in real-world setting</b> Flavia Passini (Vita-Salute San Raffaele University, Italy)	09:00 - 09:00
eP456	<b>Opportunities to Prevent Human Immunodeficiency Virus (HIV) Acquisition: Global Survey Results on Sexual Health Engagement in Newly Diagnosed People Living With HIV From the VOLITION Study</b> Cassidy A Gutner (ViiV Healthcare, United States)	09:00 - 09:00
eP457	<b>Pre-Exposure prophylaxis to prevent HIV transmission among migrant men who have sex with men in Georgia</b> Maia Tsintsadze (T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia)	09:00 - 09:00
eP458	<b>Prevalence and Correlates of Intimate Partner Violence among Gay, Bisexual, and Other Men Who Have Sex with Men (GBMSM) Using PrEP in Pre-War Ukraine</b> Nikolay Lunchenkov (Technical University of Munich, Germany)	09:00 - 09:00
eP459	<b>Real-World Experience with Oral PrEP in Italy: A Descriptive Study from a Single-Center Cohort (2018-2024)</b> Andrea Carbone (Catholic University of Sacred Heart, Italy)	09:00 - 09:00
eP460	<b>Reasons for HIV-Preexposure Prophylaxis (PrEP) discontinuation and its predictors in people still at risk for HIV acquisition</b> Virginia Barchi (National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, Italy)	09:00 - 09:00
eP461	<b>Sexual health knowledge, interest and acceptability of PrEP in migrant women: the MIMOSA study</b> Maria Mazzitelli (Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, Italy)	09:00 - 09:00
eP462	<b>Social Media Communication for Recruitment and Adherence to Combined HIV/STI Prevention with a Focus on the Trans Population at a Research Center, São Paulo, Brazil</b> Vinicius Francisco da Silva (Centro de Referência e Treinamento DST/AIDS, Brazil)	09:00 - 09:00
eP463	<b>Systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men</b> David Comer (University of Galway, Ireland)	09:00 - 09:00
eP464	<b>Use of whole blood capillary samples to estimate glomerular filtration rate using enzymatic analysis of creatinine among HIV PrEP users</b> Maurice Pelsers (Dr. Stein & Collegae Maastricht, Germany)	09:00 - 09:00
eP465	<b>Would infant lamivudine prophylaxis during breastfeeding be an option to prevent from vertical transmission of HIV ?</b> Laetitia Gay (Inserm, France)	09:00 - 09:00
eP466	<b>Durable viral load suppression and viral load rebound among people living with HIV in North America and Europe. A systematic review and meta-analysis</b> Mariam Salim Mbwana (Primary Health Care Institute, Tanzania)	09:00 - 09:00
eP467	<b>HIV Self-Testing by Mail Among Sex Workers: A Virtual Harm Reduction Initiative in Montpellier, France</b> Victor Duperret (Médecins du Monde, France)	09:00 - 09:00
eP468	<b>MEASURING HIV PREVENTION KNOWLEDGE (U=U, PEP, PrEP) AND ATTITUDES IN THE HEALTHCARE SETTING: SERBIAN RESULTS FROM AN ECDC/EACS SURVEY</b>	09:00 - 09:00

	Gordana Dragović (Faculty of Medicine, University of Belgrade, Serbia)	
eP469	<b>Treatment as Prevention: The Impact of the National Care and Support Program for People Living with HIV Amid Russia's Full-Scale Military Invasion of Ukraine</b> Nataliia Zapolska (Nataliia Zapolska, Ukraine)	09:00 - 09:00
	<b>C3. Social Sciences</b>	09:00 - 09:00
eP470	<b>Advancing HIV Cure Research in Latin America and the Caribbean: Perspectives, Priorities, and Advocacy Needs of Civil Society</b> Luciana Kamel (Fundação Oswaldo Cruz (Fiocruz), Brazil)	09:00 - 09:00
eP471	<b>Behavioral Change Related to Stigma and Discrimination Among People Living with HIV</b> Monica Pudaruth (PILS (Prévention Information et Lutte contre le SIDA), Mauritius)	09:00 - 09:00
eP472	<b>Evaluation of Health-Related Quality of Life Over a Six-Month Period in Newly Diagnosed People Living with HIV</b> Hakki Meric Turkkan (Sisli Hamidiye Etfal Training and Research Hospital Istanbul,Turkey, Turkey)	09:00 - 09:00
eP473	<b>Evolving Influences on HIV Knowledge in Young Filipino Women: Education, Media, and Stigma</b> Sophia Palma (University of Debrecen, Hungary)	09:00 - 09:00
eP474	<b>Memory rehabilitation for HIV-Associated Neurocognitive Disorders (HAND) : A review of the literature</b> Signe Andersen (Centre Hospitalier Universitaire, France)	09:00 - 09:00
eP475	<b>Multi-dimensional impulsivity in people living with HIV on effective cART</b> Chloe Knox (University Hospitals Sussex NHS Trust, United Kingdom)	09:00 - 09:00
eP476	<b>Preliminary findings from a new group-based memory rehabilitation program, <i>Coaching Memory</i>, for HIV-Associated Neurocognitive Disorders (HAND)</b> Signe Andersen (Centre Hospitalier Universitaire, France)	09:00 - 09:00
eP477	<b>Reframing HIV: How Personal Growth and Acceptance Could Improve ART Adherence</b> Andrea Norcini-Pala (SUNY Downstate Health Sciences University, United States)	09:00 - 09:00
eP478	<b>Time to Suboptimal Treatment Patterns Among People With HIV on Antiretroviral Therapy in the United States</b> Travis Lim (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP479	<b>A Telegram Bot as a Digital Tool for Transgender People in Ukraine: Access to HIV Services and Gender-Affirmative Support</b> Vitalii Apanasenko (Youth Public Movement "Partner", Ukraine)	09:00 - 09:00
eP480	<b>Bimonthly long acting cabotegravir and rilpivirine in transgender women with HIV: evidence from the Spanish RELATIVITY cohort.</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP481	<b>Integrated biobehavioral survey among transgender and non-binary people in Ukraine, 2024</b> Sofia Ohorodnik (Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
eP482	<b>Effect of SARS-CoV-2 vaccination on HIV viral load in patients under BIC/TAF/FTC therapy: a retrospective observational study</b> Giuseppe Pipitone (ARNAS Civico Hospital, Italy)	09:00 - 09:00
eP483	<b>Gamified Education: Utilizing Interactive Play to Enhance</b>	09:00 - 09:00

	<b>HIV/AIDS Awareness and Prevention</b> Olga Feger (State University «Uzhhorod National University», Ukraine)	
eP484	<b>Loneliness and HIV in Adults 50+: Voices on Needed Interventions</b> Rosa De Miguel Buckley (La Paz- Carlos III University Hospital, Spain)	09:00 - 09:00
eP485	<b>More than just a drink: Identifying and intervening on silent risk profiles for alcohol misuse in People Living With HIV</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP486	<b>Perspectives on HIV Cure-Related Trials with Analytical Treatment Interruption among People Living with HIV and Healthcare Practitioners</b> Kwanza Price (Gilead Sciences, Inc., United States)	09:00 - 09:00
eP487	<b>Reasons for interrupting antiretroviral therapy, results of the study</b> Yaroslava Lopatina (AHF Ukraine, Ukraine)	09:00 - 09:00
eP488	<b>Silent Crisis: Loneliness in Older Adults Living with HIV</b> Joanna Cano-Smith (La Paz- Carlos III University Hospital, Spain)	09:00 - 09:00
eP489	<b>Stigma and Quality of Life in People Living with HIV: Psychosocial vulnerability and clinical implications</b> Carolina Olmos Mata (Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP490	<b>Cost analysis and diagnostic yield of asymptomatic sexually transmitted infections (STIs) screening in a high-risk cohort of men who have sex with men (MSM)</b> Pierluigi Francesco Salvo (Università Cattolica del Sacro Cuore, Italy)	09:00 - 09:00
eP491	<b>Feelings, experiences and coping strategies after HIV diagnosis amongst people with recently acquired HIV in Europe</b> Inés Suárez-García (Hospital Universitario Infanta Sofía, FIIB HUIS HHEN, Spain)	09:00 - 09:00
eP492	<b>Leveraging Interactive SMS Training to Equip Health Workers for Inclusive HIV Services Amid Uganda's Anti-Gay Law Implementation</b> Christine Nabukera Rwabyogamu (Infectious Diseases Initiative, Uganda)	09:00 - 09:00
eP493	<b>Navigating Sexual Dysfunction with HIV: Experiences of Gay, Bisexual, and Other Men Who Have Sex with Men in Montreal, Canada</b> Francesco Avallone (McGill University, Canada)	09:00 - 09:00
eP494	<b>Risk reduction strategies for HIV transmission during time among men who have sex with men in Slovenia: Qualitative study</b> Miran Solinc (University of Ljubljana, Slovenia)	09:00 - 09:00
eP495	<b>"Even Me Myself, I Don't See Myself as a Human Being": Migration, Violence, and HIV Exposure Among African Refugee Male Sex Workers in Transit to Italy</b> Marco Barracchia (Maastricht University, Netherlands)	09:00 - 09:00
eP496	<b>Assessing Mental Health in an Immigrant-Dominated HIV Cohort Using PHQ-9: A Pilot Analysis from a Greek HIV Unit</b> Vissaria Sakka (National Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP497	<b>Characterisation of migrant PLWHIV from sub-Saharan Africa in a hospital in Europe - mixed-methods study in the Lisbon region, Portugal</b> Rita Patrocínio de Jesus (Hospital Prof. Doutor Fernando Fonseca, Portugal)	09:00 - 09:00
eP498	<b>Where Health Begins: Mobile Health as a Tool for HIV/STI Access Among LGBTQI+ Migrants in Italy</b>	09:00 - 09:00

	Marco Barracchia (Maastricht University, Netherlands)	
eP499	<b>Attitudes towards PrEP among women engaged in sex work who use drugs (WESW-UD) in Kazakhstan</b> Tara McCrimmon (Columbia University Mailman School of Public Health, United States)	09:00 - 09:00
eP500	<b>Barriers to STI Prevention among Female Sex Workers in Türkiye: A Qualitative Study</b> Ismail Orbay (Hacettepe University, Turkey)	09:00 - 09:00
eP501	<b>Did the AEGIDA Intervention Reduce Sexual Behaviors Associated with HIV Acquisition among Women who Exchange Sex and/or Use Substances in Kazakhstan?</b> Victoria Frye (Columbia University School of Social Work, United States)	09:00 - 09:00
eP502	<b>Health issues in sex workers attending a sexual health clinic in Paris: an observational cohort</b> Sarah Gaston-Dreyfus (Saint Antoine hospital, France)	09:00 - 09:00
eP503	<b>Internalized Stigma and Mental Health Symptoms among females who engage in sex work and use drugs in Kazakhstan: Baseline insights from the AEGIDA Study</b> Assel Terlikbayeva (Center for Scientific and Practical Initiatives, Kazakhstan)	09:00 - 09:00
eP504	<b>Intersectional identities and barriers</b> Trajche Janushev (Regional Network Sex Workers' Rights Advocacy Network (SWAN), Hungary)	09:00 - 09:00
eP505	<b>Retention Cascade and Predictors in a Sexual Health Program for Sex Workers: Expanded Access Through NGO Collaboration</b> Diana Corona-Mata (Hospital Universitario Reina Sofía, Spain)	09:00 - 09:00
eP506	<b>Associations Between Marijuana Use Patterns and HIV Care Continuum Outcomes Among Adults with HIV in Florida</b> Robert Cook (University of Florida, United States)	09:00 - 09:00
eP507	<b>Chemsex Trajectories among GBMSM in Almaty, Kazakhstan: A Reflexive Thematic Analysis Using a Life Course Framework</b> Nikolay Lunchenkov (Technical University of Munich, Germany)	09:00 - 09:00
eP508	<b>Co-designing community-led, comprehensive chemsex harm reduction services for young men who have sex with men in Thailand: sexual health-focused, legal/rights-focused, and on-the-spot models</b> Sudarat Thongsuksangcharoen (Institute of HIV Research and Innovation, Thailand)	09:00 - 09:00
eP509	<b>Describing substance use related to sex (chemsex) among individuals newly diagnosed with HIV at a sexual health clinic in Spain</b> Inés Armenteros (Centro Sanitario Sandoval - Hospital Clínico San Carlos, Spain)	09:00 - 09:00
eP510	<b>Peer-to-peer needle and syringe programmes (P2PNSP) as a way of engaging PWID in HIV prevention: 7 case studies</b> Alexei Lakhov (European Network of People who Use Drugs, Germany)	09:00 - 09:00
eP511	<b>The Silent Epidemic: Chemsex Practices and Their Implications in Türkiye</b> Gökhan Vatansever (Ege University, Turkey)	09:00 - 09:00
eP512	<b>Trends in HIV prevalence among key populations between 2009 and 2021</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00



eP513	<b>AEGIDA: A Behavioral HIV Intervention Associated with Reduced Partner Violence Among Women Who Exchange Sex and Use Substances (WESUS) in Kazakhstan</b> Sholpan Primbetova (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP514	<b>Barriers to HIV Services for LGBT+ People in Armenia: Legal Gaps, Stigma, and Human Rights Concerns</b> Vaghinak Ter-Hovhannisyan (Gavar State University, Armenia)	09:00 - 09:00
eP515	<b>Community and provider-driven strategies to reduce HIV-related stigma in Kazakhstan: opportunities for change</b> Meruyert Darisheva (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP516	<b>Empowering High-Risk Communities: Peer Educators as Catalysts for HIV Prevention in Kumba, Cameroon</b> Alemju Fontu (Alliance for Community Initiative, Cameroon)	09:00 - 09:00
eP517	<b>From Tokenism to Transformation: Tackling Structural Inequities in HIV Grant Revisions</b> Gayane Arustamyan (Advancing Global Health Solutions, Portugal)	09:00 - 09:00
eP518	<b>HIV and STIs Prevention in Women in Italy: the importance of the educational setting in WomanIST project</b> Dario Bernacchia (ASST Ovest Milanese - Legnano Hospital, Italy)	09:00 - 09:00
eP519	<b>HIV-RELATED STIGMA AND DISCRIMINATION IN ARGENTINA'S POPULATION: RESULTS OF A CROSS-SECTIONAL STUDY EMPLOYING AN ONLINE SURVEY</b> José A. E. Barletta (Hospital Fernández, Argentina)	09:00 - 09:00
eP520	<b>Medical Mistrust as a Barrier to Healthcare Access Among Women Vulnerable to HIV</b> Meruyert Darisheva (Global Health Research Center of Central Asia, Kazakhstan)	09:00 - 09:00
eP521	<b>Overview on the epidemiology of HIV/AIDS among key populations in Tunisia, 2024</b> Arwa Neffati (Directorate of Primary Healthcare (DSSB), Tunisia)	09:00 - 09:00
eP522	<b>Prison: An Essential Piece in the 'Towards Zero' Puzzle</b> Pankaj Sethi (Positive East, United Kingdom)	09:00 - 09:00
eP523	<b>Reaching neglected Vulnerable Populations: Addressing the HIV Knowledge Gap in UK prisons</b> Sophie Strachan (Sophia Forum, United Kingdom)	09:00 - 09:00
eP524	<b>Religiosity and Perceived Stress Among Filipino People Living with HIV: Evidence from a Community-Led Treatment Hub in Metro Manila, Philippines</b> Emmanuel S. Baja (Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Philippines)	09:00 - 09:00
eP525	<b>Understanding HIV and Key Population Stigma in Kazakhstan's Healthcare Workforce: A Cross-Sectional Analysis</b> Gaukhar Mergenova (Asfendiyarov Kazakh National Medical University, Kazakhstan)	09:00 - 09:00
eP526	<b>HIV/AIDS IN LVIV (UKRAINE) IN WAR CONDITIONS: EPIDEMIOLOGICAL CHANGES</b> Olena Mysano (Communal Non-Profit Enterprise "Lviv Territorial Medical Association 2", Lviv, Ukraine (CNE "Lviv TMO 2"), Ukraine)	09:00 - 09:00
eP527	<b>Impact of the War on HIV Diagnosis Timeliness: CD4 Level Dynamics Among Newly Registered PLHIV in Ukraine</b>	09:00 - 09:00

	Larysa Hetman (Public Health Center of the MOH of Ukraine, Ukraine)	
eP528	<b>Resilience of Harm Reduction and HIV Prevention Services for People Who Inject Drugs in Ukraine Amid War: Insights from 2021-2023</b> Liudmyla Legkostup (Public Health Center of the MOH of Ukraine, Ukraine)	09:00 - 09:00
	<b>Clinical Cases</b>	09:00 - 09:00
eP.C001	<b>Possible CNS Compartmentalization and Lenacapavir Resistance in Multidrug-Resistant HIV</b> Annalisa Marinosci (University Hospitals of Geneva, Switzerland)	09:00 - 09:00
eP.C002	<b>Virological failure with NNRTI resistance on CAB+RPV-LA in a man with subtherapeutic cabotegravir levels</b> Nian Li (North Middlesex University Hospital, United Kingdom)	09:00 - 09:00
eP.C003	<b>Bictegravir in Aging Adults Living with HIV: Sustained Virologic Control and Age-Appropriate Safety Profile</b> Marcello Trizzino (University of Palermo, Infectious and Tropical Disease Unit and Sicilian Regional Reference Center for the Fight Against AIDS, Palermo, Italy, Italy)	09:00 - 09:00
eP.C004	<b>Central nervous system lesions in late-presenting person living with HIV - opportunistic infection or a brain tumour?</b> Filip Glavac (University Hospital for Infectious Diseases, Zagreb, Croatia, Croatia)	09:00 - 09:00
eP.C005	<b>Case Report: Late Diagnosis of HIV at Clinical Stage 4 With Pulmonary and CNS Tuberculosis</b> Oleksandra Bezrodna (Bogomolets National Medical University, Ukraine)	09:00 - 09:00
eP.C006	<b>Evolving Genital Lesions of Unusual Etiology in a Man Who Have Sex with Man: Case Report</b> Carlo Bieńkowski (Medical University of Warsaw, Poland)	09:00 - 09:00
eP.C007	<b>CMV-related cholangiopathy as part of IRIS in an HIV-infected patient with invasive pulmonary aspergillosis</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C008	<b>Bacillary Angiomatosis in a HIV Patient with High CD4 Count: An Unexpected Manifestation of IRIS?</b> Hayat Kumbasar Karaosmanoğlu (Taksim Training and Research Hospital, Turkey)	09:00 - 09:00
eP.C009	<b>Disseminated Whipple's Disease and Kaposi's Sarcoma with IRIS-PML in an individual with Advanced HIV</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C010	<b>Disseminated MAC, Leishmaniasis, and CMV in a patient with advanced HIV: A complex case of IRIS</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C011	<b>A case of AIDS-associated Progressive Multifocal Leukoencephalopathy with significant improvement in higher brain function following glucocorticoid therapy</b> Motoki Kon (NHO Sendai Medical Center, Japan)	09:00 - 09:00
eP.C012	<b>Fatal Case of KSHV-Associated Diseases with Airway Involvement: Kaposi Sarcoma, Multicentric Castleman Disease, and Diffuse Large B-Cell Lymphoma in a Person living with HIV</b> Vitor José da Silva Classmann (Evandro Chagas National Institute of Infectious Diseases (INI-Fiocruz), Brazil)	09:00 - 09:00
eP.C013	<b>When the Fever Won't Break: A Case of Disseminated MAC in</b>	09:00 - 09:00

	<b>Advanced HIV</b> ilkay akbulut (Health Sciences University Tepecik Training and Research Hospital, Turkey)	
eP.C014	<b>Visceral Leishmaniasis and HIV coinfection: unusual clinical presentation</b> Lorenzo Albertini (Università degli Studi di Milano, Italy)	09:00 - 09:00
eP.C015	<b>A Rare and Fatal Case of Cerebral and Renal Toxoplasmosis in a Non-adherent Person Living with Advanced HIV</b> Büşra Akmaz (Izmir Katip Celebi University, Atatürk Educational Research Hospital, Turkey)	09:00 - 09:00
eP.C016	<b>Encephalitis caused by ganciclovir-resistant cytomegalovirus in a late-presenting person living with HIV, diffuse large B-cell lymphoma, and multiple opportunistic infections</b> Marija Santini (University Hospital for Infectious Diseases, Croatia)	09:00 - 09:00
eP.C017	<b>Disseminated Mycobacterium Avium Complex (dMAC) and Ophthalmoplegia - a diagnostic challenge</b> Niroshan Dayalan (Chelsea and Westminster Hospital, United Kingdom)	09:00 - 09:00
eP.C018	<b>The first case of lung abscess and bacteremia caused by Rhodococcus hoagii in a patient with advanced HIV Infection in Croatia - a therapeutic challenge</b> Nikola Kudoić (University Hospital for Infectious Diseases Dr. Fran Mihaljevic, Croatia)	09:00 - 09:00
eP.C019	<b>First reported case of Trichophyton mentagrophytes genotype VII infection in a Portuguese HIV-positive patient</b> Fábio Reis (Hospital Pedro Hispano, Portugal)	09:00 - 09:00
eP.C020	<b>Maribavir Salvage Therapy for ganciclovir-resistant cytomegalovirus in two women with HIV-related lymphoma</b> Guillaume THIZY (Saint Louis Hospital, AHP, France)	09:00 - 09:00
eP.C021	<b>Paradoxical Immune Reconstitution Inflammatory Syndrome associated with Pneumocystis jirovecii pneumonia in a person living with HIV: a case report</b> Dara Mbanze (Unidade Local de Saúde Gaia e Espinho, Portugal)	09:00 - 09:00
eP.C022	<b>Treatment of refractory Giardiasis with quinacrine in a young refugee with HIV and HCV coinfection</b> Alberto Diaz De Santiago (Puerta de Hierro University Hospital, Spain)	09:00 - 09:00
eP.C023	<b>HIV-associated chronic inflammatory demyelinating polyneuropathy successfully managed with immunoadsorption</b> Yuanmei Che (Jiangxi Provincial People's Hospital/The First Affiliated Hospital of Nanchang Medical College, China)	09:00 - 09:00
eP.C024	<b>Polymorphic Kaposi Sarcoma in the shadows of isolation and migration</b> Andronikos Spyrou (G. Gennimatas, General Hospital of Athens, Greece)	09:00 - 09:00
eP.C025	<b>Mycobacterium avium Complex Infection Following Immune Reconstitution Inflammatory Syndrome: A Diagnostic Journey</b> Daniela Rodrigues Nogueira (Unidade Local de Saúde de Santo António, Portugal)	09:00 - 09:00
eP.C026	<b>Oral ulcerations associated with Epstein-Barr virus in a severely immunocompromised person living with HIV-1</b> Márcia Daniela Silva (Unidade Local de Saúde de Santo António, Portugal)	09:00 - 09:00
eP.C027	<b>Genital and Oral Ulcerative Vasculitis in a Recently Diagnosed PWH with Negative Microbiological Workup</b> Alberto Foncillas (Hospital Clínic de Barcelona, Universitat de Barcelona,	09:00 - 09:00


	Spain)	
eP.C028	<b>An atypical presentation of psychosis in Progressive Multifocal Leukoencephalopathy</b> Natasha Somani (Chelsea and Westminster NHS Foundation Trust, United Kingdom)	09:00 - 09:00
eP.C029	<b>Fatal Overlapping CMV Encephalitis, Adrenal Insufficiency, and IRIS in an Individual with Advanced HIV and Disseminated MAI</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C030	<b>Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution</b> Maria Felipe Medeiros (Casa da Pesquisa CRT DST AIDS São Paulo, Brazil)	09:00 - 09:00
eP.C031	<b>Emergence of Maribavir Resistance in an AIDS Patient with Refractory Cytomegalovirus Viremia and Retinitis</b> Vissaria Sakka (National Kapodistrian University of Athens, Greece)	09:00 - 09:00
eP.C032	<b>Severe disseminated cryptococcosis, with asymptomatic central nervous system involvement, in a very late presenter</b> Sever Membulat (National Institute for Infectious Diseases "Matei Bals", Romania)	09:00 - 09:00
eP.C033	<b>A case of an AIDS related multifocal cryptococcus infection</b> Sergei Rakovich (Belarusian State Medical University, Belarus)	09:00 - 09:00
eP.C034	<b>Unmasking IRIS due to <i>Toxoplasma gondii</i> in a new HIV-positive individual with CD4 <math>\geq 200</math> cells/mm<sup>3</sup> and disseminated tuberculosis</b> Francisco Vale (Unidade Local de Saúde Almada-Seixal, Hospital Garcia de Orta, Portugal)	09:00 - 09:00
eP.C035	<b>Cryptococcal meningitis in a 34-Year-Old Man with Advanced HIV and Left insular Astrocytoma.</b> Alexy Inciarte Portillo (Hospital Clinic, Spain)	09:00 - 09:00
eP.C036	<b>Nocardia Abscessus diagnosis in a cis gender woman living with HIV</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP.C037	<b>Clinical Case of Advanced HIV With Multiple Opportunistic Diseases: Pneumocystis Pneumonia, CMV Chorioretinitis, and Kaposi's Sarcoma</b> Olena Vinnytska (Bogomolets National Medical University, Ukraine)	09:00 - 09:00
eP.C038	<b>Immune reconstitution inflammatory syndrome with atypical presentation of varicella zoster virus encephalitis</b> Javier José Ricart (Hospital de Infecciosas "F. J. Muñoz", Argentina)	09:00 - 09:00
eP.C039	<b>Diagnostic and therapeutic challenges in a case of cerebral mass lesions in a person living with HIV</b> Emma Rubenstein (Hôpital Saint Louis, France)	09:00 - 09:00
eP.C040	<b>Spondylodiscitis caused by <i>M. avium</i> complex in a man living with HIV and poor immunological - recovery after HAART</b> Luca Baldassari (ASST Ospedale papa Giovanni XXIII, Italy)	09:00 - 09:00
eP.C041	<b>Multiple concurrent opportunistic infections in newly diagnosed HIV-positive patient</b> GRACIANA LUCIA CARDENAS (Francisco J. Muñoz Hospital, Argentina)	09:00 - 09:00
eP.C042	<b>Disseminated <i>Talaromyces Marneffei</i> Infection Presenting as Pulmonary Cavitary Nodules: A Case Report</b> Xiaoying Qin (The Second Affiliated Hospital of Guangxi Medical	09:00 - 09:00

	University, China)	
eP.C043	<b>A case of Disseminated <i>Trichosporon asahii</i> Infection in a Patient with Advanced Human Immunodeficiency Virus Disease and Kaposi Sarcoma</b> Eleni Papantoniou (Aristotle University of Thessaloniki, Greece)	09:00 - 09:00
eP.C044	<b>Coexistence of Multicentric Castleman Disease and Visceral Kaposi Sarcoma : A Case-Report</b> Su Jung Choi (Hospital Español, Mexico)	09:00 - 09:00
eP.C045	<b>Multicentric Castleman Disease as a Cause of Fever of Unknown Origin: A Case Report</b> Su Jung Choi (Hospital Español, Mexico)	09:00 - 09:00
eP.C046	<b>Overcoming Barriers in Care: Managing HIV in people with Disabilities</b> Thyago César da Silva Pires (State University of Ponta Grossa, Brazil)	09:00 - 09:00
eP.C047	<b>Advanced Coronary Artery Disease in a Low-Risk HIV Patient - A Case for Early Statin Intervention</b> Aishriah Kalearasu (Maidstone Hospital, United Kingdom)	09:00 - 09:00
eP.C048	<b>Diffuse Large B-Cell Lymphoma in a Person Living with HIV and a History of Leprosy: A Diagnostic Challenge</b> UMUT OZGUR (Sisli Hamidiye Etfal Training and Research Hospital, Turkey)	09:00 - 09:00
eP.C049	<b>Use of PCSK9 Inhibitor Evolocumab in PLWH with persistent hyperlipidemia despite statin therapy: two case reports</b> Layla Pagnucco (Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo- University of Pavia - Italy, Italy)	09:00 - 09:00
eP.C050	<b>Complete remission of a Large B-cell Lymphoma in a person living with HIV: a case report with a 16 year follow-up</b> Kateryna Lytvyn (Dnipro State Medical University, Ukraine)	09:00 - 09:00
eP.C051	<b>Interaction between GLP-1 receptor agonists and cART in PLWH and Obesity: A case report</b> Raffaele Ferri (Università degli Studi "G.D'Annunzio", Italy)	09:00 - 09:00

*Plenary lecture*

09:15 - 09:45

Grand Amphitheatre

**PL3 - "Five years left!" What targets are in reach in Europe and which will we struggle to make?**Live broadcasted session 

Cristiana Oprea (Carol Davila University of Medicine and Pharmacy, Romania)

**"Five years left!" What targets are in reach in Europe and which will we struggle to make?**


09:15 - 09:45

Teymur Noori (European Centre for Diseases Prevention and Control (ECDC), Sweden)

*Plenary lecture*

09:45 - 10:15

Grand Amphitheatre

**PL4 - HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies**Live broadcasted session 

Justyna Kowalska (Medical University of Warsaw, Hospital for Infectious Diseases in Warsaw, Poland)

**HIV, hepatitis & syphilis prevention of vertical transmission - It's not all about babies**

09:45 - 10:15

Jeanne Sibiude (Sorbonne Université, France)

*Breaks*

10:15 - 11:00

Grand Amphitheatre

**Coffee break***Oral presentations*

10:45 - 12:00

Room 252 AB

**O2 - Oral cross track session**

- |      |   |               |
|------|---|---------------|
| O2.1 | <b>Review of HIV and Breastfeeding Guidelines Across Europe: Insights from the WAVE Survey ‘Same, same, but different: European Guidelines on HIV and breastfeeding’</b>  | 10:45 - 10:54 |
| O2.2 | <b>Long-acting injectable cabotegravir/rilpivirine in young adults with perinatally acquired HIV. RELATIVITY cohort study</b><br>Jose I Bernardino (Hospital Universitario La Paz. IdiPAZ, Spain)   | 10:54 - 11:03 |
| O2.3 | <b>Impact of a revised late HIV diagnosis definition on late HIV estimates in Europe: A multi-country pilot study</b>   | 11:03 - 11:12 |
| O2.4 | <b>Estimating HIV incidence and number of people with undiagnosed HIV in the European Union/European Economic Area in 2023</b><br>Ard van Sighem (stichting hiv monitoring, Netherlands)  | 11:12 - 11:21 |
| O2.5 | <b>Predictors of linkage to prevention services after HIV Post-Exposure Prophylaxis (PEP): a retrospective analysis from 2019 to 2024</b><br>Rozenn Esvan (National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Italy) | 11:21 - 11:30 |
| O2.6 | <b>Comparison of the Time to Reach Viral Suppression after ART Initiation Between Transgender Women and Other PWH in France: Results from the ANRS CO4 FHDH</b><br>Juliette Hemery (Iplesp, Sorbonne, INSERM, France)                     | 11:30 - 11:39 |
| O2.7 | <b>Analysis of Barriers to Testing for HIV Prevention and Linkage to Care Among Migrants in Europe</b><br>Michael Bogart (Gilead Sciences, Inc., United States)   | 11:39 - 11:48 |

*Parallel session*

11:00 - 12:00

Grand Amphitheatre

**PS08 - HIV Prevention: Current modalities and Future Horizons**

Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)

Šime Zekan (University Hospital for Infectious Diseases, Croatia)

- |        |  |               |
|--------|--|---------------|
|        | <b>HIV testing, PEP and Partner Notification</b>   | 11:00 - 11:10 |
|        | Fiona Burns (University College London, United Kingdom)  |               |
| PS08.1 | <b>“TelePrEP” - An online program for the delivery of remote PrEP services</b>   | 11:10 - 11:19 |
|        | Maria Luisa Cosmaro (Fondazione LILA Milano ETS, Italy)  |               |
| PS08.2 | <b>Intention to use long-acting injectable Pre-Exposure Prophylaxis among Belgian men who have sex with men - results of an online survey</b>                    | 11:19 - 11:28 |
|        | Thijs Reyniers (Institute of Tropical Medicine, Belgium)   |               |
| PS08.3 | <b>Tolerability and Safety of Long-Acting Cabotegravir for HIV Pre-Exposure Prophylaxis: preliminary data from a multicenter prospective observational study</b> | 11:28 - 11:37 |
|        | Davide Moschese (Luigi Sacco University Hospital, Italy)   |               |

PS08.4	<b>Preliminary Results of Long-Acting Injectable PrEP with Cabotegravir at San Raffaele Institute in Milan</b> Angelo Roberto Raccagni (Vita-Salute San Raffaele University, Italy)	11:37 - 11:46
PS08.5	<b>Annual Persistence to Twice-Yearly Lenacapavir Versus Daily Oral F/TDF for PrEP in the PURPOSE 2 Trial</b> Onyema Ogbuagu (Yale School of Medicine, United States)	11:46 - 11:55

*Parallel session*

11:00 - 12:00

Amphithéâtre Bordeaux

**PS09 - New drugs in the pipeline**

Gordana Dragović (Faculty of Medicine, University of Belgrade, Serbia)

Caroline Solas (APHM - Aix-Marseille Université, France)

	<b>New HIV drugs: virological and pharmacological mechanisms</b> Anne-Genevieve Marcelin (Sorbonne Université, INSERM, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, France)	11:00 - 11:10
PS09.1	<b>Safety and Tolerability of N6LS Administered Intravenously or Subcutaneously: Promising Results From Part 1 of the EMBRACE Study</b> Peter Leone (ViiV Healthcare, United States)	11:10 - 11:19
PS09.2	<b>Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results</b> Onyema Ogbuagu (Yale School of Medicine, United States)	11:19 - 11:28
PS09.3	<b>A French national real-world observatory of people initiating a lenacapavir-based treatment during the post-approval period</b> Charlotte Charpentier (Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, INSERM, IAME, France)	11:28 - 11:37
PS09.4	<b>Fostemsavir in a real-world setting: over one year of data from the PRESTIGIO Registry</b> Rebecka Papaioannu Borjesson (IRCCS San Raffaele Scientific Institute, Italy)	11:37 - 11:46

*Parallel session*

11:00 - 12:00

Salle Maillot

**PS10 - How can AI be used to advance in HIV prevention, treatment and care?**

Jens D. Lundgren (Rigshospitalet, University of Copenhagen, Denmark)

Dan Turner (Tel Aviv Sourasky Medical Center/ Faculty of Medicine, Tel Aviv University, Israel)

	<b>How can AI be used to advance in HIV prevention, treatment and care?</b> Rodolphe Thiébaud (Bordeaux University, France)	11:00 - 11:10
	<b>AI use in HIV prevention, case finding and early treatment uptake in Eastern Europe and Central Asia</b> Tetiana Doshko (Alliance for Public Health, Ukraine)	11:10 - 11:20
PS10.1	<b>Artificial Intelligence Meets HIV Education: Comparing Three Large Language Models on Accuracy, Readability, and Reliability</b> Özge Eren Korkmaz (Izmir Dokuz Eylül University, Turkey)	11:20 - 11:29
PS10.2	<b>A machine learning-based prognostic algorithm for serious non-aids events after initiation of antiretroviral therapy</b> Giota Touloumi (Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Greece)	11:29 - 11:38
PS10.3	<b>Identifying patterns of low-level viremia with increased risk of</b>	11:38 - 11:47

**subsequent viral failure using machine learning**

Katharina Kusejko (University Hospital Zurich, Switzerland)

*Breaks*

12:00 - 14:30

Grand Amphitheatre

**Lunch break***Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP15 - Clinical Cases - Complex Presentations and Co-Infections in Advanced HIV**

MeP15.C1	<b>Disseminated Histoplasmosis and CMV Ileocolitis in a Late Presenter with Advanced HIV and IRIS</b>	12:05 - 12:10
MeP15.C2	<b>Prophylaxis failure or IRIS reality? A case of unmasking <i>Mycobacterium avium</i> complex (MAC)-associated IRIS</b> Nikolaos Mazonakis (General Hospital of Thoracic Diseases "Sotiria", Greece)	12:10 - 12:15
MeP15.C3	<b>Disseminated Kaposi Sarcoma as Initial AIDS-Defining Illness in a Transgender Woman with Advanced HIV: Mucocutaneous, Pulmonary, Gastrointestinal and Nodal Involvement</b> Alberto Foncillas (Hospital Clínic de Barcelona, Universitat de Barcelona, Spain)	12:15 - 12:20
MeP15.C4	<b>Disseminated Cryptococcosis and Pneumocystosis as a Rare and Unusual Presentation of Primary HIV Infection: Case Report and Literature Insights</b> Lorenzo Ciullini (Geneva University Hospitals, Switzerland)	12:20 - 12:25

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**Moderated ePoster Sessions 13 - 16***Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP16 - Practical implementation of novel PrEP modalities**

Nicolas Nagot (University of Montpellier, France)

MeP16.1	<b>Commonly Prescribed Concomitant Medications and Clinical Safety Findings With Lenacapavir for Pre-Exposure Prophylaxis in PURPOSE 2</b> Anchalee Avihingsanon (HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Thailand)	12:05 - 12:10
MeP16.2	<b>The Potential Impact of Twice-Yearly Injectable Lenacapavir Among Cisgender Gay, Bisexual, and Other Men Who Have Sex With Men (GBMSM) and Other Priority HIV Prevention Populations (Transgender People and Highly Exposed Heterosexual People) in France</b> Henri Leleu (public health expertise, France)	12:10 - 12:15
MeP16.3	<b>Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men who have sex with men in a European country</b>	12:15 - 12:20
MeP16.4	<b>Evaluation of the completion rate and associated factors in HIV-Post-Exposure Prophylaxis regimen containing Doravirine (DORASPEP): a prospective observational cohort</b>	12:20 - 12:25



*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP14 - Innovative and Integrated Approaches to HIV Prevention and Care**

- |         |   |               |
|---------|---|---------------|
| MeP14.1 | <b>Evaluating the Impact of Integrating HIV Pre-Exposure Prophylaxis (PrEP) into Routine Health Insurance in Switzerland: A Mixed-Methods Analysis</b><br>Andrea Farnham (Department of Public Health & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland) | 12:05 - 12:10 |
| MeP14.2 | <b>High PrEP Uptake Among Men Who Have Sex with Men (MSM) Recruited Via Digital and Physical Community-Led Outreach in Paris, France</b><br>Anton Eremin (Aix-Marseille University, SESSTIM, ISSPAM, France)  | 12:10 - 12:15 |
| MeP14.3 | <b>Working with Mentor Mothers as an Implementation Strategy for Supporting Perinatal Mental Health of Kenyan Women Living with HIV</b><br>Janet Turan (University of Alabama at Birmingham, United States)   | 12:15 - 12:20 |
| MeP14.4 | <b>Integration of Geriatric Concepts into HIV Care Structures: A Single-Center Pilot Study in Dakar</b><br>Alassane NDIAYE (Outpatient Treatment Center, Senegal)   | 12:20 - 12:25 |

*Moderated ePosters*

12:05 - 12:25

ePoster Exhibition

**MeP13 - Knowledge and beliefs about HIV prevention strategies**


Robert Hejzák (European AIDS Treatment Group (EATG) / Czech AIDS Help Association, Czech Republic)

- |         |   |               |
|---------|---|---------------|
| MeP13.1 | <b>Unpacking Chemsex in Amsterdam: What Distinguishes Non-Users, Non-Problematic, and Problematic Users?</b><br>Doortje van den Dungen (Public Health Service Amsterdam (GGD Amsterdam), Netherlands)   | 12:05 - 12:10 |
| MeP13.2 | <b>Identification of Migrant Women's Care Needs and Barriers to HIV Testing - The SERAY Study</b><br>Giota Lourida (Evangelismos General Hospital, Athens, Greece)  | 12:10 - 12:15 |
| MeP13.3 | <b>Barriers to tobacco smoking cessation support during hospital follow-up of adult people living with HIV/AIDS: a clinicians' perspective</b><br>Fabienne Marcellin (Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, France) | 12:15 - 12:20 |
| MeP13.4 | <b>Perceived neurocognitive impairment is associated with levels of depression and quality of life in adults seeking memory rehabilitation for HIV associated neurocognitive disorders (HAND)</b>   | 12:20 - 12:25 |

*Industry sponsored session*

12:30 - 14:00

Amphithéâtre Bleu

**Industry sponsored session**Live broadcasted session *Oral presentations*

12:30 - 13:30

Amphithéâtre Bordeaux

**RO1 - Mpox - from prevention to clinics**

Ole Kirk (CHIP and Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark)  
 Chloe Orkin (Queen Mary University of London, United Kingdom)

RO1.1	<b>What is the impact of MVA-BN vaccine among people living with HIV in Israel?</b> Zohar Mor (Ministry of Health, Israel)	12:30 - 12:37
RO1.2	<b>Smallpox Vaccine Reduces Mpox Disease Severity and Symptoms</b> Christoph Boesecke (Department of Medicine I, Bonn University Hospital, Germany)	12:37 - 12:44
RO1.3	<b>Immune Profiling Reveals Hyperinflammatory Signature in Acute Mpox Infection</b> Joanne Byrne (University College Dublin, Ireland)	12:44 - 12:51
RO1.4	<b>Single-Cell RNA Sequencing of Mpox Lesions Reveals Tissue-Resident Memory T Cell Dynamics and Replenishment in the Skin</b> Simona Saluzzo (Medical University of Vienna, Austria)	12:51 - 12:58
RO1.5	<b>Systematic molecular screening for mpox in anal/pharyngeal swabs in high-risk MSM on PrEP: a substudy of the ANRS-DOXYVAC trial</b> Jade Ghosn (Bichat University Hospital, France)	12:58 - 13:05
RO1.6	<b>Breakthrough Mpox cases among different vaccination routes and under distinct HIV status</b> Susana Benet (Hospital Universitari Germans Trias i Pujol, Spain)	13:05 - 13:12
RO1.7	<b>Disproportionate presentation of Mpox among people with HIV: A multicenter retrospective cohort study in Taiwan</b> Andrew Po-Liang Chen (Taipei Veterans General Hospital, Taiwan)	13:12 - 13:19

*Oral presentations*

12:30 - 13:30

Salle Maillot

**RO2 - Advancing prevention and care: insights from providers and perspectives from the community**

Casper Rokx (Erasmus MC University Medical Center, Netherlands)

RO2.1	<b>The Jasmine Project: Revolutionary Digital Solutions to Prevent Violence and HIV Among Sex Workers in France</b> PG Macioti (Médecins du Monde, France)	12:30 - 12:37
RO2.2	<b>Profiles and follow-up of cis women using HIV pre-exposure prophylaxis (PrEP)</b> Karen Champenois (IAME Inserm UMR1137, Université Paris Cité et Université Sorbonne Paris Nord, France)	12:37 - 12:44
RO2.3	<b>Expanding PrEP Access in France: Clinical Challenges and Community Perspectives from the QualiPrEP Study</b>	12:44 - 12:51
RO2.4	<b>More HIV pre-exposure prophylaxis options expected to increase overall use among Toronto sexual minority men: Projections from a discrete choice experiment</b> Darrell H. S. Tan (St. Michael's Hospital, Canada)	12:51 - 12:58
RO2.5	<b>The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC</b> Cassidy A Gutner (ViiV Healthcare, United States)	12:58 - 13:05
RO2.6	<b>Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers' perspectives and experiences</b>	13:05 - 13:12
RO2.7	<b>More Than Undetectable: Addressing Psychosocial Needs and Community Support</b> Joanna Cano-Smith (La Paz- Carlos III University Hospital, Spain)	13:12 - 13:19

*Oral presentations*

12:30 - 13:30

Room 252 AB

**RO3 - Progress in clinical care**

Clotilde Allavena (CHU Nantes, France)

Mojca Maticic (University Medical Centre Ljubljana, Slovenia)

- |       |  |               |
|-------|--|---------------|
| RO3.1 | <b>Association Between Upregulated IL32 Expression and Inflammatory Patterns in Treated People with HIV</b><br>Dana Alalwan (University College Dublin, Ireland)   | 12:30 - 12:37 |
| RO3.2 | <b>HPV-16 Clearance at the Anal Site in MSM with HIV: Impact of Immunization and Host Immune Status</b><br>Elena Bruzzesi (IRCCS Ospedale San Raffaele, Italy)   | 12:37 - 12:44 |
| RO3.3 | <b>Implementation of EACS 2023 Cardiovascular Prevention Guidance in a Real-Life HIV Metabolic Clinic: A Longitudinal Cohort Study from Modena</b><br>Marcella Manicardi (Università di Modena e Reggio Emilia, Policlinico di Modena, Italy)  | 12:44 - 12:51 |
| RO3.4 | <b>LDL Target Achievement in people with HIV Over 40: Impact of Updated EACS Guidelines</b><br>Giorgia Carrozzo (Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Italy)   | 12:51 - 12:58 |
| RO3.5 | <b>Advancing HIV Care in Pregnancy: Trends in Virological Suppression, Mother-to-Child Transmission, and Postpartum Retention Over Two Decades</b><br>Federica Casari (Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Italy) | 12:58 - 13:05 |
| RO3.6 | <b>The impact of immunosuppression on course of puberty in girls living with HIV in Ukraine</b>  | 13:05 - 13:12 |
| RO3.7 | <b>Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: A substudy of the RELATIVITY cohort</b><br>María José Galindo Puerto (Hospital Clinico Universitario of Valencia, Spain)  | 13:12 - 13:19 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP18 - Mind the Gaps: Socio-demographic Disparities, Resistance, and HIV Elimination Pathways**

- |         |   |               |
|---------|---|---------------|
| MeP18.1 | <b>2023 HIV Cascade of care by specific groups in the Québec HIV Cohort</b><br>Alexandra de Pokomandy (McGill University Health Centre, Canada)   | 14:05 - 14:10 |
| MeP18.2 | <b>Targeting the Gaps: Testing Trends and Intersectional Analysis of HIV Testing Among Women Across Key Populations (2017-2023) in the COBATEST Network</b><br>Laura Fernàndez-López (Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya,, Spain) | 14:10 - 14:15 |
| MeP18.3 | <b>Harnessing national registry data to identify socio-demographic and socio-economic gaps in HIV care in the Netherlands</b><br>Vita Jongen (Stichting hiv monitoring, Netherlands)  | 14:15 - 14:20 |
| MeP18.4 | <b>Impact of continental spread of HIV-1 integrase resistance on progress toward the WHO's 2030 elimination goals</b>   | 14:20 - 14:25 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**Moderated ePoster Sessions 17 - 20**

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP19 - Beyond with DTG/3TC**

Silvia Nozza (Vita-Salute San Raffaele University, Italy)

- |         |   |               |
|---------|---|---------------|
| MeP19.1 | <b>"Leaving no stones unturned": 10 years results on the tolerability and metabolic safety of DTG+3TC as a switch regimen</b>   | 14:05 - 14:10 |
|         | Arturo Ciccullo (San Salvatore Hospital, Italy)   |               |
| MeP19.2 | <b>Switching to Dolutegravir/Lamivudine is Non-Inferior to Continuing Triple-Drug ART in Virologically Suppressed People With HIV: 2 year results of the DUALING Prospective Matched Nationwide Clinical Practice Study</b> | 14:10 - 14:15 |
|         | Marta Vasylyev (Erasmus University Medical Center, Netherlands)   |               |
| MeP19.3 | <b>Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort</b>  | 14:15 - 14:20 |
|         | Arturo Ciccullo (San Salvatore Hospital, Italy)   |               |
| MeP19.4 | <b>48-WEEK RESULTS OF SWITCHING FROM DTG/3TC TO BIC/FTC/TAF IN PWH AND NEUROPSYCHIATRIC COMORBIDITIES</b>   | 14:20 - 14:25 |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP20 - Prevention and HIV testing - innovative approaches and access**

Nicolas Nagot (University of Montpellier, France)

- |         |  |               |
|---------|--|---------------|
| MeP20.1 | <b>A novel way to improve access to Pre-Exposure Prophylaxis (PrEP) in the community via primary care</b>  | 14:05 - 14:10 |
|         | Rachel Kirby (The Northern Contraception, Sexual Health & HIV Service. Manchester University NHS Foundation Trust, United Kingdom)   |               |
| MeP20.2 | <b>Comparative benefits of Pre-exposure Prophylaxis versus Test-and-Treat to reduce community viral load: a systematic review of PrEP trials</b>   | 14:10 - 14:15 |
| MeP20.3 | <b>Randomized controlled clinical pilot study to evaluate the feasibility and acceptability of a telemedicine approach for HIV prevention with HIV Pre-Exposure Prophylaxis versus standard of care in Germany</b> | 14:15 - 14:20 |
|         | Florian Voit (Technical University of Munich, TUM School of Medicine and Health, TUM University Hospital, Germany)   |               |
| MeP20.4 | <b>Enhancing access to HIV self-testing services among returned migrants in Tajikistan</b>   | 14:20 - 14:25 |
|         | Farkhod Saydullaev (CDC, Tajikistan)   |               |

*Moderated ePosters*

14:05 - 14:25

ePoster Exhibition

**MeP17 - Viruses establishing infection and Vaccines**

Antonella Castagna (Vita-Salute San Raffaele University, Italy)

- |         |   |               |
|---------|---|---------------|
| MeP17.1 | <b>Genetic and functional characteristics of CXCR4-using viral envelope glycoproteins in acute HIV-1 infection</b>            | 14:05 - 14:10 |
|         | Dorine Martres (Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), France)                           |               |
| MeP17.2 | <b>Identification of a broad and potent V3 glycan site bNAbs targeting an N332<sub>gp120</sub> glycan-independent epitope</b> | 14:10 - 14:15 |
|         | Malena Rohde (University of Cologne, Institute of Virology, Germany)  |               |
| MeP17.3 | <b>Safety of a ChAdOx1.tHIVconsvX prime - MVA.tHIVconsvX boost vaccination regimen in people with HIV treated in primary</b>  | 14:15 - 14:20 |

	<b>infection: a phase I/II randomized, placebo-controlled trial (HIV-CORE 007)</b>	
	Elena Bruzzesi (IRCCS Ospedale San Raffaele, Italy)	
MeP17.4	<b>Assessment of the specific cellular immune response to the recombinant Herpes Zoster vaccine in people living with HIV</b>	14:20 - 14:25
	Grazia Alessio (Tor Vergata University of Rome, Italy)	
<i>Parallel session</i>		
14:30 - 15:30		Grand Amphitheatre
<b>PS11 - Emerging Challenges and Opportunities in STI Screening and Management</b>		
Jade Ghosn (Bichat University Hospital, France)		
Monika Bociąga-Jasik (Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Krakow, Poland, Poland)		
	<b>Should we screen for asymptomatic STI in MSM on PrEP?</b>	14:30 - 14:40
	Charles Cazanave (University Hospital of Bordeaux, France)	
	<b>Key questions and evidence gaps in the implementations of Doxypep</b>	14:40 - 14:50
	Fiona Lyons (St. James's Hospital, Ireland)	
PS11.1	<b>Bacterial STIs incidence among MSM with HIV in France: the ANRS PRIMO cohort</b>	14:50 - 14:59
	Sophie Novelli (Université Paris-Saclay, UVSQ, Inserm, CESP, France)	
PS11.2	<b>Clinical Features of Syphilis in MSM on Doxycycline Post-Exposure Prophylaxis (doxy-PEP): Real-World Data from a Single-Center Cohort</b>	14:59 - 15:08
	Cristina Gómez-Ayerbe (Hospital Universitario Virgen de la Victoria, Spain)	
PS11.3	<b>Bacterial Sexually Transmitted Infections over a 4-year-period of follow-up in MSM on PrEP enrolled in the prospective ANRS-PREVENIR cohort</b>	15:08 - 15:17
	Jade Ghosn (Bichat University Hospital, France)	
PS11.4	<b>PrEP and STIs screening policies: one size fit to all?</b>	15:17 - 15:26
<i>Parallel session</i>		
14:30 - 15:30		Amphithéâtre Bleu
<b>PS12 - Innovations, personalised medical services and social impacts</b>		
Daniela Rojas Castro (MoiPatient, France)		
Ben Collins (ReShape/International HIV Partnerships (IHP), United Kingdom)		
	<b>Personalised medical approaches - is it the best approach to end the epidemic?</b>	14:30 - 14:45
	Udi Davidovich (Amsterdam Public Health Service & The university of Amsterdam, Netherlands)	
PS12.1	<b>Public Knowledge, Views, Perceptions and Attitudes towards HIV and People with HIV in Europe - Combined Results of an HIV Public Opinion Survey Conducted in 11 European Countries</b>	14:45 - 14:54
	Konstantinos Protopapas (ATTIKON University Hospital, National and Kapodistrian University of Athens, Greece)	
PS12.2	<b>Risk of Income Loss in People Living With and Without HIV - a Comparative Swedish Nationwide Study Between 2019 to 2021</b>	14:54 - 15:03
	Isabela Killander Möller (Karolinska Institutet, Sweden)	
PS12.3	<b>Self-Reported Wellbeing and Integration Levels of Migrants with HIV in Italy: A Cross-Sectional Analysis from the ICONA Cohort</b>	15:03 - 15:12
	Andrea Giacomelli (Università degli studi di Milano, Italy)	

PS12.4	<b>Transgender People with HIV in Italy: Higher Risk of Disengagement from Care and Adverse Outcomes in the ICONA Cohort</b> Davide Moschese (Luigi Sacco University Hospital, Italy)	15:12 - 15:21
--------	--	---------------

*Parallel session*

14:30 - 15:30

Amphithéâtre Bordeaux

**PS13 - Ensuring access to HIV prevention and care for migrant populations in Europe**

Deniz Gökengin (Ege University Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Turkey)

Marta Vasylyev (Erasmus University Medical Center, Netherlands)

	<b>The new EU framework for migration and its potential impact on migrant health</b> Denis Onyango (Africa Advocacy Foundation (AAF), United Kingdom)	14:30 - 14:40
	<b>Post-migration HIV acquisition in migrants receiving HIV care in Europe</b> Romain Palich (Pitié-Salpêtrière University Hospital, AP-HP, France)	14:40 - 14:50
PS13.1	<b>Community-Based Screening for HIV and Viral Hepatitis Using Dried Blood Spots in a Migrant Population in Spain: the HEPINMIGRA study</b> Jara Llenas-García (Hospital Vega Baja, Spain)	14:50 - 14:59
PS13.2	<b>Seroprevalence of HIV, HBV, HCV, and Syphilis Among Syrian Refugees in Istanbul: Results from a Population-Based Prospective Study</b> Asuman İnan (Saglik Bilimleri University, Turkey)	14:59 - 15:08
PS13.3	<b>The Impact of War on HIV and TB Epidemics in Ukraine: Challenges in Detection, Late Presentation, and Disease Burden</b> Tetiana Koval (Poltava State Medical University, Ukraine)	15:08 - 15:17
PS13.4	<b>The Impact of Russia's War in Ukraine on Opioid Agonist Treatment (OAT) Services, a Primary Hiv Prevention Strategy among People who Inject Drugs (PWID)</b> Roman Ivasiy (Yale University School of Medicine, United States)	15:17 - 15:26

*Parallel session*

14:30 - 15:30

Salle Maillot

**PS14 - HIV-exposed uninfected children: A topic of clinical significance?**

Karoline Aebi-Popp (University Hospital Bern- Inselspital, Switzerland)

Mariana Mardarescu (National Institute for Infectious Diseases 'Prof. Dr.

Matei Bals', Romania)

PS14.1	<b>Outcomes of HIV-Exposed Uninfected Children Born to HIV-Positive Mothers at Bichat-Claude Bernard Hospital: The ENIVIH Study</b> ANTOINE Bachelard (Assistance Publique-Hôpitaux de Paris Nord, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, France)	14:30 - 14:39
	<b>PRO</b> Claire Thorne (University College London, United Kingdom)	14:39 - 14:54
	<b>CON</b> Pablo Rojo Corneo (Universidad Complutense/Penta, Spain)	14:54 - 15:09

*Breaks*

15:30 - 16:15

Grand Amphitheatre

**Networking break**

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP21 - Cabotegravir and rilpivirine in real word**

Silvia Nozza (Vita-Salute San Raffaele University, Italy)

- |         |   |               |
|---------|---|---------------|
| MeP21.1 | <b>Pharmacokinetics and safety data after switching from injectable cabotegravir (CAB) + rilpivirine (RPV) to oral bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)</b><br>Priyanka Arora (Gilead Sciences, Inc., United States)   | 15:35 - 15:40 |
| MeP21.2 | <b>Comparable efficacy, but increased adverse events and treatment-emergent resistance with injectable cabotegravir/rilpivirine compared to standard oral antiretroviral therapy: two systematic reviews and meta-analyses</b><br>Cassandra Fairhead (Royal Free London NHS Foundation Trust, United Kingdom) | 15:40 - 15:45 |
| MeP21.3 | <b>Impact of liver fibrosis on cabotegravir and rilpivirine long-acting plasma concentrations</b>   | 15:45 - 15:50 |
| MeP21.4 | <b>Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV-1</b><br>Alexandra Calmy (Geneva University Hospital, University of Geneva, Switzerland)              | 15:50 - 15:55 |
| MeP21.5 | <b>Antiretroviral Switch and Weight Gain: Cardiometabolic Implications of Switching to Darunavir/Cobicistat + Lamivudine</b>  | 15:55 - 16:00 |
| MeP21.6 | <b>Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living with HIV in Spain: A Substudy of the RELATIVITY Cohort</b><br>Jara Llenas-García (Hospital Vega Baja, Spain)  | 16:00 - 16:05 |
| MeP21.7 | <b>Determinants of Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A Cause-Specific Analysis from Real-World Data</b><br>Miguel Torralba (Hospital Universitario de Guadalajara, Spain)  | 16:05 - 16:10 |

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP22 - Screening for Comorbidities**

Casper Rokx (Erasmus MC University Medical Center, Netherlands)

- |         |   |               |
|---------|---|---------------|
| MeP22.1 | <b>Systematic screening for age-related comorbidities: Health care optimization among individuals living with HIV in the out-patient clinic in Copenhagen, Denmark</b><br>Anna Katrine Haslund Roed (Copenhagen University Hospital, Denmark) | 15:35 - 15:40 |
| MeP22.2 | <b>Evolving dynamics with prolonged life expectancy: The cancer profile in people living with HIV</b><br>inci Yilmaz Nakir (University of Health Sciences, Haseki Training & Research Hospital, Turkey)                                       | 15:40 - 15:45 |
| MeP22.3 | <b>The Validity of the Montreal Cognitive Assessment as a Screening Tool for Neurocognitive Impairment in people living with HIV</b>  | 15:45 - 15:50 |
| MeP22.4 | <b>Missed opportunities for anal cancer screening in women living with HIV: results from a survey across the European Region</b><br>Dagny Krankowska (Medical University of Warsaw and Hospital for Infectious Diseases, Poland)              | 15:50 - 15:55 |
| MeP22.5 | <b>Prevalence and Risk Factors of Frailty Among Japanese People with HIV: Implications for Health-Related Quality of Life</b>   | 15:55 - 16:00 |

	Hideta Nakamura (University of the Ryukyus, Japan)	
MeP22.6	<b>Long Term Trends For Bone Mineral Density and Trabecular Bone Scores In Men Living With and Without HIV: Impact of Tenofovir Disoproxil Fumarate Exposure</b> Henning Drechsler (VA North Texas Health Care System, United States)	16:00 - 16:05
MeP22.7	<b>Screening for bone health in older people with HIV: uptake and outcomes from a large UK outpatient HIV service</b> Rhys Nicholas (Brighton and Sussex Medical School, United Kingdom)	16:05 - 16:10

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP23 - Clinical Cases - Diagnostic Dilemmas, Immunologic Mysteries & ART Challenges**

MeP23.C.1	<b>ART switch challenges: Hepatitis B reactivation in people living with HIV &amp; HBV co-infection and longstanding HBsAg loss</b> Flora Olcott (University College London, United Kingdom)	15:35 - 15:40
MeP23.C.2	<b>Management of HIV-Related Progressive Multifocal Leukoencephalopathy: Insights from Metagenomic Next-Generation Diagnosis and Pembrolizumab-Lenalidomide Therapy, a case report</b> Yongzheng Guo (The Department of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, China)	15:40 - 15:45
MeP23.C.3	<b>A Challenging Diagnosis of VEXAS Syndrome in a Person Living with HIV: A Case of Recurrent Systemic Inflammation and Cytopenia</b> Buse Kenanoglu (Ege University Medical Faculty, Turkey)	15:45 - 15:50
MeP23.C.4	<b>Hemophagocytic Lymphohistiocytosis in HIV: A Diagnostic and Therapeutic Challenge Highlighted by a Rapidly Fatal Case</b> Banu Çiçek Aktaş (University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Turkey)	15:50 - 15:55
MeP23.C.5	<b>Recurrent fever of unknown origin in a patient with advanced HIV-2 infection: think beyond infectious diseases</b>	15:55 - 16:00
MeP23.C.6	<b>UNUSUAL HIV SEROCONVERSION IN PREP USER CARRYING HETEROZYGOUS CCR5-DELTA32 MUTATION: DID HE CONTRACT HIV?</b> Hélène Laroche (Assistance Publique-Hôpitaux de Marseille (AP-HM), France)	16:00 - 16:05
MeP23.C.7	<b>The Dancer, the Cave, and the Squatters</b> Alberto Díaz-de Santiago (Puerta de Hierro University Hospital, Spain)	16:05 - 16:10

*Moderated ePosters*

15:35 - 16:10

ePoster Exhibition

**MeP24 - HIV Infection and Coinfection: Trends, Risks, and treatment**

MeP24.1	<b>Differences in ART regimen initiation among people with recently acquired HIV: 2015-2021</b>	15:35 - 15:40
MeP24.2	<b>Elite controllers in a cohort of people with well-estimated dates of HIV seroconversion: characteristics, time to lose elite status and natural CD4 evolution</b> Nikos Pantazis (National and Kapodistrian University of Athens, Medical School, Greece)	15:40 - 15:45
MeP24.3	<b>Increasing prevalence of highly viremic persons diagnosed with chronic HIV infection: data from the ICONA cohort study</b> Antonella d'Arminio Monforte (Icona Foundation, Italy)	15:45 - 15:50




MeP24.4	<b>Epidemiology of HIV infection and HIV/HCV coinfection in marginalized populations of Madrid (2019-2023)</b> Jorge Valencia La Rosa (Hospital Universitario Infanta Leonor, Spain)	15:50 - 15:55
MeP24.5	<b>Declining HIV Incidence in MSM diagnosed with syphilis: A Retrospective Longitudinal Study</b> Alessandra Latini (San Gallicano Dermatological Institute IRCCS, Italy)	15:55 - 16:00
MeP24.6	<b>Coverage and determinants of prenatal screening for HIV, syphilis and hepatitis B: a cross-sectional survey in Burkina Faso and The Gambia (TRI-MOM project)</b> Marion Coste (Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, France)	16:00 - 16:05
MeP24.7	<b>Integrated cervical cancer - high-risk human papillomavirus testing - screening strategy with other sexually transmitted infections offered to vulnerable women far from health facilities. Pilot intervention with sex-working women in Paris, France and Yerevan, Armenia</b> Marc SHELLY (Association AREMEDIA, France)	16:05 - 16:10
<i>Moderated ePosters</i> 15:35 - 16:10		
<b>Moderated ePoster Sessions 21 - 24</b>		ePoster Exhibition
<i>Special session</i> 16:15 - 17:15		
<b>SPS5 - ANRS</b>		Amphithéâtre Bleu
<i>Special session</i> 16:15 - 17:15		
<b>SPS6 - University of Liverpool Drug Interaction Team</b>		Amphithéâtre Bordeaux
<i>Roundtable Discussion</i> 16:15 - 17:15		
<b>RT3 - HIV related stigma in healthcare settings - What next?</b> Live broadcasted session 		Salle Maillot
Teymur Noori (European Centre for Diseases Prevention and Control (ECDC), Sweden)		
	<b>Setting the stage</b> Katie Darling (Lausanne University Hospital, Switzerland)	16:15 - 16:25
	<b>Roundtable Discussion on HIV related stigma in healthcare settings - What next?</b> Ricardo Fernandes (GAT - Grupo de Ativistas em Tratamentos, Portugal) Florence Thune (Sidaction, France) Joseph Larmarange (Institut de Recherche pour le Développement, France)	16:25 - 17:15
<i>Special session</i> 16:15 - 17:15		
<b>SPS7 - (ESTISG) and Sexually Transmitted Infections (STI) journal</b>		Room 252 AB

*Meet-the-expert*

16:15 - 17:15

Room 242 AB

**MTE6 - The Rational behind Remnants and Replication: Managing low-level viremia**Live broadcasted session 

Huldrych Günthard (University Hospital Zürich, Switzerland)

Annemarie Wensing (University Medical Center Utrecht, Netherlands)

MTE6.1

**Low-level viremia during antiretroviral treatment is not associated with impaired immunological recovery in the second-generation INSTI era**


16:15 - 16:24

Tommaso Clemente (IRCCS San Raffaele Scientific Institute, Italy)

*Industry sponsored session*

17:30 - 18:30

Amphithéâtre Bleu


**Industry sponsored session**Live broadcasted session 

Saturday, October 18, 2025

*Roundtable Discussion*

08:00 - 09:00

Amphithéâtre Bordeaux

**RT4 - Guidelines versus Gospels (Guidelines, Evidence, and Reality)**Live broadcasted session 

Pierre Delobel (Toulouse University Hospital, France)

**Roundtable Discussion on "Guidelines versus Gospels (Guidelines, Evidence, and Reality)"**

08:00 - 09:00

Iain Reeves (Homerton Healthcare NHS trust, United Kingdom)


Juan Ambrosioni (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain)

Dagny Krankowska (Medical University of Warsaw and Hospital for Infectious Diseases, Poland)

*Parallel session*

09:15 - 10:15

Amphithéâtre Bordeaux

**PS15 - Co-Chairs Choice**Live broadcasted session 

Milosz Parczewski (Pomeranian Medical University, Poland)

Karine Lacombe (Sorbonne Université, France)

Jean-Michel Molina (University of Paris Cité, France)

Bruno Spire (INSERM U1252, France)

PS15.1

**Trends and Timing of HIV Diagnoses Among Migrants: A 15-Year Analysis from the Swiss HIV Cohort Study**

09:15 - 09:24

Jessy J. Duran Ramirez (University Hospital Zurich, Switzerland)

PS15.2

**Doxycycline postexposure prophylaxis and the 4-component meningococcal B vaccine among persons living with HIV at high risk for bacterial sexually transmitted infections in Switzerland**

09:24 - 09:33

David Wimmersberger (Stadtspital Zürich, Switzerland)

PS15.3

**Chemsex, novel chemsex substances, associated risks for STIs, and an extended PrEP cascade among HIV-negative MSM, trans\* individuals in 20 European countries: A latent class analysis**

09:33 - 09:42

Kai J Jonas (Maastricht University, Netherlands)

PS15.4

**Metabolic and Body Composition Outcomes at 48 Weeks among People with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide Switching to Doravirine with or without Tenofovir Disoproxil Fumarate: ACTG A5391 (the DO-IT Trial)**

09:42 - 09:51

John Koethe (Vanderbilt University Medical Center, United States)

*Breaks*


10:15 - 10:45

Amphithéâtre Bordeaux

**Coffee break***Special session*

10:45 - 11:30

Amphithéâtre Bordeaux


**SPS8 - EuroTest special session**Live broadcasted session 

*Special session*

11:45 - 13:15

Amphithéâtre Bordeaux

**SPS9 - EACS Standard of Care session**

Live broadcasted session 

*Ceremony*

13:15 - 13:30

Amphithéâtre Bordeaux

**Closing remarks**

Live broadcasted session 